


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:49:14Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12405140" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12405140</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>discon</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Discov Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Discov Oncol</journal-id><journal-id journal-id-type="pmc-domain-id">4139</journal-id><journal-id journal-id-type="pmc-domain">discon</journal-id><journal-title-group><journal-title>Discover Oncology</journal-title></journal-title-group><issn pub-type="epub">2730-6011</issn><publisher><publisher-name>Springer</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12405140</article-id><article-id pub-id-type="pmcid-ver">PMC12405140.1</article-id><article-id pub-id-type="pmcaid">12405140</article-id><article-id pub-id-type="pmcaiid">12405140</article-id><article-id pub-id-type="pmid">40892177</article-id><article-id pub-id-type="doi">10.1007/s12672-025-03309-1</article-id><article-id pub-id-type="publisher-id">3309</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Long non-coding RNA-based single and combination independent prognostic biomarkers for hepatocellular carcinoma</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Jeng</surname><given-names initials="LB">Long-Bin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yang</surname><given-names initials="HR">Horng-Ren</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-5218-0571</contrib-id><name name-style="western"><surname>Teng</surname><given-names initials="CF">Chiao-Fang</given-names></name><address><email>chiaofangteng@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0368s4g32</institution-id><institution-id institution-id-type="GRID">grid.411508.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 0572 9415</institution-id><institution>Organ Transplantation Center, </institution><institution>China Medical University Hospital, </institution></institution-wrap>Taichung, 404 Taiwan </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0368s4g32</institution-id><institution-id institution-id-type="GRID">grid.411508.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 0572 9415</institution-id><institution>Department of Surgery, </institution><institution>China Medical University Hospital, </institution></institution-wrap>Taichung, 404 Taiwan </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0368s4g32</institution-id><institution-id institution-id-type="GRID">grid.411508.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 0572 9415</institution-id><institution>Cell Therapy Center, </institution><institution>China Medical University Hospital, </institution></institution-wrap>Taichung, 404 Taiwan </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00v408z34</institution-id><institution-id institution-id-type="GRID">grid.254145.3</institution-id><institution-id institution-id-type="ISNI">0000 0001 0083 6092</institution-id><institution>School of Medicine, </institution><institution>China Medical University, </institution></institution-wrap>Taichung, 404 Taiwan </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00v408z34</institution-id><institution-id institution-id-type="GRID">grid.254145.3</institution-id><institution-id institution-id-type="ISNI">0000 0001 0083 6092</institution-id><institution>Graduate Institute of Biomedical Sciences, </institution><institution>China Medical University, </institution></institution-wrap>No.91, Hsueh-Shih Rd., Northern Dist., Taichung City, 404 Taiwan </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00v408z34</institution-id><institution-id institution-id-type="GRID">grid.254145.3</institution-id><institution-id institution-id-type="ISNI">0000 0001 0083 6092</institution-id><institution>Master Program for Cancer Biology and Drug Discovery, </institution><institution>China Medical University, </institution></institution-wrap>Taichung, 404 Taiwan </aff></contrib-group><pub-date pub-type="epub"><day>2</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2025</year></pub-date><volume>16</volume><issue-id pub-id-type="pmc-issue-id">478248</issue-id><elocation-id>1674</elocation-id><history><date date-type="received"><day>22</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>25</day><month>7</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 00:25:59.930"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="12672_2025_Article_3309.pdf"/><abstract id="Abs1"><p id="Par1">Although significant advances have been made in the prevention and therapy, hepatocellular carcinoma (HCC) is still one of the most frequent and fatal human cancers worldwide. Discovery of independent prognostic biomarkers for the early identification and timely treatment of HCC patients with poor prognosis remains a key goal to achieve better patient survival. Long non-coding RNA (lncRNA) is one of the most-investigated classes of non-coding RNAs and plays important roles in controlling the occurrence and development of HCC through regulation of oncogene and tumor suppressor gene expression. Moreover, alterations in the expression levels of many lncRNAs are frequently observed in tumor tissues and blood circulation of HCC patients. LncRNAs have emerged as potential independent biomarkers for predicting the prognosis of HCC patients. This review comprehensively summarizes the evidence in the literature validating a single or a combination of lncRNA biomarker(s) with independent prognostic value in HCC patients.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Hepatocellular carcinoma</kwd><kwd>Long non-coding RNA</kwd><kwd>Single</kwd><kwd>Combination</kwd><kwd>Independent prognostic biomarker</kwd></kwd-group><funding-group><award-group><funding-source><institution>China Medical University Hospital, Taichung, Taiwan</institution></funding-source><award-id>DMR-114-036</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Science+Business Media LLC, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">Hepatocellular carcinoma (HCC) is the most predominant histological form of primary liver cancer, which constitutes more than 90% of total liver cancer cases worldwide [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Although many surgical and non-surgical therapeutic options have been well established for treatment of HCC patients, the overall therapeutic efficacy, treatment response, and survival benefit remain unsatisfactory [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. HCC still ranks third in mortality rate among all human cancers worldwide, resulting in over 800,000 people died of this disease annually [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. Therefore, development of valuable biomarkers for independent prediction of HCC prognosis is vital for timely identification and better management of the patients with poor prognosis to improve their survival.</p><p id="Par3">Among the most-studied types of non-coding RNAs, long non-coding RNAs (lncRNAs) can regulate gene expression in different ways, including: (1) serving as a signaling molecule to recruit transcription factors in response to various stimuli; (2) acting as a guiding molecule to direct chromatin-modifying enzymes to specific genomic location; (3) functioning as a decoy molecule to sequester transcription factors or microRNAs from their targets; (4) working as a scaffolding molecule to mediate the formation of multiple-component complexes [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. It has been shown that lncRNAs play essential roles in the occurrence and development of various types of cancer, including HCC, through regulating the expression of oncogenes and tumor suppressor genes to control the malignant functions of tumor cells, such as cell growth, proliferation, cell cycle progression, apoptosis, migration, epithelial-to-mesenchymal transition, invasion, and metastasis [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Moreover, the altered expression levels of many tissue and circulating lncRNAs have emerged as not only promising biomarkers for diagnosing the occurrence and predicting the prognosis and treatment response of cancer but also potential targets for developing novel cancer therapeutic strategies [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>].</p><p id="Par4">This review provides a comprehensive summary of the literature showing evidence to demonstrate the independent prognostic significance of a variety of lncRNA-based single or combination biomarkers in tissue and blood-derived specimens of HCC patients.</p><sec id="Sec2"><title>Independent prognostic significance of single lncRNA biomarkers in HCC patients</title><p id="Par5">Multiple studies were conducted to evaluate the independent prognostic value of individual lncRNAs showing altered expression levels in tumor tissues of HCC patients by multivariate Cox proportional hazards regression analysis (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>). The study conducted by Wang et al. revealed that a high pre-treatment expression level of long intergenic non-protein coding RNA (LINC) 152 (LINC00152) in tumor tissues as detected by quantitative reverse-transcription polymerase chain reaction (qRT-PCR) independently predicted a shorter overall survival (OS) (hazard ratio (HR), 2.524; 95% confidence interval (CI), 1.661&#8211;4.015; P value&#8201;=&#8201;0.001) in 63 retrospectively recruited HCC patients treated with curative surgical resection [<xref ref-type="bibr" rid="CR13">13</xref>]. Using in situ hybridization (ISH)-based detection of LINC00294, Zhang et al. showed that a high pre-treatment expression level of LINC00294 in tumor tissues was independently correlated with a shorter OS (HR, 2.434; 95% CI, 1.143&#8211;3.185; P value&#8201;=&#8201;0.021) in 94 retrospectively recruited HCC patients [<xref ref-type="bibr" rid="CR14">14</xref>]. Based on RNA sequencing (RNAseq) analysis of LINC01094, Yang et al. identified that a high pre-treatment expression level of LINC01094 in tumor tissues was a factor independently associated with a shorter OS (HR, 2.091; 95% CI, 1.447&#8211;3.021; P value&#8201;&lt;&#8201;0.001) in 365 retrospectively recruited HCC patients [<xref ref-type="bibr" rid="CR15">15</xref>]. Li et al. performed qRT-PCR to measure LINC01139 and ascertained that a high pre-treatment expression level of LINC01139 in tumor tissues was an independent factor which predicted a shorter OS (HR, 2.721; 95% CI, 1.289&#8211;4.183; P value&#8201;=&#8201;0.019) in 109 retrospectively recruited HCC patients treated with curative surgical resection [<xref ref-type="bibr" rid="CR16">16</xref>]. In 85 retrospectively recruited HCC patients treated with curative surgical resection, Ma et al. carried out qRT-PCR to measure LINC01146 and confirmed an independent association between high pre-treatment expression level of LINC01146 in tumor tissues and longer OS (HR, 0.38; 95% CI, 0.16&#8211;0.92; P value&#8201;=&#8201;0.033) [<xref ref-type="bibr" rid="CR17">17</xref>]. The study conducted by Zheng et al. verified that a low pre-treatment expression level of LINC01554 in tumor tissues as detected by qRT-PCR was an independent predictor for a shorter OS (HR, 2.507; 95% CI, 1.153&#8211;2.832; P value&#8201;=&#8201;0.017) in 167 retrospectively recruited HCC patients treated with curative surgical resection [<xref ref-type="bibr" rid="CR18">18</xref>]. Using qRT-PCR-based detection of homeobox C13 antisense RNA (HOXC13-AS), Zhou et al. found that a high pre-treatment expression level of HOXC13-AS in tumor tissues was independently associated with a shorter OS (HR, 2.894; 95% CI, 1.183&#8211;4.223; P value&#8201;=&#8201;0.015) and recurrence-free survival (RFS) (HR, 3.201; 95% CI, 1.372&#8211;4.653; P value&#8201;=&#8201;0.004) in 197 retrospectively recruited HCC patients treated with curative surgical resection [<xref ref-type="bibr" rid="CR19">19</xref>]. Based on qRT-PCR analysis of LIM and SH3 protein 1 antisense RNA (LASP1-AS), Yin et al. unraveled that a low pre-treatment expression level of LASP1-AS in tumor tissues independently predicted a shorter OS (training cohort: HR, 1.884; 95% CI, 1.427&#8211;2.841; P value&#8201;&lt;&#8201;0.0001; validation cohort: HR, 3.539; 95% CI, 2.698&#8211;6.030; P value&#8201;&lt;&#8201;0.0001) and RFS (training cohort: HR, 1.967; 95% CI, 1.380&#8211;2.803; P value&#8201;&lt;&#8201;0.0001; validation cohort: HR, 2.793; 95% CI, 2.154&#8211;4.672; P value&#8201;&lt;&#8201;0.0001) in 423 retrospectively recruited HCC patients treated with curative surgical resection (205 as training cohort and 218 as validation cohort) [<xref ref-type="bibr" rid="CR20">20</xref>]. Chen et al. performed RNAseq to measure E74 like ETS transcription factor 3 antisense RNA 1 (ELF3-AS1) and demonstrated that a high pre-treatment expression level of ELF3-AS1 in tumor tissues was independently correlated with a shorter OS (HR, 1.667; 95% CI, 1.127&#8211;2.468; P value&#8201;=&#8201;0.011) in 373 retrospectively recruited HCC patients [<xref ref-type="bibr" rid="CR21">21</xref>]. In 222 retrospectively recruited HCC patients treated with curative surgical resection (110 as training cohort and 112 as validation cohort), Luo et al. carried out qRT-PCR to measure engulfment and cell motility 1 antisense RNA 1 (ELMO1-AS1) and determined that a high pre-treatment expression level of ELMO1-AS1 in tumor tissues was a factor independently associated with a longer OS (training cohort: HR, 0.518; 95% CI, 0.277&#8211;0.968; P value&#8201;=&#8201;0.039; validation cohort: HR, 0.430; 95% CI, 0.225&#8211;0.824; P value&#8201;=&#8201;0.011) and RFS (training cohort: HR, 0.557; 95% CI, 0.323&#8211;0.960; P value&#8201;=&#8201;0.035; validation cohort: HR, 0.616; 95% CI, 0.363&#8211;1.045; P value&#8201;=&#8201;0.072) [<xref ref-type="bibr" rid="CR22">22</xref>]. The study conducted by Liang et al. revealed that a high pre-treatment expression level of forkhead box P4 antisense RNA 1 (FOXP4-AS1) in tumor tissues as detected by qRT-PCR was an independent factor which predicted a shorter OS (training cohort: HR, 2.712; 95% CI, 1.140&#8211;6.450; P value&#8201;=&#8201;0.024; validation cohort: HR, 6.505; 95% CI, 1.165&#8211;36.399; P value&#8201;=&#8201;0.033) and RFS (training cohort: HR, 2.574; 95% CI, 1.126&#8211;5.885; P value&#8201;=&#8201;0.025; validation cohort: HR, 6.826; 95% CI, 1.228&#8211;37.945; P value&#8201;=&#8201;0.028) in 121 retrospectively recruited HCC patients treated with curative surgical resection (87 as training cohort and 34 as validation cohort) [<xref ref-type="bibr" rid="CR23">23</xref>]. Using qRT-PCR-based detection of growth arrest specific 5 antisense RNA 1 (GAS5-AS1), Wang et al. showed an independent association between high pre-treatment expression level of GAS5-AS1in tumor tissues and longer OS (HR, 0.370; 95% CI, 0.153&#8211;0.898; P value&#8201;=&#8201;0.028) in 83 retrospectively recruited HCC patients treated with curative surgical resection [<xref ref-type="bibr" rid="CR24">24</xref>]. Based on qRT-PCR analysis of major histocompatibility complex, class I, F antisense RNA 1 (HLA-F-AS1), Zhang et al. identified that a high pre-treatment expression level of HLA-F-AS1 in tumor tissues was an independent predictor for a shorter OS (HR, 2.290; 95% CI, 1.191&#8211;4.403; P value&#8201;=&#8201;0.013) in 100 retrospectively recruited HCC patients treated with curative surgical resection [<xref ref-type="bibr" rid="CR25">25</xref>]. In 374 retrospectively recruited HCC patients, Li et al. carried out RNAseq to measure inka box actin regulator 2 antisense RNA 1 (INKA2-AS1) and ascertained that a high pre-treatment expression level of INKA2-AS1 in tumor tissues was independently associated with a shorter OS (HR, 1.722; 95% CI, 1.180&#8211;2.514; P value&#8201;=&#8201;0.005) [<xref ref-type="bibr" rid="CR26">26</xref>]. The study conducted by Song et al. confirmed that a high pre-treatment expression level of nucleolar protein interacting with the FHA domain of MKI67 antisense RNA 1 (NIFK-AS1) in tumor tissues as detected by RNAseq independently predicted a shorter OS (HR, 2.31; 95% CI, 1.36&#8211;3.90; P value&#8201;=&#8201;0.002) in 368 retrospectively recruited HCC patients [<xref ref-type="bibr" rid="CR27">27</xref>]. Using RNAseq-based detection of DNA polymerase eta antisense RNA 1 (POLH-AS1), Dong et al. verified that a high pre-treatment expression level of POLH-AS1 in tumor tissues was independently correlated with a shorter OS (HR, 2.400; 95% CI, 1.154&#8211;4.992; P value&#8201;=&#8201;0.019) in 374 retrospectively recruited HCC patients [<xref ref-type="bibr" rid="CR28">28</xref>]. Based on RNAseq analysis of proline rich 11 antisense RNA 1 (PRR11-AS1), Abulihaiti et al. found that a high pre-treatment expression level of PRR11-AS1 in tumor tissues was a factor independently associated with a shorter OS (HR, 2.137; 95% CI, 1.406&#8211;3.248; P value&#8201;=&#8201;0.00037) in 343 retrospectively recruited HCC patients [<xref ref-type="bibr" rid="CR29">29</xref>]. Sheng et al. performed qRT-PCR to measure repulsive guidance molecule BMP co-receptor b antisense RNA 1 (RGMB-AS1) and unraveled that a high pre-treatment expression level of RGMB-AS1 in tumor tissues was an independent factor which predicted a longer OS (HR, 0.528; 95% CI, 0.304&#8211;0.919; P value&#8201;=&#8201;0.024) in 108 retrospectively recruited HCC patients [<xref ref-type="bibr" rid="CR30">30</xref>]. In 127 retrospectively recruited HCC patients treated with curative surgical resection, Zhang et al. carried out qRT-PCR to measure rhophilin Rho GTPase binding protein 1 antisense RNA 1 (RHPN1-AS1) and demonstrated an independent association between high pre-treatment expression level of RHPN1-AS1 in tumor tissues and shorter OS (HR, 3.329; 95% CI, 1.482&#8211;4.776; P value&#8201;=&#8201;0.015) [<xref ref-type="bibr" rid="CR31">31</xref>]. The study conducted by Sun et al. determined that a high pre-treatment expression level of ribonuclease H1 antisense RNA 1 (RNASEH1-AS1) in tumor tissues as detected by RNAseq was an independent predictor for a shorter OS (HR, 1.479; 95% CI, 1.039&#8211;2.106; P value&#8201;=&#8201;0.024) in 370 retrospectively recruited HCC patients [<xref ref-type="bibr" rid="CR32">32</xref>]. Using qRT-PCR-based detection of SRY-box transcription factor 21 antisense RNA 1 (SOX21-AS1), Wei et al. revealed that a high pre-treatment expression level of SOX21-AS1 in tumor tissues was independently associated with a shorter OS (HR, unreported; P value&#8201;=&#8201;0.007) in 68 retrospectively recruited HCC patients [<xref ref-type="bibr" rid="CR33">33</xref>]. Based on qRT-PCR analysis of THAP domain containing 9 antisense RNA 1 (THAP9-AS1), Su et al. showed that a high pre-treatment expression level of THAP9-AS1 in tumor tissues independently predicted a shorter OS (HR, 2.774; 95% CI, 1.443&#8211;5.332; P value&#8201;=&#8201;0.002) in 79 retrospectively recruited HCC patients treated with curative surgical resection [<xref ref-type="bibr" rid="CR34">34</xref>]. Lu et al. performed RNAseq to measure homeobox A antisense RNA 2 (HOXA-AS2) and identified that a high pre-treatment expression level of HOXA-AS2 in tumor tissues was independently correlated with a shorter OS (HR, 2.764; 95% CI, 1.115&#8211;6.848; P value&#8201;=&#8201;0.028) in 116 retrospectively recruited HCC patients treated with curative surgical resection [<xref ref-type="bibr" rid="CR35">35</xref>]. In 303 retrospectively recruited HCC patients, Zhang et al. carried out RNAseq to measure zinc finger protein 385D antisense RNA 2 (ZNF385D-AS2) and ascertained that a high pre-treatment expression level of ZNF385D-AS2 in tumor tissues was a factor independently associated with a shorter OS (HR, unreported; P value&#8201;=&#8201;0.0079) [<xref ref-type="bibr" rid="CR36">36</xref>]. The studies conducted by Sun et al. confirmed that a high pre-treatment expression level of <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC092171.4">AC092171.4</ext-link> in tumor tissues as detected by qRT-PCR was an independent factor which predicted a shorter OS (HR, 2.66; 95% CI, 1.14&#8211;6.19; P value&#8201;=&#8201;0.02) and RFS (HR, 2.51; 95% CI, 1.08&#8211;5.84; P value&#8201;=&#8201;0.03) in 95 retrospectively recruited HCC patients treated with curative surgical resection [<xref ref-type="bibr" rid="CR37">37</xref>]. Using qRT-PCR-based detection of BRAF-activated non-protein coding RNA (BANCR), Zhou et al. verified an independent association between high pre-treatment expression level of BANCR in tumor tissues and shorter OS (HR, 4.245; 95% CI, unreported; P value&#8201;=&#8201;0.015) in 109 retrospectively recruited HCC patients treated with curative surgical resection [<xref ref-type="bibr" rid="CR38">38</xref>]. Based on qRT-PCR analysis of cancer susceptibility 19 (CASC19), Hou et al. found that a high pre-treatment expression level of CASC19 in tumor tissues was an independent predictor for a shorter OS (HR, 3.037; 95% CI, 1.297&#8211;7.110; P value&#8201;=&#8201;0.010) in 124 retrospectively recruited HCC patients treated with curative surgical resection [<xref ref-type="bibr" rid="CR39">39</xref>]. Two studies were conducted to evaluate the independent prognostic value of colon cancer associated transcript 2 (CCAT2). Xu et al. performed qRT-PCR to measure CCAT2 and unraveled that a high pre-treatment expression level of CCAT2 in tumor tissues was independently associated with a shorter OS (HR, 1.849; 95% CI, 1.064&#8211;3.213; P value&#8201;=&#8201;0.029) in 96 retrospectively recruited HCC patients treated with curative surgical resection [<xref ref-type="bibr" rid="CR40">40</xref>]. In 122 retrospectively recruited HCC patients treated with curative surgical resection, Fu et al. carried out qRT-PCR to measure CCAT2 and demonstrated that a high pre-treatment expression level of CCAT2 in tumor tissues independently predicted a shorter OS (HR, 2.126; 95% CI, 1.273&#8211;8.775; P value&#8201;=&#8201;0.021) [<xref ref-type="bibr" rid="CR41">41</xref>]. The studies conducted by Peng et al. determined that a low pre-treatment expression level of cervical carcinoma high-expressed lncRNA 1 (CCHE1) in tumor tissues as detected by qRT-PCR was independently correlated with a longer OS (HR, 0.977; 95% CI, 0.312&#8211;3.434; P value&#8201;=&#8201;0.041) in 112 retrospectively recruited HCC patients treated with curative surgical resection [<xref ref-type="bibr" rid="CR42">42</xref>]. Using RNAseq-based detection of CTC-297N7.9, Zhu et al. revealed that a high pre-treatment expression level of CTC-297N7.9 in tumor tissues was a factor independently associated with a longer OS (HR, 0.457; 95% CI, 0.318&#8211;0.659; P value&#8201;&lt;&#8201;0.001) and RFS (HR, 0.717; 95% CI, 0.529&#8211;0.972; P value&#8201;=&#8201;0.032) in 368 retrospectively recruited HCC patients treated with curative surgical resection [<xref ref-type="bibr" rid="CR43">43</xref>]. Based on qRT-PCR analysis of <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="D16366">D16366</ext-link>, Chao et al. showed that a low pre-treatment expression level of <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="D16366">D16366</ext-link> in tumor tissues was an independent factor which predicted a shorter OS (HR, 6.472; 95% CI, 2.046&#8211;20.470; P value&#8201;=&#8201;0.001) in 107 retrospectively recruited HCC patients [<xref ref-type="bibr" rid="CR44">44</xref>]. Huang et al. performed qRT-PCR to measure DiGeorge syndrome critical region gene 5 (DGCR5) and identified an independent association between high pre-treatment expression level of DGCR5 in tumor tissues and longer cancer-specific survival (CSS) (HR, 0.506; 95% CI, 0.310&#8211;0.825; P value&#8201;=&#8201;0.006) in 110 retrospectively recruited HCC patients treated with curative surgical resection [<xref ref-type="bibr" rid="CR45">45</xref>]. In 84 retrospectively recruited HCC patients, Zeng et al. carried out qRT-PCR to measure <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="DQ786243">DQ786243</ext-link> and ascertained that a high pre-treatment expression level of <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="DQ786243">DQ786243</ext-link> in tumor tissues was an independent predictor for a shorter OS (HR, 3.15; 95% CI, 1.37&#8211;7.19; P value&#8201;=&#8201;0.007) [<xref ref-type="bibr" rid="CR46">46</xref>]. The study conducted by Mo et al. confirmed that a high pre-treatment expression level of family with sequence similarity 99 member A (FAM99A) in tumor tissues as detected by qRT-PCR was independently associated with a longer OS (HR, 0.425; 95% CI, 0.189&#8211;0.958; P value&#8201;=&#8201;0.039) in 62 retrospectively recruited HCC patients treated with curative surgical resection [<xref ref-type="bibr" rid="CR47">47</xref>]. Using qRT-PCR-based detection of growth arrest specific 5 (GAS5), Tu et al. verified that a high pre-treatment expression level of GAS5 in tumor tissues independently predicted a longer OS (HR, 0.417; 95% CI, 0.244&#8211;0.617; P value&#8201;=&#8201;0.002) in 71 retrospectively recruited HCC patients treated with curative surgical resection [<xref ref-type="bibr" rid="CR48">48</xref>]. Based on qRT-PCR analysis of gastric carcinoma proliferation enhancing transcript 1 (GHET1), Jin et al. found that a high pre-treatment expression level of GHET1 in tumor tissues was independently correlated with a shorter OS (HR, unreported; P value&#8201;=&#8201;0.001) in 68 retrospectively recruited HCC patients treated with curative surgical resection [<xref ref-type="bibr" rid="CR49">49</xref>]. Yang et al. performed qRT-PCR to measure HOX transcript antisense RNA (HOTAIR) and unraveled that a high pre-treatment expression level of HOTAIR in tumor tissues was a factor independently associated with a shorter RFS (HR, 3.564; 95% CI, 1.666&#8211;7.628; P value&#8201;=&#8201;0.001) in 60 retrospectively recruited HCC patients treated with liver transplantation [<xref ref-type="bibr" rid="CR50">50</xref>]. In 155 retrospectively recruited HCC patients treated with liver transplantation, Wu et al. carried out qRT-PCR to measure HOXA distal transcript antisense RNA (HOTTIP) and demonstrated that a high pre-treatment expression level of HOTTIP in tumor tissues was an independent factor which predicted a shorter OS (HR, 2.059; 95% CI, 1.743&#8211;2.375; P value&#8201;=&#8201;0.022) [<xref ref-type="bibr" rid="CR51">51</xref>]. The study conducted by Ma et al. determined that a high pre-treatment expression level of JPX transcript, XIST activator (JPX) in tumor tissues as detected by qRT-PCR was an independent factor which predicted a shorter OS (HR, 2.294; 95% CI, 1.178&#8211;4.468; P value&#8201;=&#8201;0.015) in 68 retrospectively recruited HCC patients treated with curative surgical resection [<xref ref-type="bibr" rid="CR52">52</xref>]. Using qRT-PCR-based detection of lncRNA activated by TGF-beta (LNCRNA-ATB), Jang et al. revealed that a high pre-treatment expression level of LNCRNA-ATB in tumor tissues was an independent predictor for a shorter OS (HR, 4.158; 95% CI, 1.226&#8211;14.107; P value&#8201;=&#8201;0.022) and progression-free survival (PFS) (HR, 2.971; 95% CI, 1.121&#8211;7.872; P value&#8201;=&#8201;0.029) in 75 retrospectively recruited HCC patients treated with curative surgical resection [<xref ref-type="bibr" rid="CR53">53</xref>]. Based on RNAseq analysis of lung cancer associated transcript 1 (LUCAT1), Jiao et al. showed that a high pre-treatment expression level of LUCAT1 in tumor tissues was independently associated with a shorter OS (HR, 2.35; 95% CI, 1.56&#8211;3.54; P value&#8201;&lt;&#8201;0.001) and RFS (HR, 2.04; 95% CI, 1.32&#8211;3.16; P value&#8201;=&#8201;0.001) in 371 retrospectively recruited HCC patients treated with radiation therapy [<xref ref-type="bibr" rid="CR54">54</xref>]. Two studies were conducted to evaluate the independent prognostic value of metastasis-associated lung adenocarcinoma transcript 1 (MALAT1). Lai et al. performed qRT-PCR to measure MALAT1 and identified that a high pre-treatment expression level of MALAT1 in tumor tissues independently predicted a shorter RFS (HR, 3.280; 95% CI, 1.516&#8211;7.094; P value&#8201;=&#8201;0.003) in 60 retrospectively recruited HCC patients treated with liver transplantation [<xref ref-type="bibr" rid="CR55">55</xref>]. In 169 retrospectively recruited HCC patients, Liao et al. carried out RNAseq to measure MALAT1 and ascertained that a high pre-treatment expression level of MALAT1 in tumor tissues was independently correlated with a shorter PFS (HR, 1.5; 95% CI, unreported; P value&#8201;=&#8201;0.014) [<xref ref-type="bibr" rid="CR56">56</xref>]. The study conducted by Jin et al. confirmed that a high pre-treatment expression level of MYC-induced long non-coding RNA (MINCR) in tumor tissues as detected by qRT-PCR was a factor independently associated with a shorter OS (HR, 3.126; 95% CI, 1.248&#8211;4.478; P value&#8201;=&#8201;0.011) in 161 retrospectively recruited HCC patients treated with curative surgical resection [<xref ref-type="bibr" rid="CR57">57</xref>]. Using qRT-PCR-based detection of MIR4435-2 host gene (MIR4435-2HG), Zhao et al. verified that a high pre-treatment expression level of MIR4435-2HG in tumor tissues was an independent factor which predicted a shorter OS (HR, 3.509; 95% CI, 1.574&#8211;7.820; P value&#8201;=&#8201;0.002) and RFS (HR, 2.579; 95% CI, 1.425&#8211;4.668; P value&#8201;=&#8201;0.002) in 88 retrospectively recruited HCC patients treated with curative surgical resection [<xref ref-type="bibr" rid="CR58">58</xref>]. Based on qRT-PCR analysis of MIR22 host gene (MIR22HG), Zhang et al. found an independent association between high pre-treatment expression level of MIR22HG in tumor tissues and longer OS (HR, 0.496; 95% CI, 0.270&#8211;0.912; P value&#8201;=&#8201;0.024) in 145 retrospectively recruited HCC patients treated with curative surgical resection [<xref ref-type="bibr" rid="CR59">59</xref>]. Wang et al. performed qRT-PCR to measure MIR503 host gene (MIR503HG) and unraveled that a high pre-treatment expression level of MIR503HG in tumor tissues was an independent predictor for a longer OS (HR, 0.51; 95% CI, 0.26&#8211;0.99; P value&#8201;=&#8201;0.048) and time to recurrence (TTR) (HR, 0.57; 95% CI, 0.33&#8211;0.99; P value&#8201;=&#8201;0.049) in 93 retrospectively recruited HCC patients treated with curative surgical resection [<xref ref-type="bibr" rid="CR60">60</xref>]. In 90 retrospectively recruited HCC patients treated with curative surgical resection, Chen et al. carried out qRT-PCR to measure NF-kappaB interacting lncRNA (NKILA) and demonstrated that a high pre-treatment expression level of NKILA in tumor tissues was independently associated with a longer OS (HR, 0.454; 95% CI, 0.251&#8211;0.822; P value&#8201;=&#8201;0.009) [<xref ref-type="bibr" rid="CR61">61</xref>]. The study conducted by Wang et al. determined that a high pre-treatment expression level of non-coding RNA in the aldehyde dehydrogenase 1A pathway (NRAD1) in tumor tissues as detected by qRT-PCR independently predicted a shorter OS (HR, 1.316; 95% CI, 1.251&#8211;2.619; P value&#8201;=&#8201;0.036) in 63 retrospectively recruited HCC patients treated with curative surgical resection [<xref ref-type="bibr" rid="CR13">13</xref>]. Using qRT-PCR-based detection of promoter of CDKN1A antisense DNA damage activated RNA (PANDAR), Peng et al. revealed that a high pre-treatment expression level of PANDAR in tumor tissues was independently correlated with a shorter OS (HR, 1.658; 95% CI, 0.842&#8211;3.633; P value&#8201;=&#8201;0.005) and TTR (HR, 0.955; 95% CI, 0.509&#8211;1.783; P value&#8201;=&#8201;0.016) in 482 retrospectively recruited HCC patients treated with curative surgical resection [<xref ref-type="bibr" rid="CR62">62</xref>]. Based on qRT-PCR analysis of prostate cancer associated transcript 1 (PCAT1), Yan et al. showed that a high pre-treatment expression level of PCAT1 in tumor tissues was a factor independently associated with a shorter OS (HR, 2.977; 95% CI, 1.107&#8211;7.912; P value&#8201;=&#8201;0.001) in 117 retrospectively recruited HCC patients treated with curative surgical resection [<xref ref-type="bibr" rid="CR63">63</xref>]. Ji et al. performed qRT-PCR to measure RNA polymerase II subunit J4 (pseudogene) (POLR2J4) and identified that a high pre-treatment expression level of POLR2J4 in tumor tissues was an independent factor which predicted a shorter OS (HR, 3.857; 95% CI, unreported; P value&#8201;=&#8201;0.016) in 109 retrospectively recruited hepatitis B virus (HBV)-related HCC patients [<xref ref-type="bibr" rid="CR64">64</xref>]. In 104 retrospectively recruited HCC patients, Li et al. carried out qRT-PCR to measure POU class 3 homeobox 3 (POU3F3) and ascertained an independent association between high pre-treatment expression level of POU3F3 in tumor tissues and shorter OS (HR, 1.914; 95% CI, 1.010&#8211;3.626; P value&#8201;=&#8201;0.046) [<xref ref-type="bibr" rid="CR65">65</xref>]. The study conducted by Bai et al. confirmed that a high pre-treatment expression level of pituitary tumor-transforming 3, pseudogene (PTTG3P) in tumor tissues as detected by RNAseq was an independent predictor for a shorter OS (HR, 2.177; 95% CI, 1.519&#8211;3.121; P value&#8201;&lt;&#8201;0.001) and RFS (HR, 2.222; 95% CI, 1.503&#8211;3.283; P value&#8201;&lt;&#8201;0.001) in 353 retrospectively recruited HCC patients treated with radiation therapy [<xref ref-type="bibr" rid="CR66">66</xref>]. Using qRT-PCR-based detection of small nucleolar RNA host gene 3 (SNHG3), Zhang et al. verified that a high pre-treatment expression level of SNHG3 in tumor tissues was independently associated with a shorter OS (HR, 3.464; 95% CI, 1.820&#8211;6.594; P value&#8201;=&#8201;0.000) in 144 retrospectively recruited HCC patients treated with curative surgical resection [<xref ref-type="bibr" rid="CR67">67</xref>]. Based on RNAseq analysis of SNHG15, Zhang et al. found that a high pre-treatment expression level of SNHG15 in tumor tissues independently predicted a shorter OS (HR, 2.247; 95% CI, 1.331&#8211;6.255; P value&#8201;=&#8201;0.001) in 152 retrospectively recruited HCC patients treated with curative surgical resection [<xref ref-type="bibr" rid="CR68">68</xref>]. Zhang et al. performed RNAseq to measure SNHG16 and unraveled that a high pre-treatment expression level of SNHG16 in tumor tissues was independently correlated with a shorter OS (HR, 1.837; 95% CI, 1.117&#8211;3.002; P value&#8201;=&#8201;0.017) and RFS (HR, 2.001; 95% CI, 3.218&#8211;6.255; P value&#8201;=&#8201;0.004) in 158 retrospectively recruited HCC patients treated with liver transplantation [<xref ref-type="bibr" rid="CR69">69</xref>]. In 84 retrospectively recruited HCC patients treated with curative surgical resection, Shi et al. carried out qRT-PCR to measure SOX2 overlapping transcript (SOX2-OT) and demonstrated that a high pre-treatment expression level of SOX2-OT in tumor tissues was a factor independently associated with a shorter OS (HR, 2.644; 95% CI, 1.473&#8211;5.845; P value&#8201;&lt;&#8201;0.001) [<xref ref-type="bibr" rid="CR70">70</xref>]. The study conducted by Yu et al. determined that a high pre-treatment expression level of small ubiquitin-like modifier 1 pseudogene 3 (SUMO1P3) in tumor tissues as detected by ISH was an independent factor which predicted a shorter OS (HR, 2.107; 95% CI, 1.478&#8211;9.014; P value&#8201;=&#8201;0.031) in 113 retrospectively recruited HCC patients treated with curative surgical resection [<xref ref-type="bibr" rid="CR71">71</xref>]. Using ISH-based detection of translation regulatory long non-coding RNA 1 (TRERNA1), Qian et al. revealed an independent association between high pre-treatment expression level of TRERNA1 in tumor tissues and shorter OS (HR, 2.322; 95% CI, 1.209&#8211;4.459; P value&#8201;=&#8201;0.011) in 111 retrospectively recruited HCC patients treated with curative surgical resection [<xref ref-type="bibr" rid="CR72">72</xref>]. Based on qRT-PCR analysis of W5, Lei et al. showed that a low pre-treatment expression level of W5 in tumor tissues was an independent predictor for a shorter OS (HR, 1.285; 95% CI, 0.867&#8211;2.155; P value&#8201;=&#8201;0.027) in 86 retrospectively recruited HCC patients treated with curative surgical resection [<xref ref-type="bibr" rid="CR73">73</xref>]. Zeng et al. performed RNAseq to measure <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="X91348">X91348</ext-link> and identified that a low pre-treatment expression level of <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="X91348">X91348</ext-link> in tumor tissues was an independent predictor for a shorter OS (HR, 5.527; 95% CI, 1.791&#8211;17.057; P value&#8201;=&#8201;0.003) in 107 retrospectively recruited HCC patients [<xref ref-type="bibr" rid="CR74">74</xref>]. In 68 retrospectively recruited HCC patients treated with curative surgical resection, Ma et al. carried out qRT-PCR to measure X inactive specific transcript (XIST) and identified that a low pre-treatment expression level of XIST in tumor tissues was an independent predictor for a shorter OS (HR, 2.207; 95% CI, 1.157&#8211;4.225; P value&#8201;=&#8201;0.017) [<xref ref-type="bibr" rid="CR52">52</xref>]. In addition, several studies were conducted to evaluate the independent prognostic value of individual lncRNAs showing altered expression levels in blood-derived specimens of HCC patients by multivariate Cox proportional hazards regression analysis (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>). The studies conducted by Wang et al. ascertained that a high pre-treatment expression level of colorectal neoplasia differentially expressed (CRNDE) in serum exosomes as detected by qRT-PCR was independently associated with a shorter OS (HR, 2.207; 95% CI, 1.157&#8211;4.225; P value&#8201;=&#8201;0.017) in 166 retrospectively recruited HCC patients [<xref ref-type="bibr" rid="CR75">75</xref>]. Using RNAseq-based detection of SNHG9, Kunadirek et al. confirmed that a high pre-treatment expression level of SNHG9 in peripheral blood mononuclear cells (PBMCs) was an independent predictor for a shorter OS (HR, 3.25; 95% CI, 1.40&#8211;7.53; P value&#8201;=&#8201;0.006) in 100 retrospectively recruited HBV-related HCC patients treated with transarterial chemoembolization (TACE) [<xref ref-type="bibr" rid="CR76">76</xref>]. Based on qRT-PCR analysis of urothelial carcinoma-associated 1 (UCA1), Zheng et al. verified that a high pre-treatment expression level of UCA1 in serum independently predicted a shorter OS (HR, 3.649; 95% CI, unreported; P value&#8201;=&#8201;0.016) in 105 retrospectively recruited HCC patients treated with curative surgical resection [<xref ref-type="bibr" rid="CR77">77</xref>].<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table&#160;1</label><caption><p>Independent prognostic significance of single lncRNA biomarkers in HCC patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Biomarkers</th><th align="left" colspan="1" rowspan="1">Sampling time</th><th align="left" colspan="1" rowspan="1">Sampling source</th><th align="left" colspan="1" rowspan="1">Detection method</th><th align="left" colspan="1" rowspan="1">Study design</th><th align="left" colspan="1" rowspan="1">Patients analyzed</th><th align="left" colspan="1" rowspan="1">Prognostic significance</th><th align="left" colspan="1" rowspan="1">Year</th><th align="left" colspan="1" rowspan="1">References</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">LINC00152</td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">qRT-PCR</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">63 HCC patients treated with curative surgical resection</td><td align="left" colspan="1" rowspan="1">High LINC00152 level predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2020</td><td align="left" colspan="1" rowspan="1">Wang et al. [<xref ref-type="bibr" rid="CR13">13</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">LINC00294</td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">ISH</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">94 HCC patients</td><td align="left" colspan="1" rowspan="1">High LINC01094 level predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2023</td><td align="left" colspan="1" rowspan="1">Zhang et al. [<xref ref-type="bibr" rid="CR14">14</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">LINC01094</td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">365 HCC patients</td><td align="left" colspan="1" rowspan="1">High LINC01094 level predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2024</td><td align="left" colspan="1" rowspan="1">Yang et al. [<xref ref-type="bibr" rid="CR15">15</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">LINC01139</td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">qRT-PCR</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">109 HCC patients treated with curative surgical resection</td><td align="left" colspan="1" rowspan="1">High LINC01139 level predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2020</td><td align="left" colspan="1" rowspan="1">Li et al. [<xref ref-type="bibr" rid="CR16">16</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">LINC01146</td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">qRT-PCR</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">85 HCC patients treated with curative surgical resection</td><td align="left" colspan="1" rowspan="1">High LINC01146 level predicted longer OS</td><td align="left" colspan="1" rowspan="1">2022</td><td align="left" colspan="1" rowspan="1">Ma et al. [<xref ref-type="bibr" rid="CR17">17</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">LINC01554</td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">qRT-PCR</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">167 HCC patients treated with curative surgical resection</td><td align="left" colspan="1" rowspan="1">Low LINC01554 level predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2019</td><td align="left" colspan="1" rowspan="1">Zheng et al. [<xref ref-type="bibr" rid="CR18">18</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">HOXC13-AS</td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">qRT-PCR</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">197 HCC patients treated with curative surgical resection</td><td align="left" colspan="1" rowspan="1">High HOXC13-AS level predicted shorter OS and RFS</td><td align="left" colspan="1" rowspan="1">2019</td><td align="left" colspan="1" rowspan="1">Zhou et al. [<xref ref-type="bibr" rid="CR19">19</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">LASP1-AS</td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">qRT-PCR</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">423 HCC patients treated with curative surgical resection</td><td align="left" colspan="1" rowspan="1">Low LASP1-AS level predicted shorter OS and RFS</td><td align="left" colspan="1" rowspan="1">2019</td><td align="left" colspan="1" rowspan="1">Yin et al. [<xref ref-type="bibr" rid="CR20">20</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">ELF3-AS1</td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">373 HCC patients</td><td align="left" colspan="1" rowspan="1">High ELF3-AS1 level predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2021</td><td align="left" colspan="1" rowspan="1">Chen et al. [<xref ref-type="bibr" rid="CR21">21</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">ELMO1-AS1</td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">qRT-PCR</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">222 HCC patients treated with curative surgical resection</td><td align="left" colspan="1" rowspan="1">High ELMO1-AS1 level predicted longer OS and RFS</td><td align="left" colspan="1" rowspan="1">2019</td><td align="left" colspan="1" rowspan="1">Luo et al. [<xref ref-type="bibr" rid="CR22">22</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">FOXP4-AS1</td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">qRT-PCR</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">121 HCC patients treated with curative surgical resection</td><td align="left" colspan="1" rowspan="1">High FOXP4-AS1 level predicted shorter OS and RFS</td><td align="left" colspan="1" rowspan="1">2021</td><td align="left" colspan="1" rowspan="1">Liang et al. [<xref ref-type="bibr" rid="CR23">23</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">GAS5-AS1</td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">qRT-PCR</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">83 HCC patients treated with curative surgical resection</td><td align="left" colspan="1" rowspan="1">High GAS5-AS1 level predicted longer OS</td><td align="left" colspan="1" rowspan="1">2018</td><td align="left" colspan="1" rowspan="1">Wang et al. [<xref ref-type="bibr" rid="CR24">24</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">HLA-F-AS1</td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">qRT-PCR</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">100 HBV-related HCC patients treated with curative surgical resection</td><td align="left" colspan="1" rowspan="1">High HLA-F-AS1 level predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2024</td><td align="left" colspan="1" rowspan="1">Zhang et al. [<xref ref-type="bibr" rid="CR25">25</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">INKA2-AS1</td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">374 HCC patients</td><td align="left" colspan="1" rowspan="1">High INKA2-AS1 level predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2023</td><td align="left" colspan="1" rowspan="1">Li et al. [<xref ref-type="bibr" rid="CR26">26</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">NIFK-AS1</td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">368 HCC patients</td><td align="left" colspan="1" rowspan="1">High NIFK-AS1 level predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2022</td><td align="left" colspan="1" rowspan="1">Song et al. [<xref ref-type="bibr" rid="CR27">27</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">POLH-AS1</td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">374 HCC patients</td><td align="left" colspan="1" rowspan="1">High POLH-AS1 level predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2024</td><td align="left" colspan="1" rowspan="1">Dong et al. [<xref ref-type="bibr" rid="CR28">28</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">PRR11-AS1</td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">343 HCC patients</td><td align="left" colspan="1" rowspan="1">High PRR11-AS1 level predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2024</td><td align="left" colspan="1" rowspan="1">Abulihaiti et al. [<xref ref-type="bibr" rid="CR29">29</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">RGMB-AS1</td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">qRT-PCR</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">108 HCC patients</td><td align="left" colspan="1" rowspan="1">High RGMB-AS1 level predicted longer OS</td><td align="left" colspan="1" rowspan="1">2018</td><td align="left" colspan="1" rowspan="1">Sheng et al. [<xref ref-type="bibr" rid="CR30">30</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">RHPN1-AS1</td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">qRT-PCR</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">127 HCC patients treated with curative surgical resection</td><td align="left" colspan="1" rowspan="1">High RHPN1-AS1 level predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2020</td><td align="left" colspan="1" rowspan="1">Zhang et al. [<xref ref-type="bibr" rid="CR31">31</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">RNASEH1-AS1</td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">370 HCC patients</td><td align="left" colspan="1" rowspan="1">High RNASEH1-AS1 level predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2024</td><td align="left" colspan="1" rowspan="1">Sun et al. [<xref ref-type="bibr" rid="CR32">32</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">SOX21-AS1</td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">qRT-PCR</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">68 HCC patients</td><td align="left" colspan="1" rowspan="1">High SOX21-AS1 level predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2018</td><td align="left" colspan="1" rowspan="1">Wei et al. [<xref ref-type="bibr" rid="CR33">33</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">THAP9-AS1</td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">qRT-PCR</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">79 HCC patients treated with curative surgical resection</td><td align="left" colspan="1" rowspan="1">High THAP9-AS1 level predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2022</td><td align="left" colspan="1" rowspan="1">Su et al. [<xref ref-type="bibr" rid="CR34">34</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">HOXA-AS2</td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">116 HCC patients treated with curative surgical resection</td><td align="left" colspan="1" rowspan="1">High HOXA-AS2 level predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2020</td><td align="left" colspan="1" rowspan="1">Lu et al. [<xref ref-type="bibr" rid="CR35">35</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">ZNF385D-AS2</td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">303 HCC patients</td><td align="left" colspan="1" rowspan="1">High ZNF385D-AS2 level predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2019</td><td align="left" colspan="1" rowspan="1">Zhang et al. [<xref ref-type="bibr" rid="CR36">36</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1"><ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC092171.4">AC092171.4</ext-link></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">qRT-PCR</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">95 HCC patients treated with curative surgical resection</td><td align="left" colspan="1" rowspan="1">High <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC092171.4">AC092171.4</ext-link> level predicted shorter OS and RFS</td><td align="left" colspan="1" rowspan="1">2020</td><td align="left" colspan="1" rowspan="1">Sun et al. [<xref ref-type="bibr" rid="CR37">37</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">BANCR</td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">qRT-PCR</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">109 HCC patients treated with curative surgical resection</td><td align="left" colspan="1" rowspan="1">High BANCR level predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2016</td><td align="left" colspan="1" rowspan="1">Zhou et al. [<xref ref-type="bibr" rid="CR38">38</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">CASC19</td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">qRT-PCR</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">124 HCC patients treated with curative surgical resection</td><td align="left" colspan="1" rowspan="1">High CASC19 level predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2023</td><td align="left" colspan="1" rowspan="1">Hou et al. [<xref ref-type="bibr" rid="CR39">39</xref>]</td></tr><tr><td align="left" rowspan="2" colspan="1">CCAT2</td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">qRT-PCR</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">96 HCC patients treated with curative surgical resection</td><td align="left" colspan="1" rowspan="1">High CCAT2 level predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2017</td><td align="left" colspan="1" rowspan="1">Xu et al. [<xref ref-type="bibr" rid="CR40">40</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">qRT-PCR</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">122 HCC patients treated with curative surgical resection</td><td align="left" colspan="1" rowspan="1">High CCAT2 level predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2019</td><td align="left" colspan="1" rowspan="1">Fu et al. [<xref ref-type="bibr" rid="CR41">41</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">CCHE1</td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">qRT-PCR</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">112 HCC patients treated with curative surgical resection</td><td align="left" colspan="1" rowspan="1">Low CCHE1 level predicted longer OS</td><td align="left" colspan="1" rowspan="1">2016</td><td align="left" colspan="1" rowspan="1">Peng et al. [<xref ref-type="bibr" rid="CR42">42</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">CTC-297N7.9</td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">368 HCC patients treated with curative surgical resection</td><td align="left" colspan="1" rowspan="1">High CTC-297N7.9 level predicted longer OS and RFS</td><td align="left" colspan="1" rowspan="1">2019</td><td align="left" colspan="1" rowspan="1">Zhu et al. [<xref ref-type="bibr" rid="CR43">43</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1"><ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="D16366">D16366</ext-link></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">qRT-PCR</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">107 HCC patients</td><td align="left" colspan="1" rowspan="1">Low <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="D16366">D16366</ext-link> level predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2019</td><td align="left" colspan="1" rowspan="1">Chao et al. [<xref ref-type="bibr" rid="CR44">44</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">DGCR5</td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">qRT-PCR</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">110 HCC patients treated with curative surgical resection</td><td align="left" colspan="1" rowspan="1">High DGCR5 level predicted longer CSS</td><td align="left" colspan="1" rowspan="1">2016</td><td align="left" colspan="1" rowspan="1">Huang et al. [<xref ref-type="bibr" rid="CR45">45</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1"><ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="DQ786243">DQ786243</ext-link></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">qRT-PCR</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">84 HCC patients</td><td align="left" colspan="1" rowspan="1">High <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="DQ786243">DQ786243</ext-link> level predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2018</td><td align="left" colspan="1" rowspan="1">Zeng et al. [<xref ref-type="bibr" rid="CR46">46</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">FAM99A</td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">qRT-PCR</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">62 HCC patients treated with curative surgical resection</td><td align="left" colspan="1" rowspan="1">High FAM99A level predicted longer OS</td><td align="left" colspan="1" rowspan="1">2022</td><td align="left" colspan="1" rowspan="1">Mo et al. [<xref ref-type="bibr" rid="CR47">47</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">GAS5</td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">qRT-PCR</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">71 HCC patients treated with curative surgical resection</td><td align="left" colspan="1" rowspan="1">High GAS5 level predicted longer OS</td><td align="left" colspan="1" rowspan="1">2014</td><td align="left" colspan="1" rowspan="1">Tu et al. [<xref ref-type="bibr" rid="CR48">48</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">GHET1</td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">qRT-PCR</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">68 HCC patients treated with curative surgical resection</td><td align="left" colspan="1" rowspan="1">High GHET1 level predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2018</td><td align="left" colspan="1" rowspan="1">Jin et al. [<xref ref-type="bibr" rid="CR49">49</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">HOTAIR</td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">qRT-PCR</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">60 HCC patients treated with liver transplantation</td><td align="left" colspan="1" rowspan="1">High HOTAIR level predicted shorter RFS</td><td align="left" colspan="1" rowspan="1">2011</td><td align="left" colspan="1" rowspan="1">Yang et al. [<xref ref-type="bibr" rid="CR50">50</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">HOTTIP</td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">qRT-PCR</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">155 HCC patients treated with liver transplantation</td><td align="left" colspan="1" rowspan="1">High HOTTIP level predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2018</td><td align="left" colspan="1" rowspan="1">Wu et al. [<xref ref-type="bibr" rid="CR51">51</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">JPX</td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">qRT-PCR</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">68 HCC patients treated with curative surgical resection</td><td align="left" colspan="1" rowspan="1">Low JPX level predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2017</td><td align="left" colspan="1" rowspan="1">Ma et al. [<xref ref-type="bibr" rid="CR52">52</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">LNCRNA-ATB</td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">qRT-PCR</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">75 HCC patients treated with curative surgical resection</td><td align="left" colspan="1" rowspan="1">High LNCRNA-ATB level predicted shorter OS and PFS</td><td align="left" colspan="1" rowspan="1">2017</td><td align="left" colspan="1" rowspan="1">Jang et al. [<xref ref-type="bibr" rid="CR53">53</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">LUCAT1</td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">371 HCC patients treated with radiation therapy</td><td align="left" colspan="1" rowspan="1">High LUCAT1 level predicted shorter OS and RFS</td><td align="left" colspan="1" rowspan="1">2019</td><td align="left" colspan="1" rowspan="1">Jiao et al. [<xref ref-type="bibr" rid="CR54">54</xref>]</td></tr><tr><td align="left" rowspan="2" colspan="1">MALAT1</td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">qRT-PCR</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">60 HCC patients treated with liver transplantation</td><td align="left" colspan="1" rowspan="1">High MALAT1 level predicted shorter RFS</td><td align="left" colspan="1" rowspan="1">2012</td><td align="left" colspan="1" rowspan="1">Lai et al. [<xref ref-type="bibr" rid="CR55">55</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">169 HCC patients</td><td align="left" colspan="1" rowspan="1">High MALAT1 level predicted shorter PFS</td><td align="left" colspan="1" rowspan="1">2022</td><td align="left" colspan="1" rowspan="1">Liao et al. [<xref ref-type="bibr" rid="CR56">56</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">MINCR</td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">qRT-PCR</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">161 HCC patients treated with curative surgical resection</td><td align="left" colspan="1" rowspan="1">High MINCR level predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2018</td><td align="left" colspan="1" rowspan="1">Jin et al. [<xref ref-type="bibr" rid="CR57">57</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">MIR4435-2HG</td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">qRT-PCR</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">88 HCC patients treated with curative surgical resection</td><td align="left" colspan="1" rowspan="1">High MIR4435-2HG level predicted shorter OS and RFS</td><td align="left" colspan="1" rowspan="1">2017</td><td align="left" colspan="1" rowspan="1">Zhao et al. [<xref ref-type="bibr" rid="CR58">58</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">MIR22HG</td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">qRT-PCR</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">145 HCC patients treated with curative surgical resection</td><td align="left" colspan="1" rowspan="1">High MIR22HG level predicted longer OS</td><td align="left" colspan="1" rowspan="1">2018</td><td align="left" colspan="1" rowspan="1">Zhang et al. [<xref ref-type="bibr" rid="CR59">59</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">MIR503HG</td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">qRT-PCR</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">93 HCC patients treated with curative surgical resection</td><td align="left" colspan="1" rowspan="1">High MIR503HG level predicted longer OS and TTR</td><td align="left" colspan="1" rowspan="1">2018</td><td align="left" colspan="1" rowspan="1">Wang et al. [<xref ref-type="bibr" rid="CR60">60</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">NKILA</td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">qRT-PCR</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">90 HCC patients treated with curative surgical resection</td><td align="left" colspan="1" rowspan="1">High NKILA level predicted longer OS</td><td align="left" colspan="1" rowspan="1">2020</td><td align="left" colspan="1" rowspan="1">Chen et al. [<xref ref-type="bibr" rid="CR61">61</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">NRAD1</td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">qRT-PCR</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">63 HCC patients treated with curative surgical resection</td><td align="left" colspan="1" rowspan="1">High NRAD1 level predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2020</td><td align="left" colspan="1" rowspan="1">Wang et al. [<xref ref-type="bibr" rid="CR13">13</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">PANDAR</td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">qRT-PCR</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">482 HCC patients treated with curative surgical resection</td><td align="left" colspan="1" rowspan="1">High PANDAR level predicted shorter OS and TTR</td><td align="left" colspan="1" rowspan="1">2015</td><td align="left" colspan="1" rowspan="1">Peng et al. [<xref ref-type="bibr" rid="CR62">62</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">PCAT1</td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">qRT-PCR</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">117 HCC patients treated with curative surgical resection</td><td align="left" colspan="1" rowspan="1">High PCAT1 level predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2015</td><td align="left" colspan="1" rowspan="1">Yan et al. [<xref ref-type="bibr" rid="CR63">63</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">POLR2J4</td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">qRT-PCR</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">109 HBV-related HCC patients</td><td align="left" colspan="1" rowspan="1">High POLR2J4 level predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2024</td><td align="left" colspan="1" rowspan="1">Ji et al. [<xref ref-type="bibr" rid="CR64">64</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">POU3F3</td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">qRT-PCR</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">104 HCC patients</td><td align="left" colspan="1" rowspan="1">High POU3F3 level predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2018</td><td align="left" colspan="1" rowspan="1">Li et al. [<xref ref-type="bibr" rid="CR65">65</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">PTTG3P</td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">353 HCC patients treated with radiation therapy</td><td align="left" colspan="1" rowspan="1">High PTTG3P level predicted shorter OS and RFS</td><td align="left" colspan="1" rowspan="1">2019</td><td align="left" colspan="1" rowspan="1">Bai et al. [<xref ref-type="bibr" rid="CR66">66</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">SNHG3</td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">qRT-PCR</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">144 HCC patients treated with curative surgical resection</td><td align="left" colspan="1" rowspan="1">High SNHG3 level predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2016</td><td align="left" colspan="1" rowspan="1">Zhang et al. [<xref ref-type="bibr" rid="CR67">67</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">SNHG15</td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">152 HCC patients treated with curative surgical resection</td><td align="left" colspan="1" rowspan="1">High SNHG15 level predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2016</td><td align="left" colspan="1" rowspan="1">Zhang et al. [<xref ref-type="bibr" rid="CR68">68</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">SNHG16</td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">158 HCC patients treated with liver transplantation</td><td align="left" colspan="1" rowspan="1">High SNHG16 level predicted shorter OS and RFS</td><td align="left" colspan="1" rowspan="1">2022</td><td align="left" colspan="1" rowspan="1">Zhang et al. [<xref ref-type="bibr" rid="CR69">69</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">SOX2-OT</td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">qRT-PCR</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">84 HCC patients treated with curative surgical resection</td><td align="left" colspan="1" rowspan="1">High SOX2-OT level predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2015</td><td align="left" colspan="1" rowspan="1">Shi et al. [<xref ref-type="bibr" rid="CR70">70</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">SUMO1P3</td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">qRT-PCR</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">113 HCC patients treated with curative surgical resection</td><td align="left" colspan="1" rowspan="1">High SUMO1P3 level predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2020</td><td align="left" colspan="1" rowspan="1">Yu et al. [<xref ref-type="bibr" rid="CR71">71</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">TRERNA1</td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">ISH</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">111 HCC patients treated with curative surgical resection</td><td align="left" colspan="1" rowspan="1">High TRERNA1 level predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2021</td><td align="left" colspan="1" rowspan="1">Qian et al. [<xref ref-type="bibr" rid="CR72">72</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">W5</td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">qRT-PCR</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">86 HCC patients treated with curative surgical resection</td><td align="left" colspan="1" rowspan="1">Low W5 level predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2021</td><td align="left" colspan="1" rowspan="1">Lei et al. [<xref ref-type="bibr" rid="CR73">73</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1"><ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="X91348">X91348</ext-link></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">qRT-PCR</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">107 HCC patients</td><td align="left" colspan="1" rowspan="1">Low <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="X91348">X91348</ext-link> level predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2019</td><td align="left" colspan="1" rowspan="1">Zeng et al. [<xref ref-type="bibr" rid="CR74">74</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">XIST</td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">qRT-PCR</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">68 HCC patients treated with curative surgical resection</td><td align="left" colspan="1" rowspan="1">Low XIST level predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2017</td><td align="left" colspan="1" rowspan="1">Ma et al. [<xref ref-type="bibr" rid="CR52">52</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">CRNDE</td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Serum exosome</td><td align="left" colspan="1" rowspan="1">qRT-PCR</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">166 HCC patients</td><td align="left" colspan="1" rowspan="1">High CRNDE level predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2021</td><td align="left" colspan="1" rowspan="1">Wang et al. [<xref ref-type="bibr" rid="CR75">75</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">SNHG9</td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">PBMC</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">100 HBV-related HCC patients treated with TACE</td><td align="left" colspan="1" rowspan="1">High SNHG9 level predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2022</td><td align="left" colspan="1" rowspan="1">Kunadirek et al. [<xref ref-type="bibr" rid="CR76">76</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">UCA1</td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Serum</td><td align="left" colspan="1" rowspan="1">qRT-PCR</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">105 HCC patients treated with curative surgical resection</td><td align="left" colspan="1" rowspan="1">High UCA1 level predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2018</td><td align="left" colspan="1" rowspan="1">Zheng et al. [<xref ref-type="bibr" rid="CR77">77</xref>]</td></tr></tbody></table><table-wrap-foot><p>lncRNA, long non-coding RNA; HCC, hepatocellular carcinoma; LINC, long intergenic non-protein coding RNA; qRT-PCR, quantitative reverse-transcription polymerase chain reaction; OS, overall survival; ISH, in situ hybridization; RNAseq, RNA sequencing; HOXC13-AS, homeobox C13 antisense RNA; RFS, recurrence-free survival; LASP1-AS, LIM and SH3 protein 1 antisense RNA; ELF3-AS1, E74 like ETS transcription factor 3 antisense RNA 1; ELMO1-AS1, engulfment and cell motility 1 antisense RNA 1; FOXP4-AS1, forkhead box P4 antisense RNA 1; GAS5-AS1, growth arrest specific 5 antisense RNA 1; HLA-F-AS1, major histocompatibility complex, class I, F antisense RNA 1; INKA2-AS1, inka box actin regulator 2 antisense RNA 1; NIFK-AS1, nucleolar protein interacting with the FHA domain of MKI67 antisense RNA 1; POLH-AS1, DNA polymerase eta antisense RNA 1; PRR11-AS1, proline rich 11 antisense RNA 1; RGMB-AS1, repulsive guidance molecule BMP co-receptor b antisense RNA 1; RHPN1-AS1, rhophilin Rho GTPase binding protein 1 antisense RNA 1; RNASEH1-AS1, ribonuclease H1 antisense RNA 1; SOX21-AS1, SRY-box transcription factor 21 antisense RNA 1; THAP9-AS1, THAP domain containing 9 antisense RNA 1; HOXA-AS2, homeobox A antisense RNA 2; ZNF385D-AS2, zinc finger protein 385D antisense RNA 2; BANCR, BRAF-activated non-protein coding RNA; CASC19, cancer susceptibility 19; CCAT2, colon cancer associated transcript 2; CCHE1, cervical carcinoma high-expressed lncRNA 1; DGCR5, DiGeorge syndrome critical region gene 5; CSS, cancer-specific survival; FAM99A, family with sequence similarity 99 member A; GAS5, growth arrest specific 5; GHET1, gastric carcinoma proliferation enhancing transcript 1; HOTAIR, HOX transcript antisense RNA; HOTTIP, HOXA distal transcript antisense RNA; JPX, JPX transcript, XIST activator; LNCRNA-ATB, lncRNA activated by TGF-beta; PFS, progression-free survival; LUCAT1, lung cancer associated transcript 1; MALAT1, metastasis-associated lung adenocarcinoma transcript 1; MINCR, MYC-induced long non-coding RNA; MIR4435-2HG, MIR4435-2 host gene; MIR22HG, MIR22 host gene; MIR503HG, MIR503 host gene; TTR, time to recurrence; NKILA, NF-kappaB interacting lncRNA; NRAD1, non-coding RNA in the aldehyde dehydrogenase 1A pathway; PANDAR, promoter of CDKN1A antisense DNA damage activated RNA; PCAT1, prostate cancer associated transcript 1; POLR2J4, RNA polymerase II subunit J4 (pseudogene); HBV, hepatitis B virus; POU3F3, POU class 3 homeobox 3; PTTG3P, pituitary tumor-transforming 3, pseudogene; SNHG, small nucleolar RNA host gene; SOX2-OT, SOX2 overlapping transcript; SUMO1P3, small ubiquitin-like modifier 1 pseudogene 3; TRERNA1, translation regulatory long non-coding RNA 1; XIST, X inactive specific transcript; CRNDE, colorectal neoplasia differentially expressed; PBMC, peripheral blood mononuclear cell; TACE, transarterial chemoembolization; UCA1, urothelial carcinoma-associated 1</p></table-wrap-foot></table-wrap><table-wrap id="Tab2" position="float" orientation="portrait"><label>Table&#160;2</label><caption><p>Independent prognostic significance of combination lncRNA biomarkers in HCC patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Biomarkers<sup>a,b</sup></th><th align="left" colspan="1" rowspan="1">Sampling time</th><th align="left" colspan="1" rowspan="1">Sampling source</th><th align="left" colspan="1" rowspan="1">Detection method</th><th align="left" colspan="1" rowspan="1">Study design</th><th align="left" colspan="1" rowspan="1">Patients analyzed</th><th align="left" colspan="1" rowspan="1">Prognostic significance</th><th align="left" colspan="1" rowspan="1">Year</th><th align="left" colspan="1" rowspan="1">References</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Four lncRNAs signature (LINC00261, CDKN2B-AS1, GBP1P1, and TREML3P)<sup>c</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">317 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2018</td><td align="left" colspan="1" rowspan="1">Sui et al. [<xref ref-type="bibr" rid="CR78">78</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Four lncRNAs signature (CTD-2574D22.4, MIR100HG, SERHL, and SNHG20)<sup>d</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">364 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2018</td><td align="left" colspan="1" rowspan="1">Ma et al. [<xref ref-type="bibr" rid="CR79">79</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Five lncRNAs signature (DCST1-AS1, FOXD2-AS1, TMCC1-AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC015908.3">AC015908.3</ext-link>, and <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC091057.3">AC091057.3</ext-link>)<sup>e</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">370 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2018</td><td align="left" colspan="1" rowspan="1">Zhao et al. [<xref ref-type="bibr" rid="CR80">80</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Thirteen lncRNAs signature (F11-AS1, FOXD2-AS1, TMCC1-AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC009005.1">AC009005.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC012339.1">AC012339.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC015908.3">AC015908.3</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC089983.1">AC089983.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC093609.1">AC093609.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC124067.4">AC124067.4</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL592043.1">AL592043.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL592466.1">AL592466.1</ext-link>, FLJ36000, and MIR663AHG)<sup>f</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">370 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2018</td><td align="left" colspan="1" rowspan="1">Liao et al. [<xref ref-type="bibr" rid="CR81">81</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Five lncRNAs signature (LINC02249, DLX2-AS1, RP11-100L22.4, RP11-104L21.3, and RP11-325L7.2)<sup>g</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">167 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2019</td><td align="left" colspan="1" rowspan="1">Sun et al. [<xref ref-type="bibr" rid="CR82">82</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Six lncRNAs signature (EIF3J-AS1, MSC-AS1, POLR2J4, PVT1, RMST, and SERHL)<sup>h</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">442 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter RFS</td><td align="left" colspan="1" rowspan="1">2019</td><td align="left" colspan="1" rowspan="1">Gu et al. [<xref ref-type="bibr" rid="CR83">83</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Seven lncRNAs signature (ZFPM2&#8208;AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC009005.2">AC009005.2</ext-link>, RP11&#8208;190C22.8, RP11&#8208;363N22.3, RP11&#8208;388C12.8, RP11&#8208;572O6.1, and RP11&#8208;932O9.10)<sup>i</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">308 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2019</td><td align="left" colspan="1" rowspan="1">Yan et al. [<xref ref-type="bibr" rid="CR84">84</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Ten lncRNAs signature (LINC00856, LINC01116, LINC01559, LINC02003, MYLK-AS1, RASGRF2-AS1, RP11-150,012.3, RP11-92C4.6, RP11-363N22.3, and RRM2)<sup>j</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">696 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2019</td><td align="left" colspan="1" rowspan="1">Zhang et al. [<xref ref-type="bibr" rid="CR85">85</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Three lncRNAs signature (RP11-150O12.3, RP11-187E13.1, and RP13-143G15.4)<sup>k</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">307 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted longer OS</td><td align="left" colspan="1" rowspan="1">2020</td><td align="left" colspan="1" rowspan="1">Yu et al. [<xref ref-type="bibr" rid="CR86">86</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Four lncRNAs signature (RUSC1&#8208;AS1, STEAP3&#8208;AS1, SNHG1, and SNHG3)<sup>l</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">157 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2020</td><td align="left" colspan="1" rowspan="1">Gu et al. [<xref ref-type="bibr" rid="CR87">87</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Four lncRNAs signature (LINC02334, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC012640.1">AC012640.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC013451.2">AC013451.2</ext-link>, and <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC062004.1">AC062004.1</ext-link>)<sup>m</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">337 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2020</td><td align="left" colspan="1" rowspan="1">Luo et al. [<xref ref-type="bibr" rid="CR88">88</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Five lncRNAs signature (LINC02043, LINC01605, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC062004.1">AC062004.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL139385">AL139385</ext-link>, and ERVH48-1)<sup>n</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">337 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter RFS</td><td align="left" colspan="1" rowspan="1">2020</td><td align="left" colspan="1" rowspan="1">Luo et al. [<xref ref-type="bibr" rid="CR88">88</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Four lncRNAs signature (LINC00556, RP11&#8208;359K18.3, RP11&#8208;495K9.6, and RP11&#8208;96O20.2)<sup>o</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">180 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2020</td><td align="left" colspan="1" rowspan="1">Jiang et al. [<xref ref-type="bibr" rid="CR89">89</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Four lncRNAs signature (LINC01116, DDX11-AS1, LUCAT1, and FIRRE)<sup>p</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">qRT-PCR</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">50 HBV-related HCC patients treated with curative surgical resection</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2020</td><td align="left" colspan="1" rowspan="1">Wu et al. [<xref ref-type="bibr" rid="CR90">90</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Eight lncRNAs signature (LINC00506, LINC00511, LINC01136, KRTAP5-AS1, MKLN1-AS, THUMPD3-AS1, TSPEAR-AS1, and ZNF252P-AS1)<sup>q</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">95 HBV-related HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2020</td><td align="left" colspan="1" rowspan="1">Zhao et al. [<xref ref-type="bibr" rid="CR91">91</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Two lncRNAs signature (CTD-2510F5.4 and DSTNP2)<sup>r</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">220 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2021</td><td align="left" colspan="1" rowspan="1">Zhou et al. [<xref ref-type="bibr" rid="CR92">92</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Six lncRNAs signature (LINC02870, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC012640.1">AC012640.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC090921.1">AC090921.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL158839.1">AL158839.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL356056.1">AL356056.1</ext-link>, and AL359853.1)<sup>s</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">338 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2021</td><td align="left" colspan="1" rowspan="1">Wu et al. [<xref ref-type="bibr" rid="CR93">93</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Nine lncRNAs signature (LINC01447, PLCE1-AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL158839.1">AL158839.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL356056.1">AL356056.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL445493.2">AL445493.2</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AP000808.1">AP000808.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AP003354.2">AP003354.2</ext-link>, MIR7-3HG, and TH2LCRR)<sup>t</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">338 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter RFS</td><td align="left" colspan="1" rowspan="1">2021</td><td align="left" colspan="1" rowspan="1">Wu et al. [<xref ref-type="bibr" rid="CR93">93</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Four lncRNAs signature (LINC00942, SRGAP3-AS2, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC010280.2">AC010280.2</ext-link>, and <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AP000844.2">AP000844.2</ext-link>)<sup>u</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">120 HCC patients</td><td align="left" colspan="1" rowspan="1">Low signature score predicted longer OS and RFS</td><td align="left" colspan="1" rowspan="1">2022</td><td align="left" colspan="1" rowspan="1">Xu et al. [<xref ref-type="bibr" rid="CR94">94</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Six lncRNAs signature (LINC02163, LINC02362, LINC02428, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC008549.1">AC008549.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC115619.1">AC115619.1</ext-link>, and CASC9)<sup>v</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">365 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2023</td><td align="left" colspan="1" rowspan="1">Gan et al. [<xref ref-type="bibr" rid="CR95">95</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Four cell cycle-related lncRNAs signature (TMCC1-AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC009549.1">AC009549.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC090018.2">AC090018.2</ext-link>, and PKD1P6-NPIPP1)<sup>w</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">370 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2024</td><td align="left" colspan="1" rowspan="1">Chen et al. [<xref ref-type="bibr" rid="CR96">96</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Two cellular senescence-related lncRNAs signature (AGAP11 and FAM182B)<sup>x</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">502 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2023</td><td align="left" colspan="1" rowspan="1">Huang et al. [<xref ref-type="bibr" rid="CR97">97</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Four oxidative stress-related lncRNAs signature (LINC02870, MKLN1-AS, TMCC1-AS1, and NRAV)<sup>y</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">343 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2022</td><td align="left" colspan="1" rowspan="1">Zhong et al. [<xref ref-type="bibr" rid="CR98">98</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Two ECM-related lncRNAs signature (MKLN1-AS and AL031985.3)<sup>z</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">365 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2022</td><td align="left" colspan="1" rowspan="1">Wu et al. [<xref ref-type="bibr" rid="CR99">99</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Six tumor microenvironment-related lncRNAs signature (LINC00426, LINC01150, LINC02273, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC007277.1">AC007277.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC008549.1">AC008549.1</ext-link>, and <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AP002954.1">AP002954.1</ext-link>)<sup>aa</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">365 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2021</td><td align="left" colspan="1" rowspan="1">Huang et al. [<xref ref-type="bibr" rid="CR100">100</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Five anoikis-related lncRNAs signature (MKLN1-AS, DDX11-AS1, TMCC1-AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC026412.3">AC026412.3</ext-link>, and AL031985.3)<sup>ab</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">377 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2024</td><td align="left" colspan="1" rowspan="1">Zhu et al. [<xref ref-type="bibr" rid="CR101">101</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Five PANoptosis-related lncRNAs signature (LINC01224, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC026356.1">AC026356.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC026412.3">AC026412.3</ext-link><bold>,</bold> <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL442125.2">AL442125.2</ext-link>, and MIR4435-2HG)<sup>ac</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">370 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2025</td><td align="left" colspan="1" rowspan="1">Shu et al. [<xref ref-type="bibr" rid="CR102">102</xref>]</td></tr><tr><td align="left" colspan="9" rowspan="1"><bold>Methylation-related lncRNAs</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Four methylated lncRNAs signature (LINC01164, LINC01183, LINC01269, and <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC025016.1">AC025016.1</ext-link>)<sup>ad</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">348 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2020</td><td align="left" colspan="1" rowspan="1">Liao et al. [<xref ref-type="bibr" rid="CR103">103</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Nine m6A regulator-related lncRNAs signature (LINC01138, LINC01224, LINC03124, MKLN1-AS, POLH-AS1, AL031985.3, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL117336.2">AL117336.2</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL158166.1">AL158166.1</ext-link>, and <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL442125.2">AL442125.2</ext-link>)<sup>ae</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">342 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2021</td><td align="left" colspan="1" rowspan="1">Jin et al. [<xref ref-type="bibr" rid="CR104">104</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Eight m6A methyltransferase-related lncRNAs signature (LINC01093, LINC02362, GAS5, SNHG6, SNHG7, SNHG17, SNHG20, and ZFAS1)<sup>af</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">260 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2021</td><td align="left" colspan="1" rowspan="1">Li et al. [<xref ref-type="bibr" rid="CR105">105</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Four m6A-related lncRNAs signature (PTOV1-AS1, AC145207.5, AL031985.3, and NRAV)<sup>ag</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">343 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2022</td><td align="left" colspan="1" rowspan="1">Chen et al. [<xref ref-type="bibr" rid="CR106">106</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Nine m7G-related lncRNAs signature (SOCS2-AS1, NAV2-AS4, RP5-1171I10.5, RP11-10A14.3, RP11-43F13.3, RP11-519G16.5, RP11-588H23.3, RP11-874J12.4, and RP11-95O2.5)<sup>ah</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">365 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2022</td><td align="left" colspan="1" rowspan="1">Wei et al. [<xref ref-type="bibr" rid="CR107">107</xref>]</td></tr><tr><td align="left" colspan="9" rowspan="1"><bold>EMT-related lncRNAs</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Five EMT-related lncRNAs signature (<ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC023157.3">AC023157.3</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC099850.3">AC099850.3</ext-link>, AL031985.3, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL365203.2">AL365203.2</ext-link>, and CYTOR)<sup>ai</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">370 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2021</td><td align="left" colspan="1" rowspan="1">Xu et al. [<xref ref-type="bibr" rid="CR108">108</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Five EMT-related lncRNAs signature (LINC01116, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC009005.1">AC009005.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC011352.3">AC011352.3</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC025176.1">AC025176.1</ext-link>, and <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AP002478.1">AP002478.1</ext-link>)<sup>aj</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">368 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2022</td><td align="left" colspan="1" rowspan="1">Tao et al. [<xref ref-type="bibr" rid="CR109">109</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Nine EMT-related lncRNAs signature (ELFN1-AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC009005.1">AC009005.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC022424.1">AC022424.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC026369.2">AC026369.2</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC068506.1">AC068506.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC068580.1">AC068580.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC079305.2">AC079305.2</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL049840.6">AL049840.6</ext-link>, and lnc-CCNY-1)<sup>ak</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">377 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2022</td><td align="left" colspan="1" rowspan="1">Zhou et al. [<xref ref-type="bibr" rid="CR110">110</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Three EMT-related lncRNAs signature (ZFPM2-AS1, AC005332.3, and lnc-CCNY-1)<sup>al</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">377 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter RFS</td><td align="left" colspan="1" rowspan="1">2022</td><td align="left" colspan="1" rowspan="1">Zhou et al. [<xref ref-type="bibr" rid="CR110">110</xref>]</td></tr><tr><td align="left" colspan="9" rowspan="1"><bold>Genomic instability-related lncRNAs</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Three genomic instability-related lncRNAs signature (ZFPM2-AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC004862.1">AC004862.1</ext-link>, and <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC145343.1">AC145343.1</ext-link>)<sup>am</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">364 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2021</td><td align="left" colspan="1" rowspan="1">Huang et al. [<xref ref-type="bibr" rid="CR111">111</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Four genomic instability-related lncRNAs signature (PRRT3-AS1, ZFPM2-AS1, LUCAT1, and MIR210HG)<sup>an</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">249 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2021</td><td align="left" colspan="1" rowspan="1">Tang et al. [<xref ref-type="bibr" rid="CR112">112</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Four genomic instability-related lncRNAs signature (ZFPM2-AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC116351.1">AC116351.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC145343.1">AC145343.1</ext-link>, and MIR210HG)<sup>ao</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">370 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2021</td><td align="left" colspan="1" rowspan="1">Wu et al. [<xref ref-type="bibr" rid="CR113">113</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Eleven genomic instability-related lncRNAs signature (LINC00501, LINC01508, LINC02055, LINC02714, AC002511.2, LOC105371967, RP11-305F18.1, RP11-342M1.3, RP11-432J24.3, RP11-96A15.1, and <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="U95743.1">U95743.1</ext-link>)<sup>ap</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">365 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2022</td><td align="left" colspan="1" rowspan="1">Jin et al. [<xref ref-type="bibr" rid="CR114">114</xref>]</td></tr><tr><td align="left" colspan="9" rowspan="1"><bold>Metabolism-related lncRNAs</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Five metabolism-related lncRNAs signature (<ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC099850.3">AC099850.3</ext-link>, AL031985.3, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL365203.2">AL365203.2</ext-link>, LUCAT1, and MIR210HG)<sup>aq</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">370 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2022</td><td align="left" colspan="1" rowspan="1">Wang et al. [<xref ref-type="bibr" rid="CR115">115</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Nine metabolism-related lncRNAs signature (POLH-AS1, TMCC1-AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC004816.1">AC004816.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC107959.3">AC107959.3</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL117336.2">AL117336.2</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC124798.1">AC124798.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC125437.1">AC125437.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC145343.1">AC145343.1</ext-link>, and SNHG4)<sup>ar</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">343 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2022</td><td align="left" colspan="1" rowspan="1">Wang et al. [<xref ref-type="bibr" rid="CR116">116</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Six cholesterol metabolism-related lncRNAs signature (WAC-AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC022613.1">AC022613.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC103760.1">AC103760.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC124798.1">AC124798.1</ext-link>, AL031985.3, and NRAV)<sup>as</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">342 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2024</td><td align="left" colspan="1" rowspan="1">Lei et al. [<xref ref-type="bibr" rid="CR117">117</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Five bile acid and bile salt metabolism-related lncRNAs signature (<ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC015908.3">AC015908.3</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL031722.1">AL031722.1</ext-link>, AL031985.3, LUCAT1, and PCCA-DT)<sup>at</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">343 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2023</td><td align="left" colspan="1" rowspan="1">Cui et al. [<xref ref-type="bibr" rid="CR118">118</xref>]</td></tr><tr><td align="left" colspan="9" rowspan="1"><bold>Immune-related lncRNAs</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Ten immune-related lncRNAs signature (LINC00200, LINC00426, LINC00623, LINC01096, LINC01554, HPN&#8208;AS1, PRKCQ&#8208;AS1, FIRRE, MIR99AHG, and SCARNA9)<sup>au</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">483 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2020</td><td align="left" colspan="1" rowspan="1">Zhang et al. [<xref ref-type="bibr" rid="CR119">119</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Seven immune-related lncRNAs signature (LINC00942, MSC-AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC007405.3">AC007405.3</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC023157.3">AC023157.3</ext-link>, CASC19, GASAL1, and NRAV)<sup>av</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">370 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2021</td><td align="left" colspan="1" rowspan="1">Xu et al. [<xref ref-type="bibr" rid="CR120">120</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Nine immune-related lncRNAs signature (LINC00205, LINC01232, DCST1-AS1, SREBF2-AS1, TMEM220-AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL049840.2">AL049840.2</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL139260.1">AL139260.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="CR936218.2">CR936218.2</ext-link>, and LUCAT1)<sup>aw</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">370 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2021</td><td align="left" colspan="1" rowspan="1">Yuan et al. [<xref ref-type="bibr" rid="CR121">121</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Four immune-related lncRNAs signature (ZFPM2-AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC015908.3">AC015908.3</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC099850.3">AC099850.3</ext-link><italic toggle="yes">,</italic> and NRAV)<sup>ax</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">342 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2022</td><td align="left" colspan="1" rowspan="1">Li et al. [<xref ref-type="bibr" rid="CR122">122</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Six immune-related lncRNAs signature (LINC01224, PRRT3-AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC099850.4">AC099850.4</ext-link>, AL031985.3, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL365203.2">AL365203.2</ext-link>, and NRAV)<sup>ay</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">329 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2022</td><td align="left" colspan="1" rowspan="1">Wang et al. [<xref ref-type="bibr" rid="CR123">123</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Nine immune-related lncRNAs signature (LINC00856, PGM5P3-AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC011287.1">AC011287.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC019257.1">AC019257.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC027288.1">AC027288.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC110285.3">AC110285.3</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL161431.1">AL161431.1</ext-link>, APCDD1L-DT, and WARS2-IT1)<sup>az</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">374 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2022</td><td align="left" colspan="1" rowspan="1">Xin et al. [<xref ref-type="bibr" rid="CR124">124</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Six immune-related lncRNAs signature (LINC01011, LINC01224, RHPN1-AS1, CTD-2510F5.4, RP1-228H13.5, and RP11-324I22.4)<sup>ba</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">370 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2023</td><td align="left" colspan="1" rowspan="1">Lu et al. [<xref ref-type="bibr" rid="CR125">125</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Six immune-related lncRNAs signature (MSC-AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC009005.1">AC009005.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC099850.3">AC099850.3</ext-link>, AL031985.3, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL117336.3">AL117336.3</ext-link>, and <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL365203.2">AL365203.2</ext-link>)<sup>bb</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">373 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2024</td><td align="left" colspan="1" rowspan="1">Kong et al. [<xref ref-type="bibr" rid="CR126">126</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Four immune- and immunogenic cell death-related lncRNAs signature (LINC01554, LINC02362, LINC02499, and TMEM220-AS1)<sup>bc</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">370 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2022</td><td align="left" colspan="1" rowspan="1">He et al. [<xref ref-type="bibr" rid="CR127">127</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Five costimulatory molecule-related lncRNAs signature (BOK-AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC099850.3">AC099850.3</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL049840.4">AL049840.4</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL365203.2">AL365203.2</ext-link>, and NRAV)<sup>bd</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">343 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2022</td><td align="left" colspan="1" rowspan="1">Wang et al. [<xref ref-type="bibr" rid="CR128">128</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Seven antigen-presenting cells- and T-cell infiltration-related lncRNAs signature (LINC01871, LINC02321, LINC02362, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC073611.1">AC073611.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL050341.2">AL050341.2</ext-link>, LUCAT1, and ZNF582-AS1)<sup>be</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">805 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2023</td><td align="left" colspan="1" rowspan="1">Wang et al. [<xref ref-type="bibr" rid="CR129">129</xref>]</td></tr><tr><td align="left" colspan="9" rowspan="1"><bold>Autophagy-related lncRNAs</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Five autophagy-related lncRNAs signature (LINC01063, MKLN1-AS, PLBS1-AS1, TMMC1-AS1, and CYTOR)<sup>bf</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">370 HCC patients</td><td align="left" colspan="1" rowspan="1">Low signature score predicted longer OS</td><td align="left" colspan="1" rowspan="1">2020</td><td align="left" colspan="1" rowspan="1">Deng et al. [<xref ref-type="bibr" rid="CR130">130</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Four autophagy-related lncRNAs signature (BACE1-AS, ZEB1-AS1, MIR210HG, and SNHG3)<sup>bg</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">573 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2021</td><td align="left" colspan="1" rowspan="1">Deng et al. [<xref ref-type="bibr" rid="CR131">131</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Seven autophagy-related lncRNAs signature (LINC01138, PRRT3-AS1, CTD-2510F5.4, CTC-297N7.9, RP11-324I22.4, RP11-479G22.8, and RP11-73M18.8)<sup>bh</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">147 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2021</td><td align="left" colspan="1" rowspan="1">Yang et al. [<xref ref-type="bibr" rid="CR132">132</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Three immune- and autophagy-related lncRNAs signature (<ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC099850.3">AC099850.3</ext-link>, CYTOR, and MIR210HG)<sup>bi</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">163 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2021</td><td align="left" colspan="1" rowspan="1">Wang et al. [<xref ref-type="bibr" rid="CR133">133</xref>]</td></tr><tr><td align="left" colspan="9" rowspan="1"><bold>Ferroptosis-related lncRNAs</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Eight immune- and ferroptosis-related lncRNAs signature (LINC01224, GDNF-AS1, ZFPM2-AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC009005.1">AC009005.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC092119.2">AC092119.2</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC099850.3">AC099850.3</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL356234.2">AL356234.2</ext-link>, and LUCAT1)<sup>bj</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">363 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2021</td><td align="left" colspan="1" rowspan="1">Huang et al. [<xref ref-type="bibr" rid="CR134">134</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Five ferroptosis-related lncRNAs signature (<ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC099850.3">AC099850.3</ext-link>, AL031985.3, AL049840.5, LNCSRLR, and NRAV)<sup>bk</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">222 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2022</td><td align="left" colspan="1" rowspan="1">Li et al. [<xref ref-type="bibr" rid="CR135">135</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Six ferroptosis-related lncRNAs signature (LINC00942, LINC01224, MKLN1-AS, POLH-AS1, AL031985.3, and PCAT6)<sup>bl</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">370 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2022</td><td align="left" colspan="1" rowspan="1">Fang et al. [<xref ref-type="bibr" rid="CR136">136</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Seven ferroptosis-related lncRNAs signature (LINC00668, LINC01224, LINC01269, FOXD2-AS1, MKLN1-AS, MSC-AS1, and TMCC1-AS1)<sup>bm</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">363 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2022</td><td align="left" colspan="1" rowspan="1">Wang et al. [<xref ref-type="bibr" rid="CR137">137</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Sixteen ferroptosis-related lncRNAs signature (LINC01871, TMEM220-AS1, ZFPM2-AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC009005.1">AC009005.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC009403.1">AC009403.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC009779.2">AC009779.2</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC012467.2">AC012467.2</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC026369.2">AC026369.2</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC068580.3">AC068580.3</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC074117.1">AC074117.1</ext-link>, AL031985.3, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL139384.1">AL139384.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL365203.2">AL365203.2</ext-link>, LUCAT1, MIR210HG, and NRAV)<sup>bn</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">364 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2022</td><td align="left" colspan="1" rowspan="1">Lian et al. [<xref ref-type="bibr" rid="CR138">138</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Seventeen ferroptosis-related lncRNAs signature (LINC00205, LINC00942, MKLN1-AS, POLH-AS1, ZFPM2-AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC012073.1">AC012073.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC026401.3">AC026401.3</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC090772.3">AC090772.3</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC099850.1">AC099850.1</ext-link>, AC145207.8, AL031985.3, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL139384.1">AL139384.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL603839.3">AL603839.3</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL928654.1">AL928654.1</ext-link>, AP001469.3, SNHG10, and SNHG21)<sup>bo</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">370 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2022</td><td align="left" colspan="1" rowspan="1">Lin et al. [<xref ref-type="bibr" rid="CR139">139</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Seventeen ferroptosis-related lncRNAs signature (LINC00205, LINC00942, MKLN1-AS, POLH-AS1, ZFPM2-AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC012073.1">AC012073.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC026401.3">AC026401.3</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC090772.3">AC090772.3</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC099850.1">AC099850.1</ext-link>, AC145207.8, AL031985.3, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL139384.1">AL139384.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL603839.3">AL603839.3</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL928654.1">AL928654.1</ext-link>, AP001469.3, SNHG10, and SNHG21)<sup>bp</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">376 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2022</td><td align="left" colspan="1" rowspan="1">Yang et al. [<xref ref-type="bibr" rid="CR140">140</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Seven ferroptosis-related lncRNAs signature (LINC00942, MKLN1-AS, POLH-AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC009403.1">AC009403.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC090772.3">AC090772.3</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC131009.1">AC131009.1</ext-link>, and AL031985.3)<sup>bq</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">370 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2024</td><td align="left" colspan="1" rowspan="1">Wang et al. [<xref ref-type="bibr" rid="CR141">141</xref>]</td></tr><tr><td align="left" colspan="9" rowspan="1"><bold>Necroptosis-related lncRNAs</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Eight necroptosis-related lncRNAs signature (LINC01224, MKLN1-AS, POLH-AS1, PRRT3-AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC040970.1">AC040970.1</ext-link>, AL031985.3, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL928654.1">AL928654.1</ext-link>, and LUCAT1)<sup>br</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">260 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2023</td><td align="left" colspan="1" rowspan="1">Zhang et al. [<xref ref-type="bibr" rid="CR142">142</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Five necroptosis-related lncRNAs signature (BACE1-AS, KDM4A-AS1, MKLN1-AS, ZFPM2-AS1, and <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC099850.3">AC099850.3</ext-link>)<sup>bs</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">370 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2024</td><td align="left" colspan="1" rowspan="1">Chen et al. [<xref ref-type="bibr" rid="CR143">143</xref>]</td></tr><tr><td align="left" colspan="9" rowspan="1"><bold>Cuproptosis-related lncRNAs</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Six cuproptosis-related lncRNAs signature (DEPDC1-AS1, DNMBP-AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC099329.2">AC099329.2</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC138904.1">AC138904.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC145343.1">AC145343.1</ext-link>, and GIHCG)<sup>bt</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">365 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2022</td><td align="left" colspan="1" rowspan="1">Zhang et al. [<xref ref-type="bibr" rid="CR144">144</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Three cuproptosis-related lncRNAs signature (<ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL365203.2">AL365203.2</ext-link>, NRAV, and SNHG4)<sup>bu</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">370 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2023</td><td align="left" colspan="1" rowspan="1">Ren et al. [<xref ref-type="bibr" rid="CR145">145</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Seven cuproptosis-related lncRNAs signature (ACVR2B-AS1, SACS-AS1, TMCC1-AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC084083.1">AC084083.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC092418.2">AC092418.2</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL021154.1">AL021154.1</ext-link>, and PCAT6)<sup>bv</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">374 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2023</td><td align="left" colspan="1" rowspan="1">Yang et al. [<xref ref-type="bibr" rid="CR146">146</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Six cuproptosis-related lncRNAs signature (MKLN1-AS, SLC6A1-AS1, TMCC1-AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC026412.3">AC026412.3</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC125437.1">AC125437.1</ext-link>, and <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL353572.4">AL353572.4</ext-link>)<sup>bw</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">370 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2024</td><td align="left" colspan="1" rowspan="1">Wei et al. [<xref ref-type="bibr" rid="CR147">147</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Nine cuproptosis-related lncRNAs signature (LINC0256.1, IQCH-AS1, WAC-AS1, ZFPM2-AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC003086.1">AC003086.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC007998.3">AC007998.3</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC009974.2">AC009974.2</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC105345.1">AC105345.1</ext-link>, and <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL353708.1">AL353708.1</ext-link>)<sup>bx</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">370 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2024</td><td align="left" colspan="1" rowspan="1">Wang et al. [<xref ref-type="bibr" rid="CR148">148</xref>]</td></tr><tr><td align="left" colspan="9" rowspan="1"><bold>Pyroptosis-related lncRNAs</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Five pyroptosis-related lncRNAs signature (MKLN1-AS, HPN-AS1, MED8-AS1, SREBF2-AS1, and ZNF232-AS1)<sup>by</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">342 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2022</td><td align="left" colspan="1" rowspan="1">Zhang et al. [<xref ref-type="bibr" rid="CR149">149</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Nine pyroptosis-related lncRNAs signature (MKLN1-AS, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC007128.1">AC007128.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC019080.5">AC019080.5</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC023157.2">AC023157.2</ext-link>, AL031985.3, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL445228.3">AL445228.3</ext-link>, AP003392.4, LNCSRLR, and PCCA-DT)<sup>bz</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">371 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2022</td><td align="left" colspan="1" rowspan="1">Zhang et al. [<xref ref-type="bibr" rid="CR150">150</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Twelve pyroptosis-related lncRNAs signature (LINC01224, MKLN1-AS, KDM4A-AS1, ZFPM2-AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC008549.1">AC008549.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC099850.3">AC099850.3</ext-link>, AL031985.3, AL049840.5, CRYZL2P-SEC16B, LUCAT1, NRAV, and SNHG4)<sup>ca</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">370 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2022</td><td align="left" colspan="1" rowspan="1">Wang et al. [<xref ref-type="bibr" rid="CR151">151</xref>]</td></tr><tr><td align="left" colspan="9" rowspan="1"><bold>Disulfidptosis-related lncRNAs</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Three disulfidptosis-related lncRNAs signature (KDM4A-AS1, MKLN1-AS, and TMCC1-AS1)<sup>cb</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">527 HCC patients treated with curative surgical resection</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter PFS</td><td align="left" colspan="1" rowspan="1">2024</td><td align="left" colspan="1" rowspan="1">Gu et al. [<xref ref-type="bibr" rid="CR152">152</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Three disulfidptosis-related lncRNAs signature (<ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC124798.1">AC124798.1</ext-link>, POLH-AS1, and TMCC1-AS1)<sup>cc</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">374 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2024</td><td align="left" colspan="1" rowspan="1">Xu et al. [<xref ref-type="bibr" rid="CR153">153</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Five disulfidptosis-related lncRNAs signature (PXN-AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC026356.1">AC026356.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC026412.3">AC026412.3</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC073254.1">AC073254.1</ext-link>, and <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC099066.2">AC099066.2</ext-link>)<sup>cd</sup></td><td align="left" colspan="1" rowspan="1">Pre-treatment</td><td align="left" colspan="1" rowspan="1">Tumor tissue</td><td align="left" colspan="1" rowspan="1">RNAseq</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">370 HCC patients</td><td align="left" colspan="1" rowspan="1">High signature score predicted shorter OS</td><td align="left" colspan="1" rowspan="1">2024</td><td align="left" colspan="1" rowspan="1">Xu et al. [<xref ref-type="bibr" rid="CR154">154</xref>]</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>The prognostic lncRNA signature was constructed based on a combination of the expression level of each prognostic lncRNA in tumor tissues normalized with normal tissues, weighted by its estimated regression coefficient in the multivariate Cox proportional hazards regression analysis as the following equation: signature score&#8201;=&#8201;expression level of lncRNA1&#8201;&#215;&#8201;coefficient of lncRNA1&#8201;+&#8201;expression level of lncRNA2&#8201;&#215;&#8201;coefficient of lncRNA2&#8201;+&#8201;&#8230; expression level of lncRNAn&#8201;&#215;&#8201;coefficient of lncRNAn</p><p><sup>b</sup>The literature reporting the lncRNA signatures related to similar functions were listed together under specific functional category subtitles</p><p><sup>c</sup>The coefficients for LINC00261, CDKN2B-AS1, GBP1P1, and TREML3P are&#8201;&#8722;&#8201;0.51, 0.45,&#8201;&#8722;&#8201;0.55, and 0.67, respectively</p><p><sup>d</sup>The coefficients for CTD-2574D22.4, MIR100HG, SERHL, and SNHG20 are 0.28,&#8201;&#8722;&#8201;0.19, 0.71, and 0.14, respectively</p><p><sup>e</sup>The coefficients for DCST1-AS1, FOXD2-AS1, TMCC1-AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC015908.3">AC015908.3</ext-link>, and <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC091057.3">AC091057.3</ext-link> are 0.49, 0.18, 0.56,&#8201;&#8722;&#8201;0.19, and 0.36, respectively</p><p><sup>f</sup>The coefficients for F11-AS1, FOXD2-AS1, TMCC1-AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC009005.1">AC009005.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC012339.1">AC012339.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC015908.3">AC015908.3</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC089983.1">AC089983.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC093609.1">AC093609.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC124067.4">AC124067.4</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL592043.1">AL592043.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL592466.1">AL592466.1</ext-link>, FLJ36000, and MIR663AHG are 0.11, 0.20, 0.31, 0.15, 0.19,&#8201;&#8722;&#8201;0.19, 0.17,&#8201;&#8722;&#8201;0.18, 0.11, 0.16,&#8201;&#8722;&#8201;0.17, 0.12, and&#8201;&#8722;&#8201;0.08, respectively</p><p><sup>g</sup>The coefficients for RP11-325L7.2, LINC02249, RP11-100L22.4, DLX2-AS1, and RP11-104L21.3 are&#8201;&#8722;&#8201;0.93,&#8201;&#8722;&#8201;0.29,&#8201;&#8722;&#8201;0.68, 0.36, and 0.68, respectively</p><p><sup>h</sup>The coefficients for EIF3J-AS1, MSC-AS1, POLR2J4, PVT1, RMST, and SERHL are 0.02, 0.02, 0.02, 0.01, 0.01, and 0.01, respectively</p><p><sup>i</sup>The coefficients for ZFPM2&#8208;AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC009005.2">AC009005.2</ext-link>, RP11&#8208;190C22.8, RP11&#8208;363N22.3, RP11&#8208;388C12.8, RP11&#8208;572O6.1, and RP11&#8208;932O9.10 are 0.33, 0.65, 0.25, 0.16, 0.46, 0.13, and 0.27, respectively</p><p><sup>j</sup>The coefficients for LINC01559, MYLK-AS1, RP11-150,012.3, RP11-92C4.6, RASGRF2-AS1, LINC01116, RRM2, LINC00856, LINC02003, and RP11-363N22.3 are 0.77, 0.53, 0.73,&#8201;&#8722;&#8201;0.51,&#8201;&#8722;&#8201;0.77, 0.73, 0.56, 0.42, 0.48, and 0.43, respectively</p><p><sup>k</sup>The coefficients for RP11-150O12.3, RP11-187E13.1, and RP13-143G15.4 are 0.53, 0.37, and 0.71, respectively</p><p><sup>l</sup>The coefficients for RUSC1&#8208;AS1, STEAP3&#8208;AS1, SNHG1, and SNHG3 are 0.30,&#8201;&#8722;&#8201;0.27, 0.38, and 0.27, respectively</p><p><sup>m</sup>The coefficients for LINC02334, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC012640.1">AC012640.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC013451.2">AC013451.2</ext-link>, and <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC062004.1">AC062004.1</ext-link> are&#8201;&#8722;&#8201;0.28, 0.19, 0.36, and&#8201;&#8722;&#8201;0.24, respectively</p><p><sup>n</sup>The coefficients for LINC02043, LINC01605, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC062004.1">AC062004.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL139385">AL139385</ext-link>, and ERVH48-1 are 0.35, 0.17,&#8201;&#8722;&#8201;0.35,&#8201;&#8722;&#8201;0.19, and 0.35, respectively</p><p><sup>o</sup>The coefficients for LINC00556, RP11&#8208;359K18.3, RP11&#8208;495K9.6, and RP11&#8208;96O20.2 are 2.17, 1.42, 1.13, and 1.35, respectively</p><p><sup>p</sup>The coefficients for LINC01116, DDX11-AS1, LUCAT1, and FIRRE are 0.04, 0.25, 0.07, and 0.11, respectively</p><p><sup>q</sup>The coefficients for LINC00506, LINC00511, LINC01136, KRTAP5-AS1, MKLN1-AS, THUMPD3-AS1, TSPEAR-AS1, and ZNF252P-AS1 are 3.22, 3.07, 1.42,&#8201;&#8722;&#8201;7.17,&#8201;&#8722;&#8201;5.17, 3.56,&#8201;&#8722;&#8201;3.19, and&#8201;&#8722;&#8201;11.93, respectively</p><p><sup>r</sup>The coefficients for CTD-2510F5.4 and DSTNP2 are 0.19 and 0.15, respectively</p><p><sup>s</sup>The coefficients for LINC02870, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC012640.1">AC012640.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC090921.1">AC090921.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL158839.1">AL158839.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL356056.1">AL356056.1</ext-link>, and AL359853.1 are 0.13, 0.14, 0.20, 0.24, 0.39, and 0.23, respectively</p><p><sup>t</sup>The coefficients for LINC01447, PLCE1-AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL158839.1">AL158839.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL356056.1">AL356056.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL445493.2">AL445493.2</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AP000808.1">AP000808.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AP003354.2">AP003354.2</ext-link>, MIR7-3HG, and TH2LCRR are&#8201;&#8722;&#8201;0.08,&#8201;&#8722;&#8201;0.45, 0.28, 0.25,&#8201;&#8722;&#8201;0.29,&#8201;&#8722;&#8201;0.10,&#8201;&#8722;&#8201;0.22, 0.29, and 0.19, respectively</p><p><sup>u</sup>The coefficients for <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AP000844.2">AP000844.2</ext-link>, LINC00942, SRGAP3-AS2, and <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC010280.2">AC010280.2</ext-link> are 1.14, 1.12, 1.20, and &#8211;0.84, respectively</p><p><sup>v</sup>The coefficient of each lncRNA is unreported</p><p><sup>w</sup>The coefficients for TMCC1-AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC009549.1">AC009549.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC090018.2">AC090018.2</ext-link>, and PKD1P6-NPIPP1 are 0.86, 0.49, 1.39, and 1.62, respectively</p><p><sup>x</sup>The coefficient of each lncRNA is unreported</p><p><sup>y</sup>The coefficients for LINC02870, MKLN1-AS, TMCC1-AS1, and NRAV are 0.37, 0.84, 0.78, and 0.38, respectively</p><p><sup>z</sup>The coefficients for MKLN1-AS and AL031985.3 are 0.94 and 0.76, respectively</p><p><sup>aa</sup>The coefficients for LINC00426, LINC01150, LINC02273, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC007277.1">AC007277.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC008549.1">AC008549.1</ext-link>, and <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AP002954.1">AP002954.1</ext-link> are&#8201;&#8722;&#8201;3.08, 0.95,&#8201;&#8722;&#8201;0.84, 0.18,&#8201;&#8722;&#8201;0.01, and 1.26, respectively</p><p><sup>ab</sup>The coefficients for MKLN1-AS, DDX11-AS1, TMCC1-AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC026412.3">AC026412.3</ext-link>, and AL031985.3 are 0.34, 0.47, 0.25, 0.53, and 0.17, respectively</p><p><sup>ac</sup>The coefficients for LINC01224, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC026356.1">AC026356.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC026412.3">AC026412.3</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL442125.2">AL442125.2</ext-link>, and MIR4435-2HG are 0.389, 0.691, 1.043, 0.903, and 0.872, respectively</p><p><sup>ad</sup>The coefficients for LINC01164, LINC01183, LINC01269, and <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC025016.1">AC025016.1</ext-link> are 0.002, 0.013, 0.006, and 0.003, respectively</p><p><sup>ae</sup>The coefficients for LINC01138, LINC01224, LINC03124, MKLN1-AS, POLH-AS1, AL031985.3, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL117336.2">AL117336.2</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL158166.1">AL158166.1</ext-link>, and <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL442125.2">AL442125.2</ext-link> are 0.01, 0.32, 0.04, 0.48, 0.61, 0.38, 0.13, 0.23, and 0.59, respectively</p><p><sup>af</sup>The coefficients for LINC01093, LINC02362, SNHG20, SNHG17, AL031985.3, AL031985.3, AL031985.3, and AL031985.3 are 0.06, 0.10, 0.08, 0.52, 0.37, 0.37, 0.37, and 0.37, respectively</p><p><sup>ag</sup>The coefficients for PTOV1-AS1, AC145207.5, AL031985.3, and NRAV are &#8211;0.24, 0.52, 0.80, and 0.23, respectively</p><p><sup>ah</sup>The coefficients for SOCS2-AS1, NAV2-AS4, RP5-1171I10.5, RP11-10A14.3, RP11-43F13.3, RP11-519G16.5, RP11-588H23.3, RP11-874J12.4, and RP11-95O2.5 are&#8201;&#8722;&#8201;0.20,&#8201;&#8722;&#8201;0.19,&#8201;&#8722;&#8201;0.37,&#8201;&#8722;&#8201;0.19, 0.17, 0.15,&#8201;&#8722;&#8201;0.16, 0.17, and 0.15, respectively</p><p><sup>ai</sup>The coefficients for <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC023157.3">AC023157.3</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC099850.3">AC099850.3</ext-link>, AL031985.3, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL365203.2">AL365203.2</ext-link>, and CYTOR are 0.49, 0.20, 0.61, 0.21, and 0.19, respectively</p><p><sup>aj</sup>The coefficients for LINC01116, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC009005.1">AC009005.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC011352.3">AC011352.3</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC025176.1">AC025176.1</ext-link>, and <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AP002478.1">AP002478.1</ext-link> are 0.12, 0.23, 0.22, 0.20, and 0.25, respectively</p><p><sup>ak</sup>The coefficients for ELFN1-AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC009005.1">AC009005.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC022424.1">AC022424.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC026369.2">AC026369.2</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC068506.1">AC068506.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC068580.1">AC068580.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC079305.2">AC079305.2</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL049840.6">AL049840.6</ext-link>, and lnc-CCNY-1 are 1.05, 1.15, 1.05, 1.52, 1.23, 1.27, 1.03, 1.08, and 1.58, respectively</p><p><sup>al</sup>The coefficients for ZFPM2-AS1, AC005332.3, and lnc-CCNY-1 are 1.09, 1.11, and 1.34, respectively</p><p><sup>am</sup>The coefficients for ZFPM2-AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC004862.1">AC004862.1</ext-link>, and <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC145343.1">AC145343.1</ext-link> are 0.13,&#8201;&#8722;&#8201;0.23, and 0.38, respectively</p><p><sup>an</sup>The coefficients for PRRT3-AS1, ZFPM2-AS1, LUCAT1, and MIR210HG are 0.02, 0.05, 0.11, and 0.10, respectively</p><p><sup>ao</sup>The coefficients for ZFPM2-AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC116351.1">AC116351.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC145343.1">AC145343.1</ext-link>, and MIR210HG are 0.12, 0.16, 0.22, and 0.11, respectively</p><p><sup>ap</sup>The coefficients for LINC00501, LINC01508, LINC02055, LINC02714, AC002511.2, LOC105371967, RP11-96A15.1, RP11-305F18.1, RP11-342M1.3, RP11-432J24.3, and <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="U95743.1">U95743.1</ext-link> are 0.09, 0.03, 0.16, 0.02, 1.03, 0.02, 0.28, 0.06, 0.05, 0.05, and 0.24, respectively</p><p><sup>aq</sup>The coefficients for <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC099850.3">AC099850.3</ext-link>, AL031985.3, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL365203.2">AL365203.2</ext-link>, LUCAT1, and MIR210HG are 0.19, 0.60, 0.23, 0.37, and 0.20, respectively</p><p><sup>ar</sup>The coefficient of each lncRNA is unreported</p><p><sup>as</sup>The coefficient of each lncRNA is unreported</p><p><sup>at</sup>The coefficients for <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC015908.3">AC015908.3</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL031722.1">AL031722.1</ext-link>, AL031985.3, LUCAT1, and PCCA-DT are&#8201;&#8722;&#8201;0.18,&#8201;&#8722;&#8201;0.25, 0.32, 0.11, and 0.03, respectively</p><p><sup>au</sup>The coefficient of each lncRNA is unreported</p><p><sup>av</sup>The coefficients for LINC00942, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC007405.3">AC007405.3</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC023157.3">AC023157.3</ext-link>, MSC-AS1, CASC19, GASAL1, and NRAV are 0.03, 0.13, 0.21, 0.14, 0.11, 0.30, and 0.20, respectively</p><p><sup>aw</sup>The coefficients for <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="CR936218.2">CR936218.2</ext-link>, SREBF2-AS1, TMEM220-AS1, LINC00205, LUCAT1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL049840.2">AL049840.2</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL139260.1">AL139260.1</ext-link>, DCST1-AS1, and LINC01232 are&#8201;&#8722;&#8201;0.44, 0.61,&#8201;&#8722;&#8201;0.38,&#8201;&#8722;&#8201;0.31, 0.27, 0.89, 0.38, 0.43, and 0.66, respectively</p><p><sup>ax</sup>The coefficients for ZFPM2-AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC099850.3">AC099850.3</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC015908.3">AC015908.3</ext-link>, and NRAV are 1.10, 1.10,&#8201;&#8722;&#8201;0.79, and 1.16, respectively</p><p><sup>ay</sup>The coefficients for <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC099850.4">AC099850.4</ext-link>, NRAV, AL031985.3, PRRT3-AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL365203.2">AL365203.2</ext-link>, and LINC01224 are 0.06, 0.10, 0.33, 0.09, 0.09, and 0.41, respectively</p><p><sup>az</sup>The coefficients for LINC00856, PGM5P3-AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC011287.1">AC011287.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC019257.1">AC019257.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC027288.1">AC027288.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC110285.3">AC110285.3</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL161431.1">AL161431.1</ext-link>, APCDD1L-DT, and WARS2-IT1 are 0.05, &#8211;0.04, 0.03, &#8211;0.03,&#8201;&#8722;&#8201;0.05, 0.05, 0.05, 0.04, and &#8211;0.05, respectively</p><p><sup>ba</sup>The coefficients for LINC01011, LINC01224, RHPN1-AS1, CTD-2510F5.4, RP1-228H13.5, and RP11-324I22.4 are 0.004, 0.003, 0.003, 0.002, 0.001, and 0.002, respectively</p><p><sup>bb</sup>The coefficients for MSC-AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC009005.1">AC009005.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC099850.3">AC099850.3</ext-link>, AL031985.3, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL117336.3">AL117336.3</ext-link>, and <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL365203.2">AL365203.2</ext-link> are 0.33, 0.31, 0.17, 0.49, 0.34, and 0.22, respectively</p><p><sup>bc</sup>The coefficients for LINC01554, LINC02362, LINC02499, and TMEM220-AS1 are&#8201;&#8722;&#8201;0.04,&#8201;&#8722;&#8201;0.06,&#8201;&#8722;&#8201;0.01, and&#8201;&#8722;&#8201;0.29, respectively</p><p><sup>bd</sup>The coefficient of each lncRNA is unreported</p><p><sup>be</sup>The coefficients for LINC01871, LINC02321, LINC02362, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC073611.1">AC073611.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL050341.2">AL050341.2</ext-link>, LUCAT1, and ZNF582-AS1 are&#8201;&#8722;&#8201;0.30, 0.20,&#8201;&#8722;&#8201;0.29, 0.45, 0.40, 0.30, and&#8201;&#8722;&#8201;0.43, respectively</p><p><sup>bf</sup>The coefficients for LINC01063, MKLN1-AS, PLBS1-AS1, TMMC1-AS1, and CYTOR are 0.30, 0.27, 0.17, 0.29, and 0.17, respectively</p><p><sup>bg</sup>The coefficients for BACE1-AS, ZEB1-AS1, MIR210HG, and SNHG3 are 0.14, 0.11, 0.07, and 0.03, respectively</p><p><sup>bh</sup>The coefficients for LINC01138, PRRT3-AS1, CTD-2510F5.4, CTC-297N7.9, RP11-324I22.4, RP11-479G22.8, and RP11-73M18.8 are 0.24, 0.10, 0.13,&#8201;&#8722;&#8201;0.54, 0.26, 0.09, and 0.06, respectively</p><p><sup>bi</sup>The coefficients for <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC099850.3">AC099850.3</ext-link>, CYTOR, and MIR210HG are 0.56, 0.60, and 0.36, respectively</p><p><sup>bj</sup>The coefficients for LINC01224, GDNF-AS1, ZFPM2-AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC009005.1">AC009005.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC092119.2">AC092119.2</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC099850.3">AC099850.3</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL356234.2">AL356234.2</ext-link>, and LUCAT1 are 0.37,&#8201;&#8722;&#8201;0.30, 0.11, 0.67,&#8201;&#8722;&#8201;2.56, 0.82,&#8201;&#8722;&#8201;0.94, and 0.22, respectively</p><p><sup>bk</sup>The coefficients for <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC099850.3">AC099850.3</ext-link>, AL031985.3, AL049840.5, LNCSRLR, and NRAV are 0.08, 0.37, 0.06, 0.52, and 0.10, respectively</p><p><sup>bl</sup>The coefficients for LINC00942, LINC01224, MKLN1-AS, POLH-AS1, AL031985.3, and PCAT6 are 0.03, 0.38, 1.05, 0.76, 0.38, and 0.18, respectively</p><p><sup>bm</sup>The coefficients for LINC00668, LINC01224, LINC01269, FOXD2-AS1, MKLN1-AS, MSC-AS1, and TMCC1-AS1 are 0.10, 0.15, 0.13, 0.05, 0.54, 0.15, and 0.51, respectively</p><p><sup>bn</sup>The coefficients for LINC01871, TMEM220-AS1, ZFPM2-AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC009005.1">AC009005.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC009403.1">AC009403.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC009779.2">AC009779.2</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC012467.2">AC012467.2</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC026369.2">AC026369.2</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC068580.3">AC068580.3</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC074117.1">AC074117.1</ext-link>, AL031985.3, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL139384.1">AL139384.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL365203.2">AL365203.2</ext-link>, LUCAT1, MIR210HG, and NRAV are&#8201;&#8722;&#8201;0.047,&#8201;&#8722;&#8201;0.026, 0.007, 0.021, 0.025, 0.011, 0.001, 0.090, 0.001, 0.085, 0.385, 0.132, 0.049, 0.032, 0.032, and 0.005, respectively</p><p><sup>bo</sup>The coefficient of each lncRNA is unreported</p><p><sup>bp</sup>The coefficients for LINC00205, LINC00942, MKLN1-AS, POLH-AS1, ZFPM2-AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC012073.1">AC012073.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC026401.3">AC026401.3</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC090772.3">AC090772.3</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC099850.1">AC099850.1</ext-link>, AC145207.8, AL031985.3, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL139384.1">AL139384.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL603839.3">AL603839.3</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL928654.1">AL928654.1</ext-link>, AP001469.3, SNHG10, and SNHG21 are&#8201;&#8722;&#8201;0.24, 0.05, 0.91, 0.92, 0.08, 0.25,&#8201;&#8722;&#8201;0.09, 0.37, 0.25,&#8201;&#8722;&#8201;0.53,&#8201;&#8722;&#8201;0.15, 0.24, 0.25, 0.58, 0.54, 0.19,&#8201;&#8722;&#8201;0.40, respectively</p><p><sup>bq</sup>The coefficients for LINC00942, MKLN1-AS, POLH-AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC009403.1">AC009403.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC090772.3">AC090772.3</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC131009.1">AC131009.1</ext-link>, and AL031985.3 are 0.01, 0.77, 0.73, 0.44, 0.24, 0.28, and 0.31, respectively</p><p><sup>br</sup>The coefficient of each lncRNA is unreported</p><p><sup>bs</sup>The coefficients for BACE1-AS, KDM4A-AS1, MKLN1-AS, ZFPM2-AS1, and <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC099850.3">AC099850.3</ext-link> are 0.10, 0.51, 0.81, 0.06, and 0.08, respectively</p><p><sup>bt</sup>The coefficients for DEPDC1-AS1, DNMBP-AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC099329.2">AC099329.2</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC138904.1">AC138904.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC145343.1">AC145343.1</ext-link>, and GIHCG are 0.15,&#8201;&#8722;&#8201;0.17,&#8201;&#8722;&#8201;0.18, 0.08, 0.22, and 0.16, respectively</p><p><sup>bu</sup>The coefficients for <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL365203.2">AL365203.2</ext-link>, NRAV, and SNHG4 are 0.04, 0.06, and 0.15, respectively</p><p><sup>bv</sup>The coefficient of each lncRNA is unreported</p><p><sup>bw</sup>The coefficient of each lncRNA is unreported</p><p><sup>bx</sup>The coefficient of each lncRNA is unreported</p><p><sup>by</sup>The coefficients for MKLN1-AS, HPN-AS1, MED8-AS1, SREBF2-AS1, and ZNF232-AS1 are 0.96,&#8201;&#8722;&#8201;0.49, 0.83, 0.27, and 0.08, respectively</p><p><sup>bz</sup>The coefficients for MKLN1-AS, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC007128.1">AC007128.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC019080.5">AC019080.5</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC023157.2">AC023157.2</ext-link>, AL031985.3, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL445228.3">AL445228.3</ext-link>, AP003392.4, LNCSRLR, and PCCA-DT are 0.103, 0.484, 0.218, 0.060, 0.163, 0.161, 0.219, 0.236, and 0.003, respectively</p><p><sup>ca</sup>The coefficients for LINC01224, MKLN1-AS, KDM4A-AS1, ZFPM2-AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC008549.1">AC008549.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC099850.3">AC099850.3</ext-link>, AL031985.3, AL049840.5, CRYZL2P-SEC16B, LUCAT1, NRAV, and SNHG4 are 0.189, 0.656, 0.352, 0.023,&#8201;&#8722;&#8201;0.006, 0.033, 0.131, 0.023,&#8201;&#8722;&#8201;0.111, 0.047, 0.007, and 0.066, respectively</p><p><sup>cb</sup>The coefficients for KDM4A-AS1, MKLN1-AS, and TMCC1-AS1 are 0.49, 0.36, and 0.28, respectively</p><p><sup>cc</sup>The coefficients for <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC124798.1">AC124798.1</ext-link>, POLH-AS1, and TMCC1-AS1 are 0.25, 0.41, and 0.82, respectively</p><p><sup>cd</sup>The coefficients for PXN-AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC026356.1">AC026356.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC026412.3">AC026412.3</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC073254.1">AC073254.1</ext-link>, and <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC099066.2">AC099066.2</ext-link> are 0.62, 1.19, 2.97, 1.19, and 0.47, respectively</p><p>lncRNA, long non-coding RNA; HCC, hepatocellular carcinoma; LINC, long intergenic non-protein coding RNA; CDKN2B-AS1, cyclin dependent kinase inhibitor 2B antisense RNA 1; GBP1P1, guanylate binding protein 1 pseudogene 1; TREML3P, triggering receptor expressed on myeloid cells like 3, pseudogene; RNAseq, RNA sequencing; OS, overall survival; MIR100HG, mir-100-let-7a-2-mir-125b-1 cluster host gene; SERHL, serine hydrolase like (pseudogene); SNHG, small nucleolar RNA host gene; DCST1-AS1, DC-STAMP domain containing 1 antisense RNA 1; FOXD2-AS1, forkhead box D2 antisense RNA 1; TMCC1-AS1, transmembrane and coiled-coil domain family 1 antisense RNA 1; F11-AS1, F11 antisense RNA 1; MIR663AHG, MIR663A host gene; DLX2-AS1, distal-less homeobox 2 antisense RNA 1; EIF3J-AS1, eukaryotic translation initiation factor 3 subunit J antisense RNA 1; MSC-AS1, musculin antisense RNA 1; POLR2J4, RNA polymerase II subunit J4 (pseudogene); PVT1, Pvt1 oncogene; RMST, rhabdomyosarcoma 2 associated transcript; RFS, recurrence-free survival; ZFPM2&#8208;AS1<bold>,</bold> zinc finger protein, FOG family member 2 antisense RNA 1; MYLK-AS1, myosin light chain kinase antisense RNA 1; RASGRF2-AS1, Ras protein specific guanine nucleotide releasing factor 2 antisense RNA 1; RRM2, ribonucleotide reductase regulatory subunit M2; RUSC1&#8208;AS1<bold>,</bold> RUN and SH3 domain containing 1 antisense RNA 1; STEAP3&#8208;AS1, STEAP3 antisense RNA 1; ERVH48-1, endogenous retrovirus group 48 member 1, envelope; DDX11-AS1, DEAD/H-box helicase 11 antisense RNA 1; LUCAT1, lung cancer associated transcript 1; FIRRE, firre intergenic repeating RNA element; qRT-PCR, quantitative reverse-transcription polymerase chain reaction; HBV, hepatitis B virus; KRTAP5-AS1, keratin associated protein 5 antisense RNA 1; MKLN1-AS, muskelin 1 antisense RNA; THUMPD3-AS1<bold>,</bold> THUMP domain 3 tRNA guanosine methyltransferase antisense RNA 1; TSPEAR-AS1, thrombospondin type laminin G domain and EAR repeats antisense RNA 1; ZNF252P-AS1, zinc finger protein 252, pseudogene antisense RNA 1; DSTNP2, DSTN pseudogene 2; PLCE1-AS1, phospholipase C epsilon 1 antisense RNA 1; MIR7-3HG, MIR7-3 host gene; TH2LCRR, T helper type 2 locus control region associated RNA; SRGAP3-AS2, SLIT-ROBO Rho GTPase activating protein 3 antisense RNA 2; CASC19, cancer susceptibility 19; PKD1P6-NPIPP1, polycystin 1, transient receptor potential channel interacting pseudogene 6-nuclear pore complex interacting protein pseudogene 1; AGAP11, ArfGAP with GTPase domain, ankyrin repeat and PH domain 11; FAM182B, family with sequence similarity 182 member B; NRAV, negative regulator of antiviral response; ECM, extracellular matrix; DDX11-AS1, DEAD/H-box helicase 11 antisense RNA 1; m6A<italic toggle="yes">,</italic> N6-methyladenine; POLH-AS1, DNA polymerase eta antisense RNA 1; GAS5, growth arrest specific 5; ZFAS1, ZNFX1 antisense RNA 1; PTOV1-AS1, PTOV1 antisense RNA 1; m7G, N7-methylguanosine; SOCS2-AS1, suppressor of cytokine signaling 2 antisense RNA 1; NAV2-AS4, neuron navigator 2 antisense RNA 4; EMT, epithelial-to-mesenchymal transition; CYTOR, cytoskeleton regulator RNA; ELFN1-AS1, extracellular leucine rich repeat and fibronectin type III domain containing 1 antisense RNA 1; CCNY, cyclin Y; ZFPM2-AS1, zinc finger protein, FOG family member 2 antisense RNA 1; PRRT3-AS1, proline rich transmembrane protein 3 antisense RNA 1; MIR210HG, MIR210 host gene; WAC-AS1, WW domain containing adaptor with coiled-coil antisense RNA 1; PCCA-DT, propionyl-CoA carboxylase subunit alpha divergent transcript; HPN&#8208;AS1, hepsin antisense RNA 1; PRKCQ&#8208;AS1<bold>,</bold> protein kinase C theta antisense RNA 1; MIR99AHG, mir-99a-let-7c cluster host gene; SCARNA9, small Cajal body-specific RNA 9; GASAL1, growth arrest associated lncRNA 1; SREBF2-AS1, sterol regulatory element binding transcription factor 2 antisense RNA 1; TMEM220-AS1, transmembrane protein 220 antisense RNA 1; PGM5P3-AS1, phosphoglucomutase 5 pseudogene 3 antisense RNA 1; APCDD1L-DT, APC down-regulated 1 like divergent transcript; WARS2-IT1, tryptophanyl tRNA synthetase 2, mitochondrial intronic transcript 1; RHPN1-AS1, rhophilin Rho GTPase binding protein 1 antisense RNA 1; BOK-AS1, BOK antisense RNA 1; ZNF582-AS1, zinc finger protein 582 antisense RNA 1; PLBS1-AS1, PLBS1 antisense RNA 1; TMMC1-AS1, TMMC1 antisense RNA 1; BACE1-AS, beta-secretase 1 antisense RNA; ZEB1-AS1, zinc finger E-box binding homeobox 1 antisense RNA 1; GDNF-AS1, glial cell derived neurotrophic factor antisense RNA 1; LNCSRLR, lncRNA sorafenib resistance in renal cell carcinoma associated; PCAT6, prostate cancer associated transcript 6; KDM4A-AS1, lysine demethylase 4A antisense RNA 1; DEPDC1-AS1, DEP domain containing 1 antisense RNA 1; DNMBP-AS1, dynamin binding protein antisense RNA 1; GIHCG, GIHCG inhibitor of miR-200b/200a/429 expression; ACVR2B-AS1, activin A receptor type 2B antisense RNA 1; SACS-AS1, sacsin molecular chaperone antisense RNA 1; SLC6A1-AS1, solute carrier family 6 member 1 antisense RNA 1; IQCH-AS1, IQ motif containing H antisense RNA 1; HPN-AS1, hepsin antisense RNA 1; MED8-AS1, mediator complex subunit 8 antisense RNA 1; ZNF232-AS1, zinc finger protein 232 antisense RNA 1; CRYZL2P-SEC16B, crystallin zeta like 2, pseudogene-SEC16 homolog B, endoplasmic reticulum export factor; PFS, progression-free survival; PXN-AS1, paxillin antisense RNA 1; MIR4435-2HG, MIR4435-2 host gene</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec3"><title>Independent prognostic significance of combination lncRNA biomarkers in HCC patients</title><p id="Par6">In addition to individual lncRNAs, multiple studies were conducted to evaluate the independent prognostic value of various combinations of lncRNAs showing altered expression levels in tumor tissues of HCC patients by multivariate Cox proportional hazards regression analysis (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). The study conducted by Sui et al. performed RNAseq to detect the pre-treatment expression levels of four lncRNAs (LINC00261, cyclin dependent kinase inhibitor 2B antisense RNA 1 (CDKN2B-AS1), guanylate binding protein 1 pseudogene 1 (GBP1P1), and triggering receptor expressed on myeloid cells like 3, pseudogene (TREML3P)) in tumor tissues as a prognostic signature and revealed that a high signature score predicted a shorter OS (HR, 2.997; 95% CI, 1.634&#8211;5.497; P value&#8201;=&#8201;0.003) in 317 retrospectively recruited HCC patients [<xref ref-type="bibr" rid="CR78">78</xref>]. Using RNAseq-based detection of the pre-treatment expression levels of four lncRNAs (CTD-2574D22.4, mir-100-let-7a-2-mir-125b-1 cluster host gene (MIR100HG), serine hydrolase like (pseudogene) (SERHL), and SNHG20) in tumor tissues as a prognostic signature, Ma et al. showed that a high signature score was independently correlated with a shorter OS (HR, 2.34; 95% CI, 1.78&#8211;3.07; P value&#8201;&lt;&#8201;0.0001) in 34 retrospectively recruited HCC patients [<xref ref-type="bibr" rid="CR79">79</xref>]. Based on RNAseq analysis of the pre-treatment expression levels of five lncRNAs (DC-STAMP domain containing 1 antisense RNA 1 (DCST1-AS1), forkhead box D2 antisense RNA 1 (FOXD2-AS1), transmembrane and coiled-coil domain family 1 antisense RNA 1 (TMCC1-AS1), <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC015908.3">AC015908.3</ext-link>, and <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC091057.3">AC091057.3</ext-link>) in tumor tissues as a prognostic signature, Zhao et al. identified that a high signature score was a factor independently associated with a shorter OS (HR, 2.830; 95% CI, 2.091&#8211;3.831; P value&#8201;&lt;&#8201;0.0001) in 370 retrospectively recruited HCC patients [<xref ref-type="bibr" rid="CR80">80</xref>]. Liao et al. performed RNAseq to measure the pre-treatment expression levels of thirteen lncRNAs (F11 antisense RNA 1 (F11-AS1), FOXD2-AS1, TMCC1-AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC009005.1">AC009005.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC012339.1">AC012339.1</ext-link><bold>,</bold> <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC015908.3">AC015908.3</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC089983.1">AC089983.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC093609.1">AC093609.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC124067.4">AC124067.4</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL592043.1">AL592043.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL592466.1">AL592466.1</ext-link>, FLJ36000, and MIR663A host gene (MIR663AHG)) in tumor tissues as a prognostic signature and ascertained that a high signature score was an independent factor which predicted a shorter OS (HR, 3.929; 95% CI, 2.678&#8211;5.765; P value&#8201;&lt;&#8201;0.0001) in 370 retrospectively recruited HCC patients [<xref ref-type="bibr" rid="CR81">81</xref>]. In 167 retrospectively recruited HCC patients treated with curative surgical resection (83 as a training cohort and 84 as an internal validation cohort), Sun et al. carried out RNAseq to measure the pre-treatment expression levels of five lncRNAs (LINC02249, distal-less homeobox 2 antisense RNA 1 (DLX2-AS1), RP11-100L22.4, RP11-104L21.3, and RP11-325L7.2) in tumor tissues as a prognostic signature and confirmed an independent association between high signature score and shorter OS (training cohort: HR, 2.452; 95% CI, 0.544&#8211;3.048; P value&#8201;=&#8201;0.024; validation cohort: HR, 2.992; 95% CI, 1.196&#8211;3.458; P value&#8201;=&#8201;0.034; entire cohort: HR, 1.906; 95% CI, 0.697&#8211;5.205; P value&#8201;=&#8201;0.021) [<xref ref-type="bibr" rid="CR82">82</xref>]. The study conducted by Gu et al. performed RNAseq to detect the pre-treatment expression levels of six lncRNAs signature (eukaryotic translation initiation factor 3 subunit J antisense RNA 1 (EIF3J-AS1), musculin antisense RNA 1 (MSC-AS1), RNA polymerase II subunit J4 (pseudogene) (POLR2J4), Pvt1 oncogene (PVT1), rhabdomyosarcoma 2 associated transcript (RMST), and SERHL) in tumor tissues as a prognostic signature and verified that a high signature score was an independent predictor for a shorter RFS (HR, 1.270; 95% CI, 1.018&#8211;1.585; P value&#8201;=&#8201;0.034) in 442 retrospectively recruited HCC patients [<xref ref-type="bibr" rid="CR83">83</xref>]. Using RNAseq-based detection of the pre-treatment expression levels of seven lncRNAs (zinc finger protein, FOG family member 2 antisense RNA 1 (ZFPM2&#8208;AS1)<bold>,</bold> <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC009005.2">AC009005.2</ext-link>, RP11&#8208;190C22.8, RP11&#8208;363N22.3, RP11&#8208;388C12.8<bold>,</bold> RP11&#8208;572O6.1, and RP11&#8208;932O9.10) in tumor tissues as a prognostic signature, Yan et al. found that a high signature score was independently associated with a shorter OS (training cohort: HR, 4.342; 95% CI, 2.326&#8211;8.107; P value&#8201;&lt;&#8201;0.0001; validation cohort: HR, 3.144; 95% CI, 1.781&#8211;5.550; P value&#8201;&lt;&#8201;0.0001; entire cohort: HR, 3.263; 95% CI, 2.181&#8211;4.881; P value&#8201;&lt;&#8201;0.0001) in 308 retrospectively recruited HCC patients (154 as a training cohort and 154 as an internal validation cohort) [<xref ref-type="bibr" rid="CR84">84</xref>]. Based on RNAseq analysis of the pre-treatment expression levels of ten lncRNAs (LINC00856, LINC01116, LINC01559, LINC02003, myosin light chain kinase antisense RNA 1 (MYLK-AS1), Ras protein specific guanine nucleotide releasing factor 2 antisense RNA 1 (RASGRF2-AS1), RP11-150012.3, RP11-92C4.6, RP11-363N22.3<bold>,</bold> and ribonucleotide reductase regulatory subunit M2 (RRM2)) in tumor tissues as a prognostic signature, Zhang et al. unraveled that a high signature score independently predicted a shorter OS (HR, 3.639; 95% CI, 2.345&#8211;5.645; P value&#8201;&lt;&#8201;0.001) in 696 retrospectively recruited HCC patients [<xref ref-type="bibr" rid="CR85">85</xref>]. Yu et al. performed RNAseq to measure the pre-treatment expression levels of three lncRNAs (RP11-150O12.3, RP11-187E13.1, and RP13-143G15.4) in tumor tissues as a prognostic signature and demonstrated that a high signature score was independently correlated with a longer OS (training cohort: HR, 0.416; 95% CI, 0.207&#8211;0.836; P value&#8201;=&#8201;0.014; validation cohort: HR, 0.459; 95% CI, 0.225&#8211;0.936; P value&#8201;=&#8201;0.032; entire cohort: HR, 0.498; 95% CI, 0.313&#8211;0.792; P value&#8201;=&#8201;0.003) in 307 retrospectively recruited HCC patients (154 as a training cohort and 153 as an internal validation cohort) [<xref ref-type="bibr" rid="CR86">86</xref>]. In 157 retrospectively recruited HCC patients, Gu et al. carried out RNAseq to measure the pre-treatment expression levels of four lncRNAs (RUN and SH3 domain containing 1 antisense RNA 1 (RUSC1&#8208;AS1)<bold>,</bold> STEAP3 antisense RNA 1 (STEAP3&#8208;AS1), SNHG1, and SNHG3) in tumor tissues as a prognostic signature and determined that a high signature score was a factor independently associated with a shorter OS (HR, 2.977; 95% CI, 1.458&#8211;6.081; P value&#8201;=&#8201;0.003) [<xref ref-type="bibr" rid="CR87">87</xref>]. The study conducted by Luo et al. performed RNAseq to detect the pre-treatment expression levels of four lncRNAs (LINC02334<bold>,</bold> <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC012640.1">AC012640.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC013451.2">AC013451.2</ext-link>, and <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC062004.1">AC062004.1</ext-link>) in tumor tissues as a prognostic signature and revealed that a high signature score was an independent factor which predicted a shorter OS (HR, 3.393; 95% CI, 1.597&#8211;7.210; P value&#8201;=&#8201;0.001) in 337 retrospectively recruited HCC patients [<xref ref-type="bibr" rid="CR88">88</xref>]. Using RNAseq-based detection of the pre-treatment expression levels of five lncRNAs (LINC02043, LINC01605, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC062004.1">AC062004.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL139385">AL139385</ext-link><bold>,</bold> and endogenous retrovirus group 48 member 1, envelope (ERVH48-1)) in tumor tissues as a prognostic signature, Luo et al. showed an independent association between high signature score and shorter RFS (HR, 2.895; 95% CI, 1.491&#8211;5.621; P value&#8201;=&#8201;0.002) in 337 retrospectively recruited HCC patients [<xref ref-type="bibr" rid="CR88">88</xref>]. Based on RNAseq analysis of the pre-treatment expression levels of four lncRNAs (LINC00556<bold>,</bold> RP11&#8208;359K18.3, RP11&#8208;495K9.6, and RP11&#8208;96O20.2) in tumor tissues as a prognostic signature, Jiang et al. identified that a high signature score was an independent predictor for a shorter OS (training cohort: HR, 3.95; 95% CI, 3.65&#8211;8.90; P value&#8201;&lt;&#8201;0.001; validation cohort: HR, 2.38; 95% CI, 1.14&#8211;4.96; P value&#8201;=&#8201;0.02; entire cohort: HR, 3.82; 95% CI, 2.17&#8211;6.71; P value&#8201;&lt;&#8201;0.001) in 180 retrospectively recruited HCC patients (90 as a training cohort and 90 as an internal validation cohort) [<xref ref-type="bibr" rid="CR89">89</xref>]. In 50 retrospectively recruited HBV-related HCC patients treated with curative surgical resection, Wu et al. carried out qRT-PCR to measure the pre-treatment expression levels of four lncRNAs (LINC01116, DEAD/H-box helicase 11 antisense RNA 1 (DDX11-AS1), lung cancer associated transcript 1 (LUCAT1), and firre intergenic repeating RNA element (FIRRE)) in tumor tissues as a prognostic signature and ascertained that a high signature score was independently associated with shorter OS (HR, 23.925; 95% CI, 5.014&#8211;114.156; P value&#8201;&lt;&#8201;0.001) [<xref ref-type="bibr" rid="CR90">90</xref>]. The study conducted by Zhao et al. performed RNAseq to detect the pre-treatment expression levels of eight lncRNAs (LINC00506, LINC00511, LINC01136, keratin associated protein 5 antisense RNA 1 (KRTAP5-AS1), muskelin 1 antisense RNA (MKLN1-AS), THUMP domain 3 tRNA guanosine methyltransferase antisense RNA 1 (THUMPD3-AS1)<bold>,</bold> thrombospondin type laminin G domain and EAR repeats antisense RNA 1 (TSPEAR-AS1), and zinc finger protein 252, pseudogene antisense RNA 1 (ZNF252P-AS1)) in tumor tissues as a prognostic signature and confirmed that a high signature score independently predicted a shorter OS (HR, 3.198; 95% CI, 1.424&#8211;7.184; P value&#8201;=&#8201;0.004) in 95 retrospectively recruited HBV-related HCC patients [<xref ref-type="bibr" rid="CR91">91</xref>]. Using RNAseq-based detection of the pre-treatment expression levels of two lncRNAs (CTD-2510F5.4 and DSTN pseudogene 2 (DSTNP2)) in tumor tissues as a prognostic signature, Zhou et al. verified that a high signature score was independently correlated with a shorter OS (HR, 3.066; 95% CI, 1.339&#8211;7.020; P value&#8201;=&#8201;0.008) in 220 retrospectively recruited HCC patients [<xref ref-type="bibr" rid="CR92">92</xref>]. Based on RNAseq analysis of the pre-treatment expression levels of six lncRNAs (LINC02870<bold>,</bold> <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC012640.1">AC012640.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC090921.1">AC090921.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL158839.1">AL158839.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL356056.1">AL356056.1</ext-link>, and AL359853.1) in tumor tissues as a prognostic signature, Wu et al. found that a high signature score was a factor independently associated with a shorter OS (HR, 2.32; 95% CI, 1.43&#8211;3.77; P value&#8201;=&#8201;0) in 338 retrospectively recruited HCC patients [<xref ref-type="bibr" rid="CR93">93</xref>]. Wu et al. performed RNAseq to measure the pre-treatment expression levels of nine lncRNAs (LINC01447<bold>,</bold> phospholipase C epsilon 1 antisense RNA 1 (PLCE1-AS1), <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL158839.1">AL158839.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL356056.1">AL356056.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL445493.2">AL445493.2</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AP000808.1">AP000808.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AP003354.2">AP003354.2</ext-link>, MIR7-3 host gene (MIR7-3HG), T helper type 2 locus control region associated RNA (TH2LCRR)) in tumor tissues as a prognostic signature and unraveled that a high signature score was an independent factor which predicted a shorter RFS (HR, 3.86; 95% CI, 2.48&#8211;6.01; P value&#8201;=&#8201;0) in 338 retrospectively recruited HCC patients [<xref ref-type="bibr" rid="CR93">93</xref>]. In 120 retrospectively recruited HCC patients, Xu et al. carried out RNAseq to measure the pre-treatment expression levels of four lncRNAs (LINC00942, SLIT-ROBO Rho GTPase activating protein 3 antisense RNA 2 (SRGAP3-AS2), <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC010280.2">AC010280.2</ext-link><bold>,</bold> and <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AP000844.2">AP000844.2</ext-link>) in tumor tissues as a prognostic signature and demonstrated an independent association between low signature score and a longer OS (HR, 0.301; 95% CI, 0.172&#8211;0.527; P value&#8201;&lt;&#8201;0.001) and RFS (HR, 0.359; 95% CI, 0.209&#8211;0.616; P value&#8201;&lt;&#8201;0.001) [<xref ref-type="bibr" rid="CR94">94</xref>]. In 365 retrospectively recruited HCC patients (183 as a training cohort and 182 as an internal validation cohort), Gan et al. performed RNAseq to measure the pre-treatment expression levels of six lncRNAs (LINC02163, LINC02362, LINC02428, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC008549.1">AC008549.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC115619.1">AC115619.1</ext-link>, and CASC9) in tumor tissues as a prognostic signature and ascertained an independent association between high signature score and shorter OS (training cohort: HR, 1.751; 95% CI, 1.273&#8211;2.408; P value&#8201;&lt;&#8201;0.001; validation cohort: HR, 1.618; 95% CI, 1.200&#8211;2.182; P value&#8201;=&#8201;0.002) [<xref ref-type="bibr" rid="CR95">95</xref>]. The study conducted by Chen et al. performed RNAseq to detect the pre-treatment expression levels of four cell cycle-related lncRNAs (TMCC1-AS1<bold>,</bold> <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC009549.1">AC009549.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC090018.2">AC090018.2</ext-link>, and polycystin 1, transient receptor potential channel interacting pseudogene 6-nuclear pore complex interacting protein pseudogene 1 (PKD1P6-NPIPP1)) in tumor tissues as a prognostic signature and confirmed that a high signature score was an independent factor which predicted a shorter OS (training cohort: HR, unreported; P value&#8201;=&#8201;0.006; validation cohort: HR, unreported; P value&#8201;&lt;&#8201;0.001) in 370 retrospectively recruited HCC patients (185 as a training cohort and 185 as an internal validation cohort) [<xref ref-type="bibr" rid="CR96">96</xref>]. Using RNAseq-based detection of the pre-treatment expression levels of two cellular senescence-related lncRNAs (ArfGAP with GTPase domain, ankyrin repeat and PH domain 11 (AGAP11) and family with sequence similarity 182 member B (FAM182B)) in tumor tissues as a prognostic signature, Huang et al. verified an independent association between high signature score and shorter OS (HR, 1.534; 95% CI, 1.278&#8211;1.841; P value&#8201;&lt;&#8201;0.001) in 502 retrospectively recruited HCC patients [<xref ref-type="bibr" rid="CR97">97</xref>]. Based on RNAseq analysis of the pre-treatment expression levels of four oxidative stress-related lncRNAs (LINC02870, MKLN1-AS<bold>,</bold> TMCC1-AS1, and negative regulator of antiviral response (NRAV)) in tumor tissues as a prognostic signature, Zhong et al. identified that a high signature score was a factor independently associated with a shorter OS (HR, 1.478; 95% CI, 1.315&#8211;1.662; P value&#8201;&lt;&#8201;0.001) in 343 retrospectively recruited HCC patients [<xref ref-type="bibr" rid="CR98">98</xref>]. Wu et al. performed RNAseq to measure the pre-treatment expression levels of two extracellular matrix (ECM)-related lncRNAs (MKLN1-AS and AL031985.3) in tumor tissues as a prognostic signature and ascertained that a high signature score was an independent factor which predicted a shorter OS (HR, 1.895; 95% CI, 1.595&#8211;2.252; P value&#8201;&lt;&#8201;0.001) in 365 retrospectively recruited HCC patients [<xref ref-type="bibr" rid="CR99">99</xref>]. In 365 retrospectively recruited HCC patients, Huang et al. carried out RNAseq to measure the pre-treatment expression levels of six tumor microenvironment-related lncRNAs (LINC00426, LINC01150, LINC02273, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC007277.1">AC007277.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC008549.1">AC008549.1</ext-link>, and <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AP002954.1">AP002954.1</ext-link>) in tumor tissues as a prognostic signature and confirmed an independent association between high signature score and shorter OS (HR, 1.255; 95% CI, 1.138&#8211;1.383; P value&#8201;&lt;&#8201;0.001) [<xref ref-type="bibr" rid="CR100">100</xref>]. The study conducted by Zhu et al. performed RNAseq to detect the pre-treatment expression levels of five anoikis-related lncRNAs (MKLN1-AS, DEAD/H-box helicase 11 antisense RNA 1 (DDX11-AS1), TMCC1-AS1<bold>,</bold> <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC026412.3">AC026412.3</ext-link>, and AL031985.3) in tumor tissues as a prognostic signature and verified that a high signature score was an independent predictor for a shorter OS (HR, 1.137; 95% CI, 1.091&#8211;1.185; P value&#8201;&lt;&#8201;0.001) in 377 retrospectively recruited HCC patients [<xref ref-type="bibr" rid="CR101">101</xref>]. The study conducted by Shu et al. performed RNAseq to detect the pre-treatment expression levels of five PANoptosis-related lncRNAs signature (LINC01224, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC026356.1">AC026356.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC026412.3">AC026412.3</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL442125.2">AL442125.2</ext-link>, and MIR4435-2HG) in tumor tissues as a prognostic signature and demonstrated that a high signature score was an independent predictor for a shorter OS (HR, 1.215; 95% CI, 1.058&#8211;1.394; P value&#8201;&lt;&#8201;0.006) in 370 retrospectively recruited HCC patients [<xref ref-type="bibr" rid="CR102">102</xref>]. Five studies were conducted to evaluate the independent prognostic value of the combination of methylation-related lncRNAs. The study conducted by Liao et al. performed RNAseq to detect the pre-treatment expression levels of four methylated lncRNAs (LINC01164, LINC01183, LINC01269<bold>,</bold> and <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC025016.1">AC025016.1</ext-link>) in tumor tissues as a prognostic signature and determined that a high signature score was an independent predictor for a shorter OS (HR, 2.469; 95% CI, 1.238&#8211;4.923; P value&#8201;=&#8201;0.01) in 348 retrospectively recruited HCC patients [<xref ref-type="bibr" rid="CR103">103</xref>]. Using RNAseq-based detection of the pre-treatment expression levels of nine N6-methyladenine (m6A) regulator-related lncRNAs (LINC01138, LINC01224, LINC03124, MKLN1-AS, POLH-AS1, AL031985.3, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL117336.2">AL117336.2</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL158166.1">AL158166.1</ext-link>, and <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL442125.2">AL442125.2</ext-link>) in tumor tissues as a prognostic signature, Jin et al. revealed that a high signature score was independently associated with a shorter OS (training cohort: HR, 1.091; 95% CI, 1.051&#8211;1.132; P value&#8201;&lt;&#8201;0.001; validation cohort: HR, 1.131; 95% CI, 1.082&#8211;1.182; P value&#8201;&lt;&#8201;0.001) in 342 retrospectively recruited HCC patients (226 as a training cohort and 116 as an internal validation cohort) [<xref ref-type="bibr" rid="CR104">104</xref>]. Based on RNAseq analysis of the pre-treatment expression levels of eight m6A methyltransferase-related lncRNAs (LINC01093, LINC02362, GAS5, SNHG6, SNHG7, SNHG17, SNHG20, and ZNFX1 antisense RNA 1 (ZFAS1)) in tumor tissues as a prognostic signature, Li et al. showed that a high signature score independently predicted a shorter OS (HR, 2; 95% CI, 1.2&#8211;3.1; P value&#8201;=&#8201;0.037) in 260 retrospectively recruited HCC patients [<xref ref-type="bibr" rid="CR105">105</xref>]. Chen et al. performed RNAseq to measure the pre-treatment expression levels of four m6A-related lncRNAs (PTOV1 antisense RNA 1 (PTOV1-AS1), AC145207.5, AL031985.3, and negative regulator of antiviral response (NRAV)) in tumor tissues as a prognostic signature and identified that a high signature score was independently correlated with a shorter OS (HR, 1.158; 95% CI, 1.1&#8211;1.219; P value&#8201;&lt;&#8201;0.001) in 343 retrospectively recruited HCC patients [<xref ref-type="bibr" rid="CR106">106</xref>]. In 365 retrospectively recruited HCC patients, Wei et al. carried out RNAseq to measure the pre-treatment expression levels of nine N7-methylguanosine (m7G)-related lncRNAs (suppressor of cytokine signaling 2 antisense RNA 1 (SOCS2-AS1), neuron navigator 2 antisense RNA 4 (NAV2-AS4), RP5-1171I10.5, RP11-10A14.3, RP11-43F13.3, RP11-519G16.5, RP11-588H23.3, RP11-874J12.4, and RP11-95O2.5) in tumor tissues as a prognostic signature and ascertained that a high signature score was a factor independently associated with a shorter OS (HR, 1.283; 95% CI, 1.198&#8211;1.374; P value&#8201;&lt;&#8201;0.001) [<xref ref-type="bibr" rid="CR107">107</xref>]. Four studies were conducted to evaluate the independent prognostic value of the combination of epithelial-to-mesenchymal transition (EMT)-related lncRNAs. Xu et al. performed RNAseq to measure the pre-treatment expression levels of five EMT-related lncRNAs (<ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC023157.3">AC023157.3</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC099850.3">AC099850.3</ext-link>, AL031985.3, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL365203.2">AL365203.2</ext-link>, and cytoskeleton regulator RNA (CYTOR)) in tumor tissues as a prognostic signature and unraveled that a high signature score was independently associated with a shorter OS (HR, 2.400; 95% CI, 1.667&#8211;3.454; P value&#8201;&lt;&#8201;0.001) in 370 retrospectively recruited HCC patients [<xref ref-type="bibr" rid="CR108">108</xref>]. In 368 retrospectively recruited HCC patients (197 as a training cohort and 171 as an internal validation cohort), Tao et al. carried out RNAseq to measure the pre-treatment expression levels of five EMT-related lncRNAs (LINC01116<bold>,</bold> <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC009005.1">AC009005.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC011352.3">AC011352.3</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC025176.1">AC025176.1</ext-link>, and <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AP002478.1">AP002478.1</ext-link>) in tumor tissues as a prognostic signature and demonstrated that a high signature score independently predicted a shorter OS (training cohort: HR, 1.690; 95% CI, 1.204&#8211;2.372; P value&#8201;=&#8201;0.002; validation cohort: HR, 1.503; 95% CI, 1.159&#8211;1.948; P value&#8201;=&#8201;0.002; entire cohort: HR, 1.448; 95% CI, 1.229&#8211;1.702; P value&#8201;&lt;&#8201;0.001) [<xref ref-type="bibr" rid="CR109">109</xref>]. The studies conducted by Zhou et al. performed RNAseq to detect the pre-treatment expression levels of nine EMT-related lncRNAs (extracellular leucine rich repeat and fibronectin type III domain containing 1 antisense RNA 1 (ELFN1-AS1), <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC009005.1">AC009005.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC022424.1">AC022424.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC026369.2">AC026369.2</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC068506.1">AC068506.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC068580.1">AC068580.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC079305.2">AC079305.2</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL049840.6">AL049840.6</ext-link><bold>,</bold> and lnc-cyclin Y (CCNY)-1) in tumor tissues as a prognostic signature and determined that a high signature score was independently correlated with a shorter OS (training cohort: HR, unreported; P value&#8201;&lt;&#8201;0.0001; validation cohort: HR, unreported; P value&#8201;=&#8201;0.012) in 377 retrospectively recruited HCC patients (264 as a training cohort and 113 as an internal validation cohort) [<xref ref-type="bibr" rid="CR110">110</xref>]. Using RNAseq-based detection of the pre-treatment expression levels of three EMT-related lncRNAs (zinc finger protein, FOG family member 2 antisense RNA 1 (ZFPM2-AS1), AC005332.3, and lnc-CCNY-1) in tumor tissues as a prognostic signature, Zhou et al. revealed that a high signature score was a factor independently associated with a shorter RFS (training cohort: HR, unreported; P value&#8201;&lt;&#8201;0.0001; validation cohort: HR, unreported; P value&#8201;=&#8201;0.086) in 377 retrospectively recruited HCC patients (264 as a training cohort and 113 as an internal validation cohort) [<xref ref-type="bibr" rid="CR110">110</xref>]. Four studies were conducted to evaluate the independent prognostic value of the combination of genomic instability-related lncRNAs. Based on RNAseq analysis of the pre-treatment expression levels of three genomic instability-related lncRNAs (ZFPM2-AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC004862.1">AC004862.1</ext-link><bold>,</bold> and <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC145343.1">AC145343.1</ext-link>) in tumor tissues as a prognostic signature, Huang et al. showed that a high signature score was an independent factor which predicted a shorter OS (training cohort: HR, 1.153; 95% CI, 1.096&#8211;1.213; P value&#8201;&lt;&#8201;0.0001; validation cohort: HR, 1.102; 95% CI, 1.042&#8211;1.145; P value&#8201;=&#8201;0.002; entire cohort: HR, 1.114; 95% CI, 1.061&#8211;1.168; P value&#8201;&lt;&#8201;0.0001) in 364 retrospectively recruited HCC patients (182 as a training cohort and 182 as an internal validation cohort) [<xref ref-type="bibr" rid="CR111">111</xref>]. Tang et al. performed RNAseq to measure the pre-treatment expression levels of four genomic instability-related lncRNAs (proline rich transmembrane protein 3 antisense RNA 1 (PRRT3-AS1), ZFPM2-AS1<bold>,</bold> LUCAT1, and MIR210 host gene (MIR210HG)) in tumor tissues as a prognostic signature and identified an independent association between high signature score and shorter OS (HR, 1.418; 95% CI, 1.220&#8211;1.648; P value&#8201;&lt;&#8201;0.001) in 249 retrospectively recruited HCC patients [<xref ref-type="bibr" rid="CR112">112</xref>]. In 370 retrospectively recruited HCC patients (187 as a training cohort and 183 as an internal validation cohort), Wu et al. carried out RNAseq to measure the pre-treatment expression levels of four genomic instability-related lncRNAs (ZFPM2-AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC116351.1">AC116351.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC145343.1">AC145343.1</ext-link>, and MIR210HG) in tumor tissues as a prognostic signature and ascertained that a high signature score was an independent predictor for a shorter OS (training cohort: HR, 1.284; 95% CI, 1.173&#8211;1.406; P value&#8201;&lt;&#8201;0.001; validation cohort: not significant; entire cohort: HR, 1.125; 95% CI, 1.058&#8211;1.196; P value&#8201;&lt;&#8201;0.001) [<xref ref-type="bibr" rid="CR113">113</xref>]. The study conducted by Jin et al. performed RNAseq to detect the pre-treatment expression levels of eleven genomic instability-related lncRNAs (LINC00501, LINC01508, LINC02055, LINC02714, AC002511.2, LOC105371967, RP11-305F18.1, RP11-342M1.3, RP11-432J24.3, RP11-96A15.1, and <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="U95743.1">U95743.1</ext-link>) in tumor tissues as a prognostic signature and confirmed that a high signature score was independently associated with a shorter OS (training cohort: HR, 2.322; 95% CI, unreported; P value&#8201;=&#8201;0.0003; validation cohort: HR, 2.167; 95% CI, unreported; P value&#8201;=&#8201;0.004; entire cohort: HR, 2.169; 95% CI, unreported; P value&#8201;&lt;&#8201;0.0001) in 365 retrospectively recruited HCC patients (182 as a training cohort and 183 as an internal validation cohort) [<xref ref-type="bibr" rid="CR114">114</xref>]. Four studies were conducted to evaluate the independent prognostic value of the combination of metabolism-related lncRNAs. Using RNAseq-based detection of the pre-treatment expression levels of five metabolism-related lncRNAs (<ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC099850.3">AC099850.3</ext-link>, AL031985.3, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL365203.2">AL365203.2</ext-link>, LUCAT1, and MIR210HG) in tumor tissues as a prognostic signature, Wang et al. verified that a high signature score independently predicted a shorter OS (HR, 2.206; 95% CI, 1.539&#8211;3.163; P value&#8201;&lt;&#8201;0.001) in 370 retrospectively recruited HCC patients [<xref ref-type="bibr" rid="CR115">115</xref>]. Based on RNAseq analysis of the pre-treatment expression levels of nine metabolism-related lncRNAs (POLH-AS1, TMCC1-AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC004816.1">AC004816.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC107959.3">AC107959.3</ext-link><bold>,</bold> <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL117336.2">AL117336.2</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC124798.1">AC124798.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC125437.1">AC125437.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC145343.1">AC145343.1</ext-link>, and SNHG4) in tumor tissues as a prognostic signature, Wang et al. found that a high signature score was independently correlated with a shorter OS (HR, 2.82; 95% CI, 1.91&#8211;4.18; P value&#8201;&lt;&#8201;0.001) in 343 retrospectively recruited HCC patients [<xref ref-type="bibr" rid="CR116">116</xref>]. Lei et al. performed RNAseq to measure the pre-treatment expression levels of six cholesterol metabolism-related lncRNAs (WW domain containing adaptor with coiled-coil antisense RNA 1 (WAC-AS1), <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC022613.1">AC022613.1</ext-link><bold>,</bold> <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC103760.1">AC103760.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC124798.1">AC124798.1</ext-link>, AL031985.3, and NRAV) in tumor tissues as a prognostic signature and unraveled that a high signature score was a factor independently associated with a shorter OS (HR, 1.092; 95% CI, 1.048&#8211;1.138; P value&#8201;&lt;&#8201;0.001) in 342 retrospectively recruited HCC patients [<xref ref-type="bibr" rid="CR117">117</xref>]. In 343 retrospectively recruited HCC patients, Cui et al. carried out RNAseq to measure the pre-treatment expression levels of five bile acid and bile salt metabolism-related lncRNAs (<ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC015908.3">AC015908.3</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL031722.1">AL031722.1</ext-link>, AL031985.3, LUCAT1, and PCCA-DT) in tumor tissues as a prognostic signature and demonstrated that a high signature score was an independent factor which predicted a shorter OS (HR, 2.926; 95% CI, 1.754&#8211;4.882; P value&#8201;&lt;&#8201;0.001) [<xref ref-type="bibr" rid="CR118">118</xref>]. Eleven studies were conducted to evaluate the independent prognostic value of the combination of immune-related lncRNAs. The study conducted by Zhang et al. performed RNAseq to detect the pre-treatment expression levels of ten immune-related lncRNAs (LINC00200, LINC00426, LINC00623, LINC01096, LINC01554, hepsin antisense RNA 1 (HPN&#8208;AS1), protein kinase C theta antisense RNA 1 (PRKCQ&#8208;AS1)<bold>,</bold> FIRRE, mir-99a-let-7c cluster host gene (MIR99AHG), and small Cajal body-specific RNA 9 (SCARNA9)) in tumor tissues as a prognostic signature and determined that a high signature score was an independent factor which predicted a shorter OS (training cohort: HR, 3.337; 95% CI, 2.191&#8211;5.084; P value&#8201;&lt;&#8201;0.001; validation cohort: HR, 4.352; 95% CI, 1.458&#8211;12.987; P value&#8201;=&#8201;0.008) in 483 retrospectively recruited HCC patients (368 as a training cohort and 115 as an external validation cohort) [<xref ref-type="bibr" rid="CR119">119</xref>]. Using RNAseq-based detection of the pre-treatment expression levels of seven immune-related lncRNAs (LINC00942<bold>,</bold> MSC-AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC007405.3">AC007405.3</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC023157.3">AC023157.3</ext-link>, CASC19, growth arrest associated lncRNA 1 (GASAL1), and NRAV) in tumor tissues as a prognostic signature, Xu et al. revealed that a high signature score was an independent predictor for a shorter OS (training cohort: HR, 1.193; 95% CI, 1.108&#8211;1.285; P value&#8201;&lt;&#8201;0.001; validation cohort: HR, 1.241; 95% CI, 1.127&#8211;1.366; P value&#8201;&lt;&#8201;0.001) in 370 retrospectively recruited HCC patients (186 as a training cohort and 184 as an internal validation cohort) [<xref ref-type="bibr" rid="CR120">120</xref>]. Based on RNAseq analysis of the pre-treatment expression levels of nine immune-related lncRNAs (LINC00205, LINC01232<bold>,</bold> DCST1-AS1, sterol regulatory element binding transcription factor 2 antisense RNA 1 (SREBF2-AS1), transmembrane protein 220 antisense RNA 1 (TMEM220-AS1), <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL049840.2">AL049840.2</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL139260.1">AL139260.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="CR936218.2">CR936218.2</ext-link>, and LUCAT1) in tumor tissues as a prognostic signature, Yuan et al. showed that a high signature score was independently associated with a shorter OS (HR, 1.255; 95% CI, 1.160&#8211;1.358; P value&#8201;&lt;&#8201;0.001) in 370 retrospectively recruited HCC patients [<xref ref-type="bibr" rid="CR121">121</xref>]. Li et al. performed RNAseq to measure the pre-treatment expression levels of four immune-related lncRNAs (ZFPM2-AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC015908.3">AC015908.3</ext-link><bold>,</bold> <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC099850.3">AC099850.3</ext-link><italic toggle="yes">,</italic> and NRAV) in tumor tissues as a prognostic signature and identified that a high signature score independently predicted a shorter OS (HR, 1.212; 95% CI, 1.137&#8211;1.293; P value&#8201;&lt;&#8201;0.001) in 342 retrospectively recruited HCC patients [<xref ref-type="bibr" rid="CR122">122</xref>]. In 329 retrospectively recruited HCC patients, Wang et al. carried out RNAseq to measure the pre-treatment expression levels of six immune-related lncRNAs (LINC01224<bold>,</bold> PRRT3-AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC099850.4">AC099850.4</ext-link>, AL031985.3, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL365203.2">AL365203.2</ext-link>, and NRAV) in tumor tissues as a prognostic signature and ascertained that a high signature score was independently correlated with a shorter OS (HR, 1.189; 95% CI, 1.109&#8211;1.275; P value&#8201;&lt;&#8201;0.0001) [<xref ref-type="bibr" rid="CR123">123</xref>]. The study conducted by Xin et al. performed RNAseq to detect the pre-treatment expression levels of nine immune-related lncRNAs (LINC00856, phosphoglucomutase 5 pseudogene 3 antisense RNA 1 (PGM5P3-AS1), <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC011287.1">AC011287.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC019257.1">AC019257.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC027288.1">AC027288.1</ext-link><bold>,</bold> <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC110285.3">AC110285.3</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL161431.1">AL161431.1</ext-link>, APC down-regulated 1 like divergent transcript (APCDD1L-DT), and tryptophanyl tRNA synthetase 2, mitochondrial intronic transcript 1 (WARS2-IT1)) in tumor tissues as a prognostic signature and confirmed that a high signature score was a factor independently associated with a shorter OS (HR, 1.444; 95% CI, 1.290&#8211;1.616; P value&#8201;&lt;&#8201;0.001) in 374 retrospectively recruited HCC patients [<xref ref-type="bibr" rid="CR124">124</xref>]. Using RNAseq-based detection of the pre-treatment expression levels of six immune-related lncRNAs (LINC01011, LINC01224, rhophilin Rho GTPase binding protein 1 antisense RNA 1 (RHPN1-AS1), CTD-2510F5.4, RP1-228H13.5, and RP11-324I22.4) in tumor tissues as a prognostic signature, Lu et al. verified that a high signature score was an independent factor which predicted a shorter OS (HR, 2.102; 95% CI, 1.742&#8211;2.535; P value&#8201;&lt;&#8201;0.0001) in 370 retrospectively recruited HCC patients [<xref ref-type="bibr" rid="CR125">125</xref>]. Based on qRT-PCR analysis of the pre-treatment expression levels of six immune-related lncRNAs (MSC-AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC009005.1">AC009005.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC099850.3">AC099850.3</ext-link><bold>,</bold> AL031985.3, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL117336.3">AL117336.3</ext-link>, and <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL365203.2">AL365203.2</ext-link>) in tumor tissues as a prognostic signature, Kong et al. found an independent association between high signature score and shorter OS (HR, 1.359; 95% CI, 1.253&#8211;1.474; P value&#8201;&lt;&#8201;0.001) in 373 retrospectively recruited HCC patients [<xref ref-type="bibr" rid="CR126">126</xref>]. He et al. performed RNAseq to measure the pre-treatment expression levels of four immune- and immunogenic cell death-related lncRNAs (LINC01554, LINC02362, LINC02499, and TMEM220-AS1) in tumor tissues as a prognostic signature and unraveled that a high signature score was an independent predictor for a shorter OS (HR, 4.600; 95% CI, 2.070&#8211;10.220; P value&#8201;&lt;&#8201;0.001) in 370 retrospectively recruited HCC patients [<xref ref-type="bibr" rid="CR127">127</xref>]. In 343 retrospectively recruited HCC patients treated with curative surgical resection, Wang et al. carried out RNAseq to measure the pre-treatment expression levels of five costimulatory molecule-related lncRNAs (BOK antisense RNA 1 (BOK-AS1), <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC099850.3">AC099850.3</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL049840.4">AL049840.4</ext-link><bold>,</bold> <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL365203.2">AL365203.2</ext-link>, and NRAV) in tumor tissues as a prognostic signature and demonstrated that a high signature score was independently associated with a shorter OS (HR, 1.348; 95% CI, 1.179&#8211;1.476; P value&#8201;&lt;&#8201;0.001) [<xref ref-type="bibr" rid="CR128">128</xref>]. Wang et al. conducted RNAseq to measure the pre-treatment expression levels of seven antigen-presenting cells- and T-cell infiltration-related lncRNAs signature (LINC01871, LINC02321, LINC02362, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC073611.1">AC073611.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL050341.2">AL050341.2</ext-link>, LUCAT1, and zinc finger protein 582 antisense RNA 1 (ZNF582-AS1)) in tumor tissues as a prognostic signature and revealed that a high signature score was an independent predictor for a shorter OS (HR, 4.273; 95% CI, 0.883&#8211;20.683; P value&#8201;=&#8201;0.071) in 805 retrospectively recruited HCC patients [<xref ref-type="bibr" rid="CR129">129</xref>]. Four studies were conducted to evaluate the independent prognostic value of the combination of autophagy-related lncRNAs. The study conducted by Deng et al. performed RNAseq to detect the pre-treatment expression levels of five autophagy-related lncRNAs (LINC01063, MKLN1-AS, PLBS1 antisense RNA 1 (PLBS1-AS1), TMMC1 antisense RNA 1 (TMMC1-AS1), and CYTOR) in tumor tissues as a prognostic signature and determined that a low signature score independently predicted a longer OS (HR, 0.40; 95% CI, 0.26&#8211;0.63; P value&#8201;&lt;&#8201;0.001) in 370 retrospectively recruited HCC patients [<xref ref-type="bibr" rid="CR130">130</xref>]. Using RNAseq-based detection of the pre-treatment expression levels of four autophagy-related lncRNAs (beta-secretase 1 antisense RNA (BACE1-AS), zinc finger E-box binding homeobox 1 antisense RNA 1 (ZEB1-AS1), MIR210HG, and SNHG3) in tumor tissues as a prognostic signature, Deng et al. revealed that a high signature score was independently correlated with a shorter OS (training cohort: HR, 1.385; 95% CI, 1.121&#8211;1.710; P value&#8201;=&#8201;0.002; validation cohort: HR, 1.704; 95% CI, 1.036&#8211;2.801; P value&#8201;=&#8201;0.036) in 573 retrospectively recruited HCC patients (343 as a training cohort and 230 as an external validation cohort) [<xref ref-type="bibr" rid="CR131">131</xref>]. Based on RNAseq analysis of the pre-treatment expression levels of seven autophagy-related lncRNAs (LINC01138, PRRT3-AS1<bold>,</bold> CTD-2510F5.4, CTC-297N7.9, RP11-324I22.4<bold>,</bold> RP11-479G22.8, and RP11-73M18.8) in tumor tissues as a prognostic signature, Yang et al. showed that a high signature score was a factor independently associated with a shorter OS (HR, 1.637; 95% CI, 1.371&#8211;1.955; P value&#8201;&lt;&#8201;0.0001) in 147 retrospectively recruited HCC patients [<xref ref-type="bibr" rid="CR132">132</xref>]. Wang et al. performed RNAseq to measure the pre-treatment expression levels of three immune- and autophagy-related lncRNAs (<ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC099850.3">AC099850.3</ext-link>, CYTOR, and MIR210HG) in tumor tissues as a prognostic signature and identified that a high signature score was an independent factor which predicted a shorter OS (HR, 1.751; 95% CI, 1.072&#8211;2.860; P value&#8201;=&#8201;0.025) in 163 retrospectively recruited HCC patients [<xref ref-type="bibr" rid="CR133">133</xref>]. Eight studies were conducted to evaluate the independent prognostic value of the combination of ferroptosis-related lncRNAs. In 363 retrospectively recruited HCC patients (218 as a training cohort and 145 as an internal validation cohort), Huang et al. carried out RNAseq to measure the pre-treatment expression levels of eight immune- and ferroptosis-related lncRNAs (LINC01224, glial cell derived neurotrophic factor antisense RNA 1 (GDNF-AS1), ZFPM2-AS1<bold>,</bold> <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC009005.1">AC009005.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC092119.2">AC092119.2</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC099850.3">AC099850.3</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL356234.2">AL356234.2</ext-link>, and LUCAT1) in tumor tissues as a prognostic signature and ascertained an independent association between high signature score and shorter OS (training cohort: HR, 2.358; 95% CI, 1.710&#8211;3.251; P value&#8201;&lt;&#8201;0.001; validation cohort: HR, 2.590; 95% CI, 1.735&#8211;3.865; P value&#8201;&lt;&#8201;0.001) [<xref ref-type="bibr" rid="CR134">134</xref>]. The study conducted by Li et al. performed RNAseq to detect the pre-treatment expression levels of five ferroptosis-related lncRNAs (<ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC099850.3">AC099850.3</ext-link>, AL031985.3<bold>,</bold> AL049840.5, lncRNA sorafenib resistance in renal cell carcinoma associated (LNCSRLR), and NRAV) in tumor tissues as a prognostic signature and confirmed that a high signature score was an independent predictor for a shorter OS (HR, 1.345; 95% CI, 1.215&#8211;1.488; P value&#8201;&lt;&#8201;0.001) in 222 retrospectively recruited HCC patients [<xref ref-type="bibr" rid="CR135">135</xref>]. Using RNAseq-based detection of the pre-treatment expression levels of six ferroptosis-related lncRNAs (LINC00942<bold>,</bold> LINC01224, MKLN1-AS, POLH-AS1, AL031985.3, and prostate cancer associated transcript 6 (PCAT6)) in tumor tissues as a prognostic signature, Fang et al. verified that a high signature score was independently associated with a shorter OS (HR, 1.096; 95% CI, 1.064&#8211;1.130; P value&#8201;&lt;&#8201;0.001) in 370 retrospectively recruited HCC patients [<xref ref-type="bibr" rid="CR136">136</xref>]. Based on RNAseq analysis of the pre-treatment expression levels of seven ferroptosis-related lncRNAs (LINC00668, LINC01224, LINC01269, FOXD2-AS1, MKLN1-AS, MSC-AS1, and TMCC1-AS1) in tumor tissues as a prognostic signature, Wang et al. found that a high signature score independently predicted a shorter OS (HR, 1.008; 95% CI, 1.004&#8211;1.012; P value&#8201;=&#8201;0.000) in 363 retrospectively recruited HCC patients [<xref ref-type="bibr" rid="CR137">137</xref>]. Lian et al. performed RNAseq to measure the pre-treatment expression levels of sixteen ferroptosis-related lncRNAs (LINC01871, TMEM220-AS1, ZFPM2-AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC009005.1">AC009005.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC009403.1">AC009403.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC009779.2">AC009779.2</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC012467.2">AC012467.2</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC026369.2">AC026369.2</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC068580.3">AC068580.3</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC074117.1">AC074117.1</ext-link>, AL031985.3, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL139384.1">AL139384.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL365203.2">AL365203.2</ext-link>, LUCAT1, MIR210HG<bold>,</bold> and NRAV) in tumor tissues as a prognostic signature and unraveled that a high signature score was independently correlated with a shorter OS (HR, 3.064; 95% CI, 2.063&#8211;4.55; P value&#8201;&lt;&#8201;0.001) in 364 retrospectively recruited HCC patients [<xref ref-type="bibr" rid="CR138">138</xref>]. In 370 retrospectively recruited HCC patients, Lin et al. carried out RNAseq to measure the pre-treatment expression levels of seventeen ferroptosis-related lncRNAs (LINC00205, LINC00942, MKLN1-AS, POLH-AS1, ZFPM2-AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC012073.1">AC012073.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC026401.3">AC026401.3</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC090772.3">AC090772.3</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC099850.1">AC099850.1</ext-link>, AC145207.8, AL031985.3, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL139384.1">AL139384.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL603839.3">AL603839.3</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL928654.1">AL928654.1</ext-link>, AP001469.3, SNHG10, and SNHG21) in tumor tissues as a prognostic signature and demonstrated that a high signature score was a factor independently associated with a shorter OS (HR, 1.604; 95% CI, 1.574&#8211;1.635; P value&#8201;&lt;&#8201;0.001) [<xref ref-type="bibr" rid="CR139">139</xref>]. The study conducted by Yang et al. performed RNAseq to detect the pre-treatment expression levels of seventeen ferroptosis-related lncRNAs (LINC00205, LINC00942, MKLN1-AS, POLH-AS1, ZFPM2-AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC012073.1">AC012073.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC026401.3">AC026401.3</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC090772.3">AC090772.3</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC099850.1">AC099850.1</ext-link>, AC145207.8, AL031985.3, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL139384.1">AL139384.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL603839.3">AL603839.3</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL928654.1">AL928654.1</ext-link>, AP001469.3, SNHG10, and SNHG21) in tumor tissues as a prognostic signature and determined that a high signature score was an independent factor which predicted a shorter OS (HR, 1.401; 95% CI, 1.281&#8211;1.532; P value&#8201;&lt;&#8201;0.001) in 376 retrospectively recruited HCC patients [<xref ref-type="bibr" rid="CR140">140</xref>]. Using RNAseq-based detection of the pre-treatment expression levels of seven ferroptosis-related lncRNAs (LINC00942, MKLN1-AS, POLH-AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC009403.1">AC009403.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC090772.3">AC090772.3</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC131009.1">AC131009.1</ext-link>, and AL031985.3) in tumor tissues as a prognostic signature, Wang et al. revealed an independent association between high signature score and shorter OS (HR, 1.316; 95% CI, 1.225&#8211;1.413; P value&#8201;&lt;&#8201;0.001) in 370 retrospectively recruited HCC patients [<xref ref-type="bibr" rid="CR141">141</xref>]. Two studies were conducted to evaluate the independent prognostic value of the combination of necroptosis-related lncRNAs. Based on RNAseq analysis of the pre-treatment expression levels of eight necroptosis-related lncRNAs (LINC01224, MKLN1-AS, POLH-AS1, PRRT3-AS1<bold>,</bold> <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC040970.1">AC040970.1</ext-link>, AL031985.3, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL928654.1">AL928654.1</ext-link>, and LUCAT1) in tumor tissues as a prognostic signature, Zhang et al. showed that a high signature score was an independent predictor for a shorter OS (HR, 1.160; 95% CI, 1.108&#8211;1.214; P value&#8201;&lt;&#8201;0.001) in 260 retrospectively recruited HCC patients [<xref ref-type="bibr" rid="CR142">142</xref>]. Chen et al. performed RNAseq to measure the pre-treatment expression levels of five necroptosis-related lncRNAs (BACE1-AS, lysine demethylase 4A antisense RNA 1 (KDM4A-AS1), MKLN1-AS<bold>,</bold> ZFPM2-AS1, and <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC099850.3">AC099850.3</ext-link>) in tumor tissues as a prognostic signature and identified that a high signature score was an independent predictor for a shorter OS (HR, 1.318; 95% CI, 1.220&#8211;1.423; P value&#8201;&lt;&#8201;0.001) in 370 retrospectively recruited HCC patients [<xref ref-type="bibr" rid="CR143">143</xref>]. Five studies were conducted to evaluate the independent prognostic value of the combination of cuproptosis-related lncRNAs. In 365 retrospectively recruited HCC patients, Zhang et al. carried out RNAseq to measure the pre-treatment expression levels of six cuproptosis-related lncRNAs (DEP domain containing 1 antisense RNA 1 (DEPDC1-AS1), dynamin binding protein antisense RNA 1 (DNMBP-AS1), <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC099329.2">AC099329.2</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC138904.1">AC138904.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC145343.1">AC145343.1</ext-link>, and GIHCG inhibitor of miR-200b/200a/429 expression (GIHCG)) in tumor tissues as a prognostic signature and identified that a high signature score was an independent predictor for a shorter OS (HR, unreported; P value&#8201;&lt;&#8201;0.0001) [<xref ref-type="bibr" rid="CR144">144</xref>]. The studies conducted by Ren et al. performed RNAseq to detect the pre-treatment expression levels of three cuproptosis-related lncRNAs (<ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL365203.2">AL365203.2</ext-link>, NRAV, and SNHG4) in tumor tissues as a prognostic signature and ascertained that a high signature score was independently associated with a shorter OS (training cohort: HR, 1.296; 95% CI, 1.042&#8211;1.610; P value&#8201;=&#8201;0.020; validation cohort: HR, 2.479; 95% CI, 1.034&#8211;5.943; P value&#8201;=&#8201;0.042) in 370 retrospectively recruited HCC patients (224 as a training cohort and 146 as an internal validation cohort) [<xref ref-type="bibr" rid="CR145">145</xref>]. Using RNAseq-based detection of the pre-treatment expression levels of seven cuproptosis-related lncRNAs (activin A receptor type 2B antisense RNA 1 (ACVR2B-AS1), sacsin molecular chaperone antisense RNA 1 (SACS-AS1), TMCC1-AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC084083.1">AC084083.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC092418.2">AC092418.2</ext-link><bold>,</bold> <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL021154.1">AL021154.1</ext-link>, and PCAT6) in tumor tissues as a prognostic signature, Yang et al. confirmed that a high signature score was an independent predictor for a shorter OS (HR, 1.063; 95% CI, 1.030&#8211;1.096; P value&#8201;&lt;&#8201;0.001) in 374 retrospectively recruited HCC patients [<xref ref-type="bibr" rid="CR146">146</xref>]. Based on RNAseq analysis of the pre-treatment expression levels of six cuproptosis-related lncRNAs (MKLN1-AS, solute carrier family 6 member 1 antisense RNA 1 (SLC6A1-AS1), TMCC1-AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC026412.3">AC026412.3</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC125437.1">AC125437.1</ext-link>, and <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL353572.4">AL353572.4</ext-link>) in tumor tissues as a prognostic signature, Wei et al. verified that a high signature score independently predicted a shorter OS (HR, 1.119; 95% CI, 1.073&#8211;1.168; P value&#8201;&lt;&#8201;0.001) in 370 retrospectively recruited HCC patients [<xref ref-type="bibr" rid="CR147">147</xref>]. Wang et al. performed RNAseq to measure the pre-treatment expression levels of nine cuproptosis-related lncRNAs (LINC0256<bold>.</bold>1, IQ motif containing H antisense RNA 1 (IQCH-AS1), WAC-AS1<bold>,</bold> ZFPM2-AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC003086.1">AC003086.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC007998.3">AC007998.3</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC009974.2">AC009974.2</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC105345.1">AC105345.1</ext-link>, and <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL353708.1">AL353708.1</ext-link>) in tumor tissues as a prognostic signature and ascertained that a high signature score was an independent factor which predicted a shorter OS (HR, 1.014; 95% CI, 1.003&#8211;1.025; P value&#8201;=&#8201;0.012) in 370 retrospectively recruited HCC patients [<xref ref-type="bibr" rid="CR148">148</xref>]. Three studies were conducted to evaluate the independent prognostic value of the combination of pyroptosis-related lncRNAs. In 342 retrospectively recruited HCC patients (240 as a training cohort and 102 as an internal validation cohort), Zhang et al. carried out RNAseq to measure the pre-treatment expression levels of five pyroptosis-related lncRNAs (MKLN1-AS, hepsin antisense RNA 1 (HPN-AS1), mediator complex subunit 8 antisense RNA 1 (MED8-AS1), SREBF2-AS1, and zinc finger protein 232 antisense RNA 1 (ZNF232-AS1)) in tumor tissues as a prognostic signature and confirmed an independent association between high signature score and shorter OS (training cohort: HR, 1.741; 95% CI, 1.464&#8211;2.069; P value&#8201;&lt;&#8201;0.001; validation cohort: HR, 1.446; 95% CI, 1.140&#8211;1.832; P value&#8201;=&#8201;0.002; entire cohort: HR, 1.578; 95% CI, 1.382&#8211;1.801; P value&#8201;&lt;&#8201;0.001) [<xref ref-type="bibr" rid="CR149">149</xref>]. The study conducted by Zhang et al. performed RNAseq to detect the pre-treatment expression levels of nine pyroptosis-related lncRNAs (MKLN1-AS, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC007128.1">AC007128.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC019080.5">AC019080.5</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC023157.2">AC023157.2</ext-link><bold>,</bold> AL031985.3, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AL445228.3">AL445228.3</ext-link>, AP003392.4, LNCSRLR, and PCCA-DT) in tumor tissues as a prognostic signature and verified that a high signature score was an independent predictor for a shorter OS (training cohort: HR, 2.163; 95% CI, 1.670&#8211;2.800; P value&#8201;&lt;&#8201;0.001; validation cohort: HR, 1.756; 95% CI, 1.208&#8211;2.554; P value&#8201;=&#8201;0.003) in 371 retrospectively recruited HCC patients (247 as a training cohort and 124 as an internal validation cohort) [<xref ref-type="bibr" rid="CR150">150</xref>]. Using RNAseq-based detection of the pre-treatment expression levels of twelve pyroptosis-related lncRNAs (LINC01224<bold>,</bold> MKLN1-AS, KDM4A-AS1, ZFPM2-AS1, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC008549.1">AC008549.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC099850.3">AC099850.3</ext-link>, AL031985.3, AL049840.5, crystallin zeta like 2, pseudogene-SEC16 homolog B, endoplasmic reticulum export factor (CRYZL2P-SEC16B), LUCAT1, NRAV, and SNHG4) in tumor tissues as a prognostic signature, Wang et al. found that a high signature score was independently associated with a shorter OS (HR, 3.837; 95% CI, 2.723&#8211;5.407; P value&#8201;&lt;&#8201;0.001) in 370 retrospectively recruited HCC patients [<xref ref-type="bibr" rid="CR151">151</xref>]. Three studies were conducted to evaluate the independent prognostic value of the combination of disulfidptosis-related lncRNAs. Based on RNAseq analysis of the pre-treatment expression levels of three disulfidptosis-related lncRNAs (KDM4A-AS1, MKLN1-AS<bold>,</bold> and TMCC1-AS1) in tumor tissues as a prognostic signature, Gu et al. unraveled that a high signature score independently predicted a shorter PFS (HR, 1.363; 95% CI, 1.195&#8211;1.556; P value&#8201;&lt;&#8201;0.001) in 527 retrospectively recruited HCC patients treated with curative surgical resection [<xref ref-type="bibr" rid="CR152">152</xref>]. Xu et al. performed RNAseq to measure the pre-treatment expression levels of three disulfidptosis-related lncRNAs (<ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC124798.1">AC124798.1</ext-link><bold>,</bold> POLH-AS1, and TMCC1-AS1) in tumor tissues as a prognostic signature and demonstrated that a high signature score was independently correlated with a shorter OS (HR, 1.277; 95% CI, 1.155&#8211;1.412; P value&#8201;&lt;&#8201;0.001) in 374 retrospectively recruited HCC patients [<xref ref-type="bibr" rid="CR153">153</xref>]. In 370 retrospectively recruited HCC patients, Xu et al. carried out RNAseq to measure the pre-treatment expression levels of five disulfidptosis-related lncRNAs (paxillin antisense RNA 1 (PXN-AS1), <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC026356.1">AC026356.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC026412.3">AC026412.3</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC073254.1">AC073254.1</ext-link>, and <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="AC099066.2">AC099066.2</ext-link>) in tumor tissues as a prognostic signature and determined that a high signature score was a factor independently associated with a shorter OS (HR, 1.159; 95% CI, 1.094&#8211;1.228; P value&#8201;&lt;&#8201;0.001) [<xref ref-type="bibr" rid="CR154">154</xref>].</p></sec></sec><sec id="Sec4"><title>Conclusions</title><p id="Par7">The comprehensive literature evidence summarized in this review demonstrates the independent prognostic significance of multiple single or combination lncRNA biomarkers in HCC patients. The current evidence highlights the potential of these prognostic lncRNA biomarkers in identifying the HCC patients with poor prognosis for timely diagnosis and early intervention to improve their survival; however, most findings are derived from retrospective cohorts with heterogeneous methodologies. Further validation through prospective, multicenter studies and mechanistic investigations is essential to confirm their clinical utility. Moreover, since lncRNAs have emerged as potential targets for cancer therapy [<xref ref-type="bibr" rid="CR155">155</xref>, <xref ref-type="bibr" rid="CR156">156</xref>], further investigation is worthwhile to evaluate the potential of the lncRNA biomarkers in selecting the HCC patients suitable for receiving lncRNA-targeting therapeutics. Considering that the HCC patient cohorts analyzed in different studies may undergo distinct therapeutic modalities, it is pivotal to choose the lncRNA biomarkers which exhibit the most optimal prognostic performance for individual patients to achieve the most accurate outcome prediction. Compared with current protein-based clinical biomarkers, lncRNAs possess an array of advantages in serving as promising biomarkers, such as high abundance in the circulation, great stability in challenging environments, rapid and cost-effective extraction in sample preparation, high specificity across tissue types, and high sensitivity for disease progression and therapeutic treatment [<xref ref-type="bibr" rid="CR157">157</xref>, <xref ref-type="bibr" rid="CR158">158</xref>]. However, although several lncRNA-based circulating diagnostic biomarkers for HCC have been discovered [<xref ref-type="bibr" rid="CR159">159</xref>, <xref ref-type="bibr" rid="CR160">160</xref>], most of the currently identified prognostic lncRNA biomarkers (except for CRNDE, SNHG9, and UCA1 which are identified from blood-derived specimens) are derived from tumor tissues at the pre-treatment time point in an invasive manner, highlighting the need for discovering prognostic lncRNA biomarkers from non-invasive liquid biopsies or at different sampling time points. Further integration of liquid biopsy technologies and multi-omics data is promising to develop novel potential lncRNA biomarkers. In addition, the accuracy and reproducibility of the currently identified prognostic lncRNA biomarkers should be taken into consideration in terms of the sample size, patient heterogeneity, methodological difference, and study design. The sample size of some studies (especially for evaluating single lncRNA biomarkers) is small (only around 60&#8211;70), which may affect the statistical power. In addition, some studies are limited by the lack of HRs reported and some studies have potential overestimation due to the HRs with a large 95% CI. The results of these studies should be interpreted with caution. Aside from CCAT2 and MALAT1 which are validated by two different lines of studies, the prognostic significance of most single lncRNA biomarkers remains only validated in one study each. More studies are still needed to reach a consensus on the outcome correlation and prognostic threshold for the current biomarkers to facilitate their translation into clinical application. Although the prognostic value of most combination lncRNA biomarkers is also evaluated in one study each, many lncRNA signatures are established by combination of specific functions-related lncRNAs from many different lines of studies, strengthening the generalizability of their prognostic results. Moreover, the patient cohorts analyzed in different studies vary in etiologies and therapeutic modalities, potentially confounding prognostic interpretations. All of the currently identified prognostic lncRNA biomarkers are based on single-center retrospective studies. The retrospective nature of included studies risks overestimating biomarker performance. It is therefore essential to conduct multicenter large prospective cohort studies with a stratified analysis of patient characteristics (such as diverse pathological backgrounds, HCC tumor stages, and treatment modalities) to provide more robust and unbiased evidence to confirm clinical utility. Furthermore, the heterogeneity in detection methods across studies may introduce technical variability. Also, the lack of standardized protocols for constructing combination lncRNA signatures complicates their reproducibility and clinical translation. The establishment of standardized methodological and technical protocols for biomarker detection processes (including specimen collection and storage, lncRNA isolation and measurement, as well as data acquisition and analysis) is necessary to improve the consistency and reliability of the biomarkers. Finally, most studies only correlate the expression of lncRNAs with prognosis, lacking functional experiments to verify their biological roles in HCC progression, highlighting the need for mechanistic studies that explore the therapeutic targeting potential of lncRNAs.</p></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>This work was supported by Grants from the China Medical University Hospital, Taichung, Taiwan (Grant number DMR-114-036).</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>L.B., H.R., and C.F. made the conceptualization and prepared the tables. C.F. acquired the funding and wrote and reviewed the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was supported by Grants from the China Medical University Hospital, Taichung, Taiwan (Grant number DMR-114-036).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par8">Not applicable.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par9">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par10">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Llovet</surname><given-names>JM</given-names></name><name name-style="western"><surname>Zucman-Rossi</surname><given-names>J</given-names></name><name name-style="western"><surname>Pikarsky</surname><given-names>E</given-names></name><name name-style="western"><surname>Sangro</surname><given-names>B</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>M</given-names></name><name name-style="western"><surname>Sherman</surname><given-names>M</given-names></name><name name-style="western"><surname>Gores</surname><given-names>G</given-names></name></person-group><article-title>Hepatocellular carcinoma</article-title><source>Nat Rev Dis Primers</source><year>2016</year><volume>2</volume><fpage>16018</fpage><pub-id pub-id-type="pmid">27158749</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrdp.2016.18</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, Gores G. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2:16018.<pub-id pub-id-type="pmid">27158749</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrdp.2016.18</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>KC</given-names></name><name name-style="western"><surname>Lin</surname><given-names>WY</given-names></name><name name-style="western"><surname>Liu</surname><given-names>CS</given-names></name><name name-style="western"><surname>Lin</surname><given-names>CC</given-names></name><name name-style="western"><surname>Lai</surname><given-names>HC</given-names></name><name name-style="western"><surname>Lai</surname><given-names>SW</given-names></name></person-group><article-title>Association of different types of liver disease with demographic and clinical factors</article-title><source>Biomedicine (Taipei)</source><year>2016</year><volume>6</volume><issue>3</issue><fpage>16</fpage><pub-id pub-id-type="pmid">27518399</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7603/s40681-016-0016-2</pub-id><pub-id pub-id-type="pmcid">PMC4996334</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Cheng KC, Lin WY, Liu CS, Lin CC, Lai HC, Lai SW. Association of different types of liver disease with demographic and clinical factors. Biomedicine (Taipei). 2016;6(3):16.<pub-id pub-id-type="pmid">27518399</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7603/s40681-016-0016-2</pub-id><pub-id pub-id-type="pmcid">PMC4996334</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name><name name-style="western"><surname>Xie</surname><given-names>H</given-names></name><name name-style="western"><surname>Hu</surname><given-names>M</given-names></name><name name-style="western"><surname>Huang</surname><given-names>T</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sang</surname><given-names>N</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name></person-group><article-title>Recent progress in treatment of hepatocellular carcinoma</article-title><source>Am J Cancer Res</source><year>2020</year><volume>10</volume><issue>9</issue><fpage>2993</fpage><lpage>3036</lpage><pub-id pub-id-type="pmid">33042631</pub-id><pub-id pub-id-type="pmcid">PMC7539784</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Chen Z, Xie H, Hu M, Huang T, Hu Y, Sang N, Zhao Y. Recent progress in treatment of hepatocellular carcinoma. Am J Cancer Res. 2020;10(9):2993&#8211;3036.<pub-id pub-id-type="pmid">33042631</pub-id><pub-id pub-id-type="pmcid">PMC7539784</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gallage</surname><given-names>S</given-names></name><name name-style="western"><surname>Garcia-Beccaria</surname><given-names>M</given-names></name><name name-style="western"><surname>Szydlowska</surname><given-names>M</given-names></name><name name-style="western"><surname>Rahbari</surname><given-names>M</given-names></name><name name-style="western"><surname>Mohr</surname><given-names>R</given-names></name><name name-style="western"><surname>Tacke</surname><given-names>F</given-names></name><name name-style="western"><surname>Heikenwalder</surname><given-names>M</given-names></name></person-group><article-title>The therapeutic landscape of hepatocellular carcinoma</article-title><source>Medicine</source><year>2021</year><volume>2</volume><issue>5</issue><fpage>505</fpage><lpage>552</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.medj.2021.03.002</pub-id><pub-id pub-id-type="pmid">35590232</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Gallage S, Garcia-Beccaria M, Szydlowska M, Rahbari M, Mohr R, Tacke F, Heikenwalder M. The therapeutic landscape of hepatocellular carcinoma. Medicine. 2021;2(5):505&#8211;52.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.medj.2021.03.002</pub-id><pub-id pub-id-type="pmid">35590232</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kulik</surname><given-names>L</given-names></name><name name-style="western"><surname>El-Serag</surname><given-names>HB</given-names></name></person-group><article-title>Epidemiology and management of hepatocellular carcinoma</article-title><source>Gastroenterology</source><year>2019</year><volume>156</volume><issue>2</issue><fpage>477</fpage><lpage>491</lpage><pub-id pub-id-type="pmid">30367835</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2018.08.065</pub-id><pub-id pub-id-type="pmcid">PMC6340716</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterology. 2019;156(2):477&#8211;91.<pub-id pub-id-type="pmid">30367835</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2018.08.065</pub-id><pub-id pub-id-type="pmcid">PMC6340716</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sung</surname><given-names>H</given-names></name><name name-style="western"><surname>Ferlay</surname><given-names>J</given-names></name><name name-style="western"><surname>Siegel</surname><given-names>RL</given-names></name><name name-style="western"><surname>Laversanne</surname><given-names>M</given-names></name><name name-style="western"><surname>Soerjomataram</surname><given-names>I</given-names></name><name name-style="western"><surname>Jemal</surname><given-names>A</given-names></name><name name-style="western"><surname>Bray</surname><given-names>F</given-names></name></person-group><article-title>Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title><source>CA Cancer J Clin</source><year>2021</year><volume>71</volume><issue>3</issue><fpage>209</fpage><lpage>249</lpage><pub-id pub-id-type="pmid">33538338</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21660</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209&#8211;49.<pub-id pub-id-type="pmid">33538338</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21660</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Statello</surname><given-names>L</given-names></name><name name-style="western"><surname>Guo</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Chen</surname><given-names>LL</given-names></name><name name-style="western"><surname>Huarte</surname><given-names>M</given-names></name></person-group><article-title>Gene regulation by long non-coding RNAs and its biological functions</article-title><source>Nat Rev Mol Cell Biol</source><year>2021</year><volume>22</volume><issue>2</issue><fpage>96</fpage><lpage>118</lpage><pub-id pub-id-type="pmid">33353982</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41580-020-00315-9</pub-id><pub-id pub-id-type="pmcid">PMC7754182</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Statello L, Guo CJ, Chen LL, Huarte M. Gene regulation by long non-coding RNAs and its biological functions. Nat Rev Mol Cell Biol. 2021;22(2):96&#8211;118.<pub-id pub-id-type="pmid">33353982</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41580-020-00315-9</pub-id><pub-id pub-id-type="pmcid">PMC7754182</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferrer</surname><given-names>J</given-names></name><name name-style="western"><surname>Dimitrova</surname><given-names>N</given-names></name></person-group><article-title>Transcription regulation by long non-coding RNAs: mechanisms and disease relevance</article-title><source>Nat Rev Mol Cell Biol</source><year>2024</year><volume>25</volume><issue>5</issue><fpage>396</fpage><lpage>415</lpage><pub-id pub-id-type="pmid">38242953</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41580-023-00694-9</pub-id><pub-id pub-id-type="pmcid">PMC11045326</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Ferrer J, Dimitrova N. Transcription regulation by long non-coding RNAs: mechanisms and disease relevance. Nat Rev Mol Cell Biol. 2024;25(5):396&#8211;415.<pub-id pub-id-type="pmid">38242953</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41580-023-00694-9</pub-id><pub-id pub-id-type="pmcid">PMC11045326</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sanchez Calle</surname><given-names>A</given-names></name><name name-style="western"><surname>Kawamura</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>Y</given-names></name><name name-style="western"><surname>Takeshita</surname><given-names>F</given-names></name><name name-style="western"><surname>Ochiya</surname><given-names>T</given-names></name></person-group><article-title>Emerging roles of long non-coding RNA in cancer</article-title><source>Cancer Sci</source><year>2018</year><volume>109</volume><issue>7</issue><fpage>2093</fpage><lpage>2100</lpage><pub-id pub-id-type="pmid">29774630</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/cas.13642</pub-id><pub-id pub-id-type="pmcid">PMC6029823</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Sanchez Calle A, Kawamura Y, Yamamoto Y, Takeshita F, Ochiya T. Emerging roles of long non-coding RNA in cancer. Cancer Sci. 2018;109(7):2093&#8211;100.<pub-id pub-id-type="pmid">29774630</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/cas.13642</pub-id><pub-id pub-id-type="pmcid">PMC6029823</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Meng</surname><given-names>Q</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>W</given-names></name><name name-style="western"><surname>Deng</surname><given-names>S</given-names></name><name name-style="western"><surname>Xue</surname><given-names>J</given-names></name></person-group><article-title>The role of long non-coding RNA in hepatocellular carcinoma</article-title><source>Aging (Albany NY)</source><year>2024</year><volume>16</volume><issue>4</issue><fpage>4052</fpage><lpage>4073</lpage><pub-id pub-id-type="pmid">38334963</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/aging.205523</pub-id><pub-id pub-id-type="pmcid">PMC10929815</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Liang W, Zhao Y, Meng Q, Jiang W, Deng S, Xue J. The role of long non-coding RNA in hepatocellular carcinoma. Aging (Albany NY). 2024;16(4):4052&#8211;73.<pub-id pub-id-type="pmid">38334963</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/aging.205523</pub-id><pub-id pub-id-type="pmcid">PMC10929815</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arun</surname><given-names>G</given-names></name><name name-style="western"><surname>Diermeier</surname><given-names>SD</given-names></name><name name-style="western"><surname>Spector</surname><given-names>DL</given-names></name></person-group><article-title>Therapeutic targeting of long non-coding RNAs in cancer</article-title><source>Trends Mol Med</source><year>2018</year><volume>24</volume><issue>3</issue><fpage>257</fpage><lpage>277</lpage><pub-id pub-id-type="pmid">29449148</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molmed.2018.01.001</pub-id><pub-id pub-id-type="pmcid">PMC5840027</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Arun G, Diermeier SD, Spector DL. Therapeutic targeting of long non-coding RNAs in cancer. Trends Mol Med. 2018;24(3):257&#8211;77.<pub-id pub-id-type="pmid">29449148</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molmed.2018.01.001</pub-id><pub-id pub-id-type="pmcid">PMC5840027</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>D</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shen</surname><given-names>J</given-names></name><name name-style="western"><surname>Du</surname><given-names>F</given-names></name><name name-style="western"><surname>Kaboli</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X</given-names></name><name name-style="western"><surname>Ji</surname><given-names>H</given-names></name><name name-style="western"><surname>Cho</surname><given-names>CH</given-names></name><name name-style="western"><surname>Wen</surname><given-names>Q</given-names></name><name name-style="western"><surname>Li</surname><given-names>W</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Chen</surname><given-names>B</given-names></name></person-group><article-title>Long non-coding RNAs: potential biomarkers and targets for hepatocellular carcinoma therapy and diagnosis</article-title><source>Int J Biol Sci</source><year>2021</year><volume>17</volume><issue>1</issue><fpage>220</fpage><lpage>235</lpage><pub-id pub-id-type="pmid">33390845</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/ijbs.50730</pub-id><pub-id pub-id-type="pmcid">PMC7757045</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Yuan D, Chen Y, Li X, Li J, Zhao Y, Shen J, Du F, Kaboli PJ, Li M, Wu X, Ji H, Cho CH, Wen Q, Li W, Xiao Z, Chen B. Long non-coding RNAs: potential biomarkers and targets for hepatocellular carcinoma therapy and diagnosis. Int J Biol Sci. 2021;17(1):220&#8211;35.<pub-id pub-id-type="pmid">33390845</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/ijbs.50730</pub-id><pub-id pub-id-type="pmcid">PMC7757045</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>B</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>W</given-names></name></person-group><article-title>Long non-coding RNA NRAD1 and LINC00152 are highly expressed and associated with prognosis in patients with hepatocellular carcinoma</article-title><source>Onco Targets Ther</source><year>2020</year><volume>13</volume><fpage>10409</fpage><lpage>10416</lpage><pub-id pub-id-type="pmid">33116620</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/OTT.S251231</pub-id><pub-id pub-id-type="pmcid">PMC7569076</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Wang B, Yang S, Zhao W. Long non-coding RNA NRAD1 and LINC00152 are highly expressed and associated with prognosis in patients with hepatocellular carcinoma. Onco Targets Ther. 2020;13:10409&#8211;16.<pub-id pub-id-type="pmid">33116620</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/OTT.S251231</pub-id><pub-id pub-id-type="pmcid">PMC7569076</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>R</given-names></name><name name-style="western"><surname>Yang</surname><given-names>R</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X</given-names></name><name name-style="western"><surname>Lv</surname><given-names>S</given-names></name><name name-style="western"><surname>Guan</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name></person-group><article-title>METTL3/YTHDC1-mediated upregulation of LINC00294 promotes hepatocellular carcinoma progression</article-title><source>Heliyon</source><year>2023</year><volume>9</volume><issue>12</issue><fpage>e22595</fpage><pub-id pub-id-type="pmid">38125436</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.heliyon.2023.e22595</pub-id><pub-id pub-id-type="pmcid">PMC10730722</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Zhang R, Yang R, Huang Z, Xu X, Lv S, Guan X, Li H, Wu J. METTL3/YTHDC1-mediated upregulation of LINC00294 promotes hepatocellular carcinoma progression. Heliyon. 2023;9(12): e22595.<pub-id pub-id-type="pmid">38125436</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.heliyon.2023.e22595</pub-id><pub-id pub-id-type="pmcid">PMC10730722</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>X</given-names></name><name name-style="western"><surname>Xu</surname><given-names>C</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Hou</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name></person-group><article-title>TGF-beta1-induced LINC01094 promotes epithelial-mesenchymal transition in hepatocellular carcinoma through the miR-122-5p/TGFBR2-SAMD2-SMAD3 axis</article-title><source>Funct Integr Genomics</source><year>2024</year><volume>24</volume><issue>4</issue><fpage>123</fpage><pub-id pub-id-type="pmid">38992207</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10142-024-01403-1</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Yang X, Xu C, Liu C, Wu X, Chen X, Hou J, Wang L. TGF-beta1-induced LINC01094 promotes epithelial-mesenchymal transition in hepatocellular carcinoma through the miR-122-5p/TGFBR2-SAMD2-SMAD3 axis. Funct Integr Genomics. 2024;24(4):123.<pub-id pub-id-type="pmid">38992207</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10142-024-01403-1</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>ZB</given-names></name><name name-style="western"><surname>Chu</surname><given-names>HT</given-names></name><name name-style="western"><surname>Jia</surname><given-names>M</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name></person-group><article-title>Long noncoding RNA LINC01139 promotes the progression of hepatocellular carcinoma by upregulating MYBL2 via competitively binding to miR-30 family</article-title><source>Biochem Biophys Res Commun</source><year>2020</year><volume>525</volume><issue>3</issue><fpage>581</fpage><lpage>588</lpage><pub-id pub-id-type="pmid">32115147</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbrc.2020.02.116</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Li ZB, Chu HT, Jia M, Li L. Long noncoding RNA LINC01139 promotes the progression of hepatocellular carcinoma by upregulating MYBL2 via competitively binding to miR-30 family. Biochem Biophys Res Commun. 2020;525(3):581&#8211;8.<pub-id pub-id-type="pmid">32115147</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbrc.2020.02.116</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>X</given-names></name><name name-style="western"><surname>Mo</surname><given-names>M</given-names></name><name name-style="western"><surname>Tan</surname><given-names>C</given-names></name><name name-style="western"><surname>Tan</surname><given-names>JHJ</given-names></name><name name-style="western"><surname>Huang</surname><given-names>H</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B</given-names></name><name name-style="western"><surname>Huang</surname><given-names>D</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>X</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>X</given-names></name></person-group><article-title>Liver-specific LINC01146, a promising prognostic indicator, inhibits the malignant phenotype of hepatocellular carcinoma cells both in vitro and in vivo</article-title><source>J Transl Med</source><year>2022</year><volume>20</volume><issue>1</issue><fpage>57</fpage><pub-id pub-id-type="pmid">35101062</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12967-021-03225-2</pub-id><pub-id pub-id-type="pmcid">PMC8802422</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Ma X, Mo M, Tan C, Tan JHJ, Huang H, Liu B, Huang D, Liu S, Zeng X, Qiu X. Liver-specific LINC01146, a promising prognostic indicator, inhibits the malignant phenotype of hepatocellular carcinoma cells both in vitro and in vivo. J Transl Med. 2022;20(1):57.<pub-id pub-id-type="pmid">35101062</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12967-021-03225-2</pub-id><pub-id pub-id-type="pmcid">PMC8802422</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>YL</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Jia</surname><given-names>YX</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>BZ</given-names></name><name name-style="western"><surname>Li</surname><given-names>JC</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>YH</given-names></name><name name-style="western"><surname>Li</surname><given-names>MQ</given-names></name><name name-style="western"><surname>He</surname><given-names>JZ</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>TT</given-names></name><name name-style="western"><surname>Ban</surname><given-names>XJ</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>YF</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Guan</surname><given-names>XY</given-names></name></person-group><article-title>LINC01554-mediated glucose metabolism reprogramming suppresses tumorigenicity in hepatocellular carcinoma via downregulating PKM2 expression and inhibiting Akt/mTOR signaling pathway</article-title><source>Theranostics</source><year>2019</year><volume>9</volume><issue>3</issue><fpage>796</fpage><lpage>810</lpage><pub-id pub-id-type="pmid">30809309</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/thno.28992</pub-id><pub-id pub-id-type="pmcid">PMC6376468</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Zheng YL, Li L, Jia YX, Zhang BZ, Li JC, Zhu YH, Li MQ, He JZ, Zeng TT, Ban XJ, Yuan YF, Li Y, Guan XY. LINC01554-mediated glucose metabolism reprogramming suppresses tumorigenicity in hepatocellular carcinoma via downregulating PKM2 expression and inhibiting Akt/mTOR signaling pathway. Theranostics. 2019;9(3):796&#8211;810.<pub-id pub-id-type="pmid">30809309</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/thno.28992</pub-id><pub-id pub-id-type="pmcid">PMC6376468</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>JF</given-names></name><name name-style="western"><surname>Shi</surname><given-names>YT</given-names></name><name name-style="western"><surname>Wang</surname><given-names>HG</given-names></name><name name-style="western"><surname>Yang</surname><given-names>XZ</given-names></name><name name-style="western"><surname>Wu</surname><given-names>SN</given-names></name></person-group><article-title>Overexpression of long noncoding RNA HOXC13-AS and its prognostic significance in hepatocellular carcinoma</article-title><source>Eur Rev Med Pharmacol Sci</source><year>2019</year><volume>23</volume><issue>17</issue><fpage>7369</fpage><lpage>7374</lpage><pub-id pub-id-type="pmid">31539123</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.26355/eurrev_201909_18843</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Zhou JF, Shi YT, Wang HG, Yang XZ, Wu SN. Overexpression of long noncoding RNA HOXC13-AS and its prognostic significance in hepatocellular carcinoma. Eur Rev Med Pharmacol Sci. 2019;23(17):7369&#8211;74.<pub-id pub-id-type="pmid">31539123</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.26355/eurrev_201909_18843</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yin</surname><given-names>L</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Deng</surname><given-names>G</given-names></name><name name-style="western"><surname>Han</surname><given-names>Y</given-names></name><name name-style="western"><surname>Guo</surname><given-names>C</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>S</given-names></name><name name-style="western"><surname>Shen</surname><given-names>H</given-names></name></person-group><article-title>Increased long noncoding RNA LASP1-AS is critical for hepatocellular carcinoma tumorigenesis via upregulating LASP1</article-title><source>J Cell Physiol</source><year>2019</year><volume>234</volume><issue>8</issue><fpage>13493</fpage><lpage>13509</lpage><pub-id pub-id-type="pmid">30677131</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcp.28028</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Yin L, Chen Y, Zhou Y, Deng G, Han Y, Guo C, Li Y, Zeng S, Shen H. Increased long noncoding RNA LASP1-AS is critical for hepatocellular carcinoma tumorigenesis via upregulating LASP1. J Cell Physiol. 2019;234(8):13493&#8211;509.<pub-id pub-id-type="pmid">30677131</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcp.28028</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>T</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>C</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Pan</surname><given-names>Y</given-names></name></person-group><article-title>LncRNA ELF3-AS1 is a prognostic biomarker and correlated with immune infiltrates in hepatocellular carcinoma</article-title><source>Can J Gastroenterol Hepatol</source><year>2021</year><volume>2021</volume><fpage>8323487</fpage><pub-id pub-id-type="pmid">34336727</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2021/8323487</pub-id><pub-id pub-id-type="pmcid">PMC8286182</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Chen T, Zhu C, Wang X, Pan Y. LncRNA ELF3-AS1 is a prognostic biomarker and correlated with immune infiltrates in hepatocellular carcinoma. Can J Gastroenterol Hepatol. 2021;2021:8323487.<pub-id pub-id-type="pmid">34336727</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2021/8323487</pub-id><pub-id pub-id-type="pmcid">PMC8286182</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>T</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Luo</surname><given-names>H</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name></person-group><article-title>Macrophage-associated lncRNA ELMO1-AS1: a novel therapeutic target and prognostic biomarker for hepatocellular carcinoma</article-title><source>Onco Targets Ther</source><year>2019</year><volume>12</volume><fpage>6203</fpage><lpage>6216</lpage><pub-id pub-id-type="pmid">31498334</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/OTT.S213833</pub-id><pub-id pub-id-type="pmcid">PMC6689543</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Luo T, Chen M, Zhao Y, Wang D, Liu J, Chen J, Luo H, Li L. Macrophage-associated lncRNA ELMO1-AS1: a novel therapeutic target and prognostic biomarker for hepatocellular carcinoma. Onco Targets Ther. 2019;12:6203&#8211;16.<pub-id pub-id-type="pmid">31498334</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/OTT.S213833</pub-id><pub-id pub-id-type="pmcid">PMC6689543</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>G</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>X</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Guo</surname><given-names>P</given-names></name></person-group><article-title>Long noncoding RNA FOXP4-AS1 predicts unfavourable prognosis and regulates proliferation and invasion in hepatocellular carcinoma</article-title><source>Biomed Res Int</source><year>2021</year><volume>2021</volume><fpage>8850656</fpage><pub-id pub-id-type="pmid">33604387</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2021/8850656</pub-id><pub-id pub-id-type="pmcid">PMC7870313</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Liang J, Wang D, Qiu G, Zhu X, Liu J, Li H, Guo P. Long noncoding RNA FOXP4-AS1 predicts unfavourable prognosis and regulates proliferation and invasion in hepatocellular carcinoma. Biomed Res Int. 2021;2021:8850656.<pub-id pub-id-type="pmid">33604387</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2021/8850656</pub-id><pub-id pub-id-type="pmcid">PMC7870313</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Jing</surname><given-names>W</given-names></name><name name-style="western"><surname>Ma</surname><given-names>W</given-names></name><name name-style="western"><surname>Liang</surname><given-names>C</given-names></name><name name-style="western"><surname>Chai</surname><given-names>H</given-names></name><name name-style="western"><surname>Tu</surname><given-names>J</given-names></name></person-group><article-title>Down-regulation of long non-coding RNA GAS5-AS1 and its prognostic and diagnostic significance in hepatocellular carcinoma</article-title><source>Cancer Biomark</source><year>2018</year><volume>22</volume><issue>2</issue><fpage>227</fpage><lpage>236</lpage><pub-id pub-id-type="pmid">29660898</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/CBM-170781</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Wang Y, Jing W, Ma W, Liang C, Chai H, Tu J. Down-regulation of long non-coding RNA GAS5-AS1 and its prognostic and diagnostic significance in hepatocellular carcinoma. Cancer Biomark. 2018;22(2):227&#8211;36.<pub-id pub-id-type="pmid">29660898</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/CBM-170781</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>W</given-names></name><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Song</surname><given-names>W</given-names></name></person-group><article-title>Potentials as biomarker and therapeutic target of upregulated long non-coding RNA HLA-F antisense RNA 1 in hepatitis B virus-associated hepatocellular carcinoma</article-title><source>Virus Genes</source><year>2024</year><volume>60</volume><issue>3</issue><fpage>243</fpage><lpage>250</lpage><pub-id pub-id-type="pmid">38568442</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11262-024-02065-8</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Zhang X, Li W, Li S, Zhang Z, Song W. Potentials as biomarker and therapeutic target of upregulated long non-coding RNA HLA-F antisense RNA 1 in hepatitis B virus-associated hepatocellular carcinoma. Virus Genes. 2024;60(3):243&#8211;50.<pub-id pub-id-type="pmid">38568442</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11262-024-02065-8</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>W</given-names></name><name name-style="western"><surname>Hong</surname><given-names>G</given-names></name><name name-style="western"><surname>Lai</surname><given-names>X</given-names></name></person-group><article-title>INKA2-AS1 is a potential promising prognostic-related biomarker and correlated with immune infiltrates in hepatocellular carcinoma</article-title><source>Mediators Inflamm</source><year>2023</year><volume>2023</volume><fpage>7057236</fpage><pub-id pub-id-type="pmid">37181806</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2023/7057236</pub-id><pub-id pub-id-type="pmcid">PMC10169249</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Li W, Hong G, Lai X. INKA2-AS1 is a potential promising prognostic-related biomarker and correlated with immune infiltrates in hepatocellular carcinoma. Mediators Inflamm. 2023;2023:7057236.<pub-id pub-id-type="pmid">37181806</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2023/7057236</pub-id><pub-id pub-id-type="pmcid">PMC10169249</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>H</given-names></name><name name-style="western"><surname>Li</surname><given-names>W</given-names></name><name name-style="western"><surname>Guo</surname><given-names>S</given-names></name><name name-style="western"><surname>He</surname><given-names>Z</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name><name name-style="western"><surname>Duo</surname><given-names>Y</given-names></name></person-group><article-title>A novel biomarker NIFK-AS1 promotes hepatocellular carcinoma cell cycle progression through interaction with SRSF10</article-title><source>J Gastrointest Oncol</source><year>2022</year><volume>13</volume><issue>4</issue><fpage>1927</fpage><lpage>1941</lpage><pub-id pub-id-type="pmid">36092356</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.21037/jgo-22-705</pub-id><pub-id pub-id-type="pmcid">PMC9459191</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Song H, Li W, Guo S, He Z, Liu S, Duo Y. A novel biomarker NIFK-AS1 promotes hepatocellular carcinoma cell cycle progression through interaction with SRSF10. J Gastrointest Oncol. 2022;13(4):1927&#8211;41.<pub-id pub-id-type="pmid">36092356</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.21037/jgo-22-705</pub-id><pub-id pub-id-type="pmcid">PMC9459191</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dong</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Gao</surname><given-names>X</given-names></name><name name-style="western"><surname>Chen</surname><given-names>D</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L</given-names></name></person-group><article-title>Comprehensive analysis of POLH-AS1 as a prognostic biomarker in hepatocellular carcinoma</article-title><source>BMC Cancer</source><year>2024</year><volume>24</volume><issue>1</issue><fpage>1112</fpage><pub-id pub-id-type="pmid">39242532</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12885-024-12857-8</pub-id><pub-id pub-id-type="pmcid">PMC11378586</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Dong Y, Chen X, Yang S, Fu Y, Wang L, Gao X, Chen D, Xu L. Comprehensive analysis of POLH-AS1 as a prognostic biomarker in hepatocellular carcinoma. BMC Cancer. 2024;24(1):1112.<pub-id pub-id-type="pmid">39242532</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12885-024-12857-8</pub-id><pub-id pub-id-type="pmcid">PMC11378586</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abulihaiti</surname><given-names>Z</given-names></name><name name-style="western"><surname>Li</surname><given-names>W</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Du</surname><given-names>A</given-names></name><name name-style="western"><surname>Tang</surname><given-names>N</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>J</given-names></name></person-group><article-title>Hypoxia-driven lncRNA CTD-2510F54: a potential player in hepatocellular carcinoma's prognostic stratification, cellular behavior, tumor microenvironment, and therapeutic response</article-title><source>Mol Biol Rep</source><year>2024</year><volume>51</volume><issue>1</issue><fpage>905</fpage><pub-id pub-id-type="pmid">39133347</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11033-024-09826-6</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Abulihaiti Z, Li W, Yang L, Zhang H, Du A, Tang N, Lu Y, Zeng J. Hypoxia-driven lncRNA CTD-2510F54: a potential player in hepatocellular carcinoma&#8217;s prognostic stratification, cellular behavior, tumor microenvironment, and therapeutic response. Mol Biol Rep. 2024;51(1):905.<pub-id pub-id-type="pmid">39133347</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11033-024-09826-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sheng</surname><given-names>N</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Qian</surname><given-names>R</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name></person-group><article-title>The clinical significance and biological function of lncRNA RGMB-AS1 in hepatocellular carcinoma</article-title><source>Biomed Pharmacother</source><year>2018</year><volume>98</volume><fpage>577</fpage><lpage>584</lpage><pub-id pub-id-type="pmid">29288973</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2017.12.067</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Sheng N, Li Y, Qian R, Li Y. The clinical significance and biological function of lncRNA RGMB-AS1 in hepatocellular carcinoma. Biomed Pharmacother. 2018;98:577&#8211;84.<pub-id pub-id-type="pmid">29288973</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2017.12.067</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Yan</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S</given-names></name><name name-style="western"><surname>Gao</surname><given-names>M</given-names></name></person-group><article-title>STAT1-induced upregulation of lncRNA RHPN1-AS1 predicts a poor prognosis of hepatocellular carcinoma and contributes to tumor progression via the miR-485/CDCA5 axis</article-title><source>J Cell Biochem</source><year>2020</year><volume>121</volume><issue>12</issue><fpage>4741</fpage><lpage>4755</lpage><pub-id pub-id-type="pmid">32065447</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcb.29689</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Zhang X, Yan Z, Wang L, Zhang S, Gao M. STAT1-induced upregulation of lncRNA RHPN1-AS1 predicts a poor prognosis of hepatocellular carcinoma and contributes to tumor progression via the miR-485/CDCA5 axis. J Cell Biochem. 2020;121(12):4741&#8211;55.<pub-id pub-id-type="pmid">32065447</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcb.29689</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tian</surname><given-names>H</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name></person-group><article-title>Comprehensive analysis identifies long non-coding RNA RNASEH1-AS1 as a potential prognostic biomarker and oncogenic target in hepatocellular carcinoma</article-title><source>Am J Cancer Res</source><year>2024</year><volume>14</volume><issue>3</issue><fpage>996</fpage><lpage>1014</lpage><pub-id pub-id-type="pmid">38590422</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.62347/JPHF4071</pub-id><pub-id pub-id-type="pmcid">PMC10998738</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Sun J, Li Y, Tian H, Chen H, Li J, Li Z. Comprehensive analysis identifies long non-coding RNA RNASEH1-AS1 as a potential prognostic biomarker and oncogenic target in hepatocellular carcinoma. Am J Cancer Res. 2024;14(3):996&#8211;1014.<pub-id pub-id-type="pmid">38590422</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.62347/JPHF4071</pub-id><pub-id pub-id-type="pmcid">PMC10998738</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>C</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Xu</surname><given-names>F</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>R</given-names></name></person-group><article-title>LncRNA SOX21-AS1 is associated with progression of hepatocellular carcinoma and predicts prognosis through epigenetically silencing p21</article-title><source>Biomed Pharmacother</source><year>2018</year><volume>104</volume><fpage>137</fpage><lpage>144</lpage><pub-id pub-id-type="pmid">29772433</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2018.05.010</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Wei C, Wang H, Xu F, Liu Z, Jiang R. LncRNA SOX21-AS1 is associated with progression of hepatocellular carcinoma and predicts prognosis through epigenetically silencing p21. Biomed Pharmacother. 2018;104:137&#8211;44.<pub-id pub-id-type="pmid">29772433</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2018.05.010</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Su</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xie</surname><given-names>R</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Q</given-names></name></person-group><article-title>LncRNA THAP9-AS1 highly expressed in tissues of hepatocellular carcinoma and accelerates tumor cell proliferation</article-title><source>Clin Res Hepatol Gastroenterol</source><year>2022</year><volume>46</volume><issue>10</issue><fpage>102025</fpage><pub-id pub-id-type="pmid">36170961</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clinre.2022.102025</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Su Y, Xie R, Xu Q. LncRNA THAP9-AS1 highly expressed in tissues of hepatocellular carcinoma and accelerates tumor cell proliferation. Clin Res Hepatol Gastroenterol. 2022;46(10): 102025.<pub-id pub-id-type="pmid">36170961</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clinre.2022.102025</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Gao</surname><given-names>J</given-names></name><name name-style="western"><surname>Tang</surname><given-names>S</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Deng</surname><given-names>C</given-names></name><name name-style="western"><surname>Hu</surname><given-names>J</given-names></name><name name-style="western"><surname>Tao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name></person-group><article-title>Integrated RNA sequencing and single-cell mass cytometry reveal a novel role of LncRNA HOXA-AS2 in tumorigenesis and stemness of hepatocellular carcinoma</article-title><source>Onco Targets Ther</source><year>2020</year><volume>13</volume><fpage>10901</fpage><lpage>10916</lpage><pub-id pub-id-type="pmid">33149607</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/OTT.S272717</pub-id><pub-id pub-id-type="pmcid">PMC7602917</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Lu Q, Gao J, Tang S, Li Z, Wang X, Deng C, Hu J, Tao Y, Wang Q. Integrated RNA sequencing and single-cell mass cytometry reveal a novel role of LncRNA HOXA-AS2 in tumorigenesis and stemness of hepatocellular carcinoma. Onco Targets Ther. 2020;13:10901&#8211;16.<pub-id pub-id-type="pmid">33149607</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/OTT.S272717</pub-id><pub-id pub-id-type="pmcid">PMC7602917</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Meng</surname><given-names>Z</given-names></name><name name-style="western"><surname>Chen</surname><given-names>F</given-names></name></person-group><article-title>Low lncRNA ZNF385D-AS2 expression and its prognostic significance in liver cancer</article-title><source>Oncol Rep</source><year>2019</year><volume>42</volume><issue>3</issue><fpage>1110</fpage><lpage>1124</lpage><pub-id pub-id-type="pmid">31322274</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/or.2019.7238</pub-id><pub-id pub-id-type="pmcid">PMC6667919</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Zhang Z, Wang S, Liu Y, Meng Z, Chen F. Low lncRNA ZNF385D-AS2 expression and its prognostic significance in liver cancer. Oncol Rep. 2019;42(3):1110&#8211;24.<pub-id pub-id-type="pmid">31322274</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/or.2019.7238</pub-id><pub-id pub-id-type="pmcid">PMC6667919</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>C</given-names></name><name name-style="western"><surname>Huang</surname><given-names>S</given-names></name><name name-style="western"><surname>Hou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Xia</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cai</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Q</given-names></name><name name-style="western"><surname>He</surname><given-names>X</given-names></name><name name-style="western"><surname>Wu</surname><given-names>L</given-names></name></person-group><article-title>Long noncoding RNA AC092171.4 promotes hepatocellular carcinoma progression by sponging microRNA-1271 and upregulating GRB2</article-title><source>Aging (Albany NY)</source><year>2020</year><volume>12</volume><issue>14</issue><fpage>14141</fpage><lpage>14156</lpage><pub-id pub-id-type="pmid">32692718</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/aging.103419</pub-id><pub-id pub-id-type="pmcid">PMC7425487</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Sun C, Huang S, Hou Y, Li Z, Xia D, Zhang L, Zhang Y, Cai Y, Wang Z, Zhou Q, He X, Wu L. Long noncoding RNA AC092171.4 promotes hepatocellular carcinoma progression by sponging microRNA-1271 and upregulating GRB2. Aging (Albany NY). 2020;12(14):14141&#8211;56.<pub-id pub-id-type="pmid">32692718</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/aging.103419</pub-id><pub-id pub-id-type="pmcid">PMC7425487</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>T</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y</given-names></name></person-group><article-title>Increased expression of LncRNA BANCR and its prognostic significance in human hepatocellular carcinoma</article-title><source>World J Surg Oncol</source><year>2016</year><volume>14</volume><issue>1</issue><fpage>8</fpage><pub-id pub-id-type="pmid">26758762</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12957-015-0757-5</pub-id><pub-id pub-id-type="pmcid">PMC4709863</pub-id><related-article related-article-type="expression-of-concern" ext-link-type="pmc" xlink:href="PMC6567905"/></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Zhou T, Gao Y. Increased expression of LncRNA BANCR and its prognostic significance in human hepatocellular carcinoma. World J Surg Oncol. 2016;14(1):8.<pub-id pub-id-type="pmid">26758762</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12957-015-0757-5</pub-id><pub-id pub-id-type="pmcid">PMC4709863</pub-id><related-article related-article-type="expression-of-concern" ext-link-type="pmc" xlink:href="PMC6567905"/></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ma</surname><given-names>C</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J</given-names></name><name name-style="western"><surname>Jia</surname><given-names>Y</given-names></name></person-group><article-title>Overexpression of CASC19 contributes to tumor progression and predicts poor prognosis after radical resection in hepatocellular carcinoma</article-title><source>Dig Liver Dis</source><year>2023</year><volume>55</volume><issue>6</issue><fpage>799</fpage><lpage>806</lpage><pub-id pub-id-type="pmid">36805849</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.dld.2022.12.001</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Hou Y, Tang Y, Ma C, Yu J, Jia Y. Overexpression of CASC19 contributes to tumor progression and predicts poor prognosis after radical resection in hepatocellular carcinoma. Dig Liver Dis. 2023;55(6):799&#8211;806.<pub-id pub-id-type="pmid">36805849</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.dld.2022.12.001</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>F</given-names></name><name name-style="western"><surname>Wang</surname><given-names>A</given-names></name><name name-style="western"><surname>Du</surname><given-names>X</given-names></name><name name-style="western"><surname>Hu</surname><given-names>P</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Fang</surname><given-names>Z</given-names></name></person-group><article-title>Long non-coding RNA CCAT2 is associated with poor prognosis in hepatocellular carcinoma and promotes tumor metastasis by regulating Snail2-mediated epithelial-mesenchymal transition</article-title><source>Onco Targets Ther</source><year>2017</year><volume>10</volume><fpage>1191</fpage><lpage>1198</lpage><pub-id pub-id-type="pmid">28280353</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/OTT.S127100</pub-id><pub-id pub-id-type="pmcid">PMC5338976</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Xu Y, Wang B, Zhang F, Wang A, Du X, Hu P, Zhu Y, Fang Z. Long non-coding RNA CCAT2 is associated with poor prognosis in hepatocellular carcinoma and promotes tumor metastasis by regulating Snail2-mediated epithelial-mesenchymal transition. Onco Targets Ther. 2017;10:1191&#8211;8.<pub-id pub-id-type="pmid">28280353</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/OTT.S127100</pub-id><pub-id pub-id-type="pmcid">PMC5338976</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fu</surname><given-names>C</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X</given-names></name><name name-style="western"><surname>Lu</surname><given-names>W</given-names></name><name name-style="western"><surname>Nie</surname><given-names>L</given-names></name><name name-style="western"><surname>Yin</surname><given-names>T</given-names></name><name name-style="western"><surname>Wu</surname><given-names>D</given-names></name></person-group><article-title>Increased expression of long non-coding RNA CCAT2 predicts poorer prognosis in patients with hepatocellular carcinoma</article-title><source>Medicine (Baltimore)</source><year>2019</year><volume>98</volume><issue>42</issue><fpage>e17412</fpage><pub-id pub-id-type="pmid">31626095</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MD.0000000000017412</pub-id><pub-id pub-id-type="pmcid">PMC6824708</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Fu C, Xu X, Lu W, Nie L, Yin T, Wu D. Increased expression of long non-coding RNA CCAT2 predicts poorer prognosis in patients with hepatocellular carcinoma. Medicine (Baltimore). 2019;98(42): e17412.<pub-id pub-id-type="pmid">31626095</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MD.0000000000017412</pub-id><pub-id pub-id-type="pmcid">PMC6824708</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>W</given-names></name><name name-style="western"><surname>Fan</surname><given-names>H</given-names></name></person-group><article-title>Long noncoding RNA CCHE1 indicates a poor prognosis of hepatocellular carcinoma and promotes carcinogenesis via activation of the ERK/MAPK pathway</article-title><source>Biomed Pharmacother</source><year>2016</year><volume>83</volume><fpage>450</fpage><lpage>455</lpage><pub-id pub-id-type="pmid">27427851</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2016.06.056</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Peng W, Fan H. Long noncoding RNA CCHE1 indicates a poor prognosis of hepatocellular carcinoma and promotes carcinogenesis via activation of the ERK/MAPK pathway. Biomed Pharmacother. 2016;83:450&#8211;5.<pub-id pub-id-type="pmid">27427851</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2016.06.056</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>S</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>K</given-names></name><name name-style="western"><surname>Tan</surname><given-names>W</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Z</given-names></name><name name-style="western"><surname>He</surname><given-names>Q</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shang</surname><given-names>C</given-names></name></person-group><article-title>Low expression of long noncoding RNA CTC-297N7.9 predicts poor prognosis in patients with hepatocellular carcinoma</article-title><source>Cancer Med</source><year>2019</year><volume>8</volume><issue>18</issue><fpage>7679</fpage><lpage>7692</lpage><pub-id pub-id-type="pmid">31674731</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cam4.2618</pub-id><pub-id pub-id-type="pmcid">PMC6912069</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Zhu S, Huang X, Zhang K, Tan W, Lin Z, He Q, Chen Y, Shang C. Low expression of long noncoding RNA CTC-297N7.9 predicts poor prognosis in patients with hepatocellular carcinoma. Cancer Med. 2019;8(18):7679&#8211;92.<pub-id pub-id-type="pmid">31674731</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cam4.2618</pub-id><pub-id pub-id-type="pmcid">PMC6912069</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>D</given-names></name></person-group><article-title>LncRNA-D16366 is a potential biomarker for diagnosis and prognosis of hepatocellular carcinoma</article-title><source>Med Sci Monit</source><year>2019</year><volume>25</volume><fpage>6581</fpage><lpage>6586</lpage><pub-id pub-id-type="pmid">31475695</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.12659/MSM.915100</pub-id><pub-id pub-id-type="pmcid">PMC6738002</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Chao Y, Zhou D. LncRNA-D16366 is a potential biomarker for diagnosis and prognosis of hepatocellular carcinoma. Med Sci Monit. 2019;25:6581&#8211;6.<pub-id pub-id-type="pmid">31475695</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.12659/MSM.915100</pub-id><pub-id pub-id-type="pmcid">PMC6738002</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>R</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhangyuan</surname><given-names>G</given-names></name><name name-style="western"><surname>Jin</surname><given-names>K</given-names></name><name name-style="western"><surname>Yu</surname><given-names>W</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Sun</surname><given-names>B</given-names></name></person-group><article-title>Down-regulation of LncRNA DGCR5 correlates with poor prognosis in hepatocellular carcinoma</article-title><source>Cell Physiol Biochem</source><year>2016</year><volume>40</volume><issue>3&#8211;4</issue><fpage>707</fpage><lpage>715</lpage><pub-id pub-id-type="pmid">27898409</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000452582</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Huang R, Wang X, Zhang W, Zhangyuan G, Jin K, Yu W, Xie Y, Xu X, Wang H, Sun B. Down-regulation of LncRNA DGCR5 correlates with poor prognosis in hepatocellular carcinoma. Cell Physiol Biochem. 2016;40(3&#8211;4):707&#8211;15.<pub-id pub-id-type="pmid">27898409</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000452582</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeng</surname><given-names>B</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ye</surname><given-names>H</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>G</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name><name name-style="western"><surname>Cai</surname><given-names>C</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>J</given-names></name><name name-style="western"><surname>Tang</surname><given-names>C</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name></person-group><article-title>Upregulation of LncDQ is associated with poor prognosis and promotes tumor progression via epigenetic regulation of the EMT pathway in HCC</article-title><source>Cell Physiol Biochem</source><year>2018</year><volume>46</volume><issue>3</issue><fpage>1122</fpage><lpage>1133</lpage><pub-id pub-id-type="pmid">29669339</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000488841</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Zeng B, Lin Z, Ye H, Cheng D, Zhang G, Zhou J, Huang Z, Wang M, Cai C, Zeng J, Tang C, Liu J. Upregulation of LncDQ is associated with poor prognosis and promotes tumor progression via epigenetic regulation of the EMT pathway in HCC. Cell Physiol Biochem. 2018;46(3):1122&#8211;33.<pub-id pub-id-type="pmid">29669339</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000488841</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mo</surname><given-names>M</given-names></name><name name-style="western"><surname>Ma</surname><given-names>X</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tan</surname><given-names>C</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B</given-names></name><name name-style="western"><surname>Tang</surname><given-names>P</given-names></name><name name-style="western"><surname>Liao</surname><given-names>Q</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name><name name-style="western"><surname>Yu</surname><given-names>H</given-names></name><name name-style="western"><surname>Huang</surname><given-names>D</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>X</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>X</given-names></name></person-group><article-title>Liver-specific lncRNA FAM99A may be a tumor suppressor and promising prognostic biomarker in hepatocellular carcinoma</article-title><source>BMC Cancer</source><year>2022</year><volume>22</volume><issue>1</issue><fpage>1098</fpage><pub-id pub-id-type="pmid">36289466</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12885-022-10186-2</pub-id><pub-id pub-id-type="pmcid">PMC9609286</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Mo M, Ma X, Luo Y, Tan C, Liu B, Tang P, Liao Q, Liu S, Yu H, Huang D, Zeng X, Qiu X. Liver-specific lncRNA FAM99A may be a tumor suppressor and promising prognostic biomarker in hepatocellular carcinoma. BMC Cancer. 2022;22(1):1098.<pub-id pub-id-type="pmid">36289466</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12885-022-10186-2</pub-id><pub-id pub-id-type="pmcid">PMC9609286</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tu</surname><given-names>ZQ</given-names></name><name name-style="western"><surname>Li</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Mei</surname><given-names>JZ</given-names></name><name name-style="western"><surname>Li</surname><given-names>XH</given-names></name></person-group><article-title>Down-regulation of long non-coding RNA GAS5 is associated with the prognosis of hepatocellular carcinoma</article-title><source>Int J Clin Exp Pathol</source><year>2014</year><volume>7</volume><issue>7</issue><fpage>4303</fpage><lpage>4309</lpage><pub-id pub-id-type="pmid">25120813</pub-id><pub-id pub-id-type="pmcid">PMC4129048</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Tu ZQ, Li RJ, Mei JZ, Li XH. Down-regulation of long non-coding RNA GAS5 is associated with the prognosis of hepatocellular carcinoma. Int J Clin Exp Pathol. 2014;7(7):4303&#8211;9.<pub-id pub-id-type="pmid">25120813</pub-id><pub-id pub-id-type="pmcid">PMC4129048</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>L</given-names></name><name name-style="western"><surname>He</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tang</surname><given-names>S</given-names></name><name name-style="western"><surname>Huang</surname><given-names>S</given-names></name></person-group><article-title>LncRNA GHET1 predicts poor prognosis in hepatocellular carcinoma and promotes cell proliferation by silencing KLF2</article-title><source>J Cell Physiol</source><year>2018</year><volume>233</volume><issue>6</issue><fpage>4726</fpage><lpage>4734</lpage><pub-id pub-id-type="pmid">29139562</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcp.26257</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Jin L, He Y, Tang S, Huang S. LncRNA GHET1 predicts poor prognosis in hepatocellular carcinoma and promotes cell proliferation by silencing KLF2. J Cell Physiol. 2018;233(6):4726&#8211;34.<pub-id pub-id-type="pmid">29139562</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcp.26257</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>L</given-names></name><name name-style="western"><surname>Wu</surname><given-names>LM</given-names></name><name name-style="western"><surname>Lai</surname><given-names>MC</given-names></name><name name-style="western"><surname>Xie</surname><given-names>HY</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>F</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>SS</given-names></name></person-group><article-title>Overexpression of long non-coding RNA HOTAIR predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation</article-title><source>Ann Surg Oncol</source><year>2011</year><volume>18</volume><issue>5</issue><fpage>1243</fpage><lpage>1250</lpage><pub-id pub-id-type="pmid">21327457</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1245/s10434-011-1581-y</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Yang Z, Zhou L, Wu LM, Lai MC, Xie HY, Zhang F, Zheng SS. Overexpression of long non-coding RNA HOTAIR predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation. Ann Surg Oncol. 2011;18(5):1243&#8211;50.<pub-id pub-id-type="pmid">21327457</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1245/s10434-011-1581-y</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>L</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Xie</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>L</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>S</given-names></name></person-group><article-title>Long noncoding RNA HOTTIP expression predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation</article-title><source>Hepatobiliary Surg Nutr</source><year>2018</year><volume>7</volume><issue>6</issue><fpage>429</fpage><lpage>439</lpage><pub-id pub-id-type="pmid">30652087</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.21037/hbsn.2018.10.07</pub-id><pub-id pub-id-type="pmcid">PMC6295384</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Wu L, Yang Z, Zhang J, Xie H, Zhou L, Zheng S. Long noncoding RNA HOTTIP expression predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation. Hepatobiliary Surg Nutr. 2018;7(6):429&#8211;39.<pub-id pub-id-type="pmid">30652087</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.21037/hbsn.2018.10.07</pub-id><pub-id pub-id-type="pmcid">PMC6295384</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>W</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Jing</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>F</given-names></name><name name-style="western"><surname>Chang</surname><given-names>L</given-names></name><name name-style="western"><surname>Hong</surname><given-names>Z</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>Y</given-names></name></person-group><article-title>Downregulation of long non-coding RNAs JPX and XIST is associated with the prognosis of hepatocellular carcinoma</article-title><source>Clin Res Hepatol Gastroenterol</source><year>2017</year><volume>41</volume><issue>2</issue><fpage>163</fpage><lpage>170</lpage><pub-id pub-id-type="pmid">27776968</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clinre.2016.09.002</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Ma W, Wang H, Jing W, Zhou F, Chang L, Hong Z, Liu H, Liu Z, Yuan Y. Downregulation of long non-coding RNAs JPX and XIST is associated with the prognosis of hepatocellular carcinoma. Clin Res Hepatol Gastroenterol. 2017;41(2):163&#8211;70.<pub-id pub-id-type="pmid">27776968</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clinre.2016.09.002</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jang</surname><given-names>SY</given-names></name><name name-style="western"><surname>Kim</surname><given-names>G</given-names></name><name name-style="western"><surname>Park</surname><given-names>SY</given-names></name><name name-style="western"><surname>Lee</surname><given-names>YR</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>SH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>HS</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>JS</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JS</given-names></name><name name-style="western"><surname>Kweon</surname><given-names>YO</given-names></name><name name-style="western"><surname>Ha</surname><given-names>HT</given-names></name><name name-style="western"><surname>Chun</surname><given-names>JM</given-names></name><name name-style="western"><surname>Han</surname><given-names>YS</given-names></name><name name-style="western"><surname>Lee</surname><given-names>WK</given-names></name><name name-style="western"><surname>Chang</surname><given-names>JY</given-names></name><name name-style="western"><surname>Park</surname><given-names>JG</given-names></name><name name-style="western"><surname>Lee</surname><given-names>B</given-names></name><name name-style="western"><surname>Tak</surname><given-names>WY</given-names></name><name name-style="western"><surname>Hur</surname><given-names>K</given-names></name></person-group><article-title>Clinical significance of lncRNA-ATB expression in human hepatocellular carcinoma</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><issue>45</issue><fpage>78588</fpage><lpage>78597</lpage><pub-id pub-id-type="pmid">29108251</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/oncotarget.21094</pub-id><pub-id pub-id-type="pmcid">PMC5667984</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Jang SY, Kim G, Park SY, Lee YR, Kwon SH, Kim HS, Yoon JS, Lee JS, Kweon YO, Ha HT, Chun JM, Han YS, Lee WK, Chang JY, Park JG, Lee B, Tak WY, Hur K. Clinical significance of lncRNA-ATB expression in human hepatocellular carcinoma. Oncotarget. 2017;8(45):78588&#8211;97.<pub-id pub-id-type="pmid">29108251</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/oncotarget.21094</pub-id><pub-id pub-id-type="pmcid">PMC5667984</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ji</surname><given-names>B</given-names></name><name name-style="western"><surname>Cai</surname><given-names>H</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name></person-group><article-title>Clinical value of lncRNA LUCAT1 expression in liver cancer and its potential pathways</article-title><source>J Gastrointestin Liver Dis</source><year>2019</year><volume>28</volume><issue>4</issue><fpage>439</fpage><lpage>447</lpage><pub-id pub-id-type="pmid">31826070</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15403/jgld-356</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Jiao Y, Li Y, Ji B, Cai H, Liu Y. Clinical value of lncRNA LUCAT1 expression in liver cancer and its potential pathways. J Gastrointestin Liver Dis. 2019;28(4):439&#8211;47.<pub-id pub-id-type="pmid">31826070</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15403/jgld-356</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lai</surname><given-names>MC</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>QQ</given-names></name><name name-style="western"><surname>Xie</surname><given-names>HY</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>F</given-names></name><name name-style="western"><surname>Wu</surname><given-names>LM</given-names></name><name name-style="western"><surname>Chen</surname><given-names>LM</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>SS</given-names></name></person-group><article-title>Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation</article-title><source>Med Oncol</source><year>2012</year><volume>29</volume><issue>3</issue><fpage>1810</fpage><lpage>1816</lpage><pub-id pub-id-type="pmid">21678027</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12032-011-0004-z</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Lai MC, Yang Z, Zhou L, Zhu QQ, Xie HY, Zhang F, Wu LM, Chen LM, Zheng SS. Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation. Med Oncol. 2012;29(3):1810&#8211;6.<pub-id pub-id-type="pmid">21678027</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12032-011-0004-z</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liao</surname><given-names>X</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Luo</surname><given-names>D</given-names></name><name name-style="western"><surname>Luo</surname><given-names>B</given-names></name><name name-style="western"><surname>Huang</surname><given-names>W</given-names></name><name name-style="western"><surname>Xie</surname><given-names>W</given-names></name></person-group><article-title>Prognostic value of long non-coding RNA MALAT1 in hepatocellular carcinoma: a study based on multi-omics analysis and RT-PCR validation</article-title><source>Pathol Oncol Res</source><year>2022</year><volume>28</volume><fpage>1610808</fpage><pub-id pub-id-type="pmid">36685103</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/pore.2022.1610808</pub-id><pub-id pub-id-type="pmcid">PMC9845286</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">Liao X, Chen J, Luo D, Luo B, Huang W, Xie W. Prognostic value of long non-coding RNA MALAT1 in hepatocellular carcinoma: a study based on multi-omics analysis and RT-PCR validation. Pathol Oncol Res. 2022;28:1610808.<pub-id pub-id-type="pmid">36685103</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/pore.2022.1610808</pub-id><pub-id pub-id-type="pmcid">PMC9845286</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>XL</given-names></name><name name-style="western"><surname>Lian</surname><given-names>JR</given-names></name><name name-style="western"><surname>Guan</surname><given-names>YH</given-names></name></person-group><article-title>Overexpression of long non-coding RNA MINCR contributes to progressive clinicopathological features and poor prognosis of human hepatocellular carcinoma</article-title><source>Eur Rev Med Pharmacol Sci</source><year>2018</year><volume>22</volume><issue>23</issue><fpage>8197</fpage><lpage>8202</lpage><pub-id pub-id-type="pmid">30556858</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.26355/eurrev_201812_16512</pub-id></element-citation><mixed-citation id="mc-CR57" publication-type="journal">Jin XL, Lian JR, Guan YH. Overexpression of long non-coding RNA MINCR contributes to progressive clinicopathological features and poor prognosis of human hepatocellular carcinoma. Eur Rev Med Pharmacol Sci. 2018;22(23):8197&#8211;202.<pub-id pub-id-type="pmid">30556858</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.26355/eurrev_201812_16512</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>X</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yu</surname><given-names>S</given-names></name></person-group><article-title>Long noncoding RNA AWPPH promotes hepatocellular carcinoma progression through YBX1 and serves as a prognostic biomarker</article-title><source>Biochim Biophys Acta Mol Basis Dis</source><year>2017</year><volume>1863</volume><issue>7</issue><fpage>1805</fpage><lpage>1816</lpage><pub-id pub-id-type="pmid">28428004</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbadis.2017.04.014</pub-id></element-citation><mixed-citation id="mc-CR58" publication-type="journal">Zhao X, Liu Y, Yu S. Long noncoding RNA AWPPH promotes hepatocellular carcinoma progression through YBX1 and serves as a prognostic biomarker. Biochim Biophys Acta Mol Basis Dis. 2017;1863(7):1805&#8211;16.<pub-id pub-id-type="pmid">28428004</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbadis.2017.04.014</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>DY</given-names></name><name name-style="western"><surname>Zou</surname><given-names>XJ</given-names></name><name name-style="western"><surname>Cao</surname><given-names>CH</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T</given-names></name><name name-style="western"><surname>Lei</surname><given-names>L</given-names></name><name name-style="western"><surname>Qi</surname><given-names>XL</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L</given-names></name><name name-style="western"><surname>Wu</surname><given-names>DH</given-names></name></person-group><article-title>Identification and functional characterization of long non-coding RNA MIR22HG as a tumor suppressor for hepatocellular carcinoma</article-title><source>Theranostics</source><year>2018</year><volume>8</volume><issue>14</issue><fpage>3751</fpage><lpage>3765</lpage><pub-id pub-id-type="pmid">30083257</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/thno.22493</pub-id><pub-id pub-id-type="pmcid">PMC6071531</pub-id></element-citation><mixed-citation id="mc-CR59" publication-type="journal">Zhang DY, Zou XJ, Cao CH, Zhang T, Lei L, Qi XL, Liu L, Wu DH. Identification and functional characterization of long non-coding RNA MIR22HG as a tumor suppressor for hepatocellular carcinoma. Theranostics. 2018;8(14):3751&#8211;65.<pub-id pub-id-type="pmid">30083257</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/thno.22493</pub-id><pub-id pub-id-type="pmcid">PMC6071531</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Liang</surname><given-names>L</given-names></name><name name-style="western"><surname>Dong</surname><given-names>Q</given-names></name><name name-style="western"><surname>Huan</surname><given-names>L</given-names></name><name name-style="western"><surname>He</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>B</given-names></name><name name-style="western"><surname>Yang</surname><given-names>C</given-names></name><name name-style="western"><surname>Jin</surname><given-names>H</given-names></name><name name-style="western"><surname>Wei</surname><given-names>L</given-names></name><name name-style="western"><surname>Yu</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>F</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Yao</surname><given-names>M</given-names></name><name name-style="western"><surname>Qin</surname><given-names>W</given-names></name><name name-style="western"><surname>Qin</surname><given-names>L</given-names></name><name name-style="western"><surname>He</surname><given-names>X</given-names></name></person-group><article-title>Long noncoding RNA miR503HG, a prognostic indicator, inhibits tumor metastasis by regulating the HNRNPA2B1/NF-kappaB pathway in hepatocellular carcinoma</article-title><source>Theranostics</source><year>2018</year><volume>8</volume><issue>10</issue><fpage>2814</fpage><lpage>2829</lpage><pub-id pub-id-type="pmid">29774077</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/thno.23012</pub-id><pub-id pub-id-type="pmcid">PMC5957011</pub-id></element-citation><mixed-citation id="mc-CR60" publication-type="journal">Wang H, Liang L, Dong Q, Huan L, He J, Li B, Yang C, Jin H, Wei L, Yu C, Zhao F, Li J, Yao M, Qin W, Qin L, He X. Long noncoding RNA miR503HG, a prognostic indicator, inhibits tumor metastasis by regulating the HNRNPA2B1/NF-kappaB pathway in hepatocellular carcinoma. Theranostics. 2018;8(10):2814&#8211;29.<pub-id pub-id-type="pmid">29774077</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/thno.23012</pub-id><pub-id pub-id-type="pmcid">PMC5957011</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>R</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Q</given-names></name><name name-style="western"><surname>Owusu-Ansah</surname><given-names>KG</given-names></name><name name-style="western"><surname>Song</surname><given-names>G</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>L</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>S</given-names></name></person-group><article-title>NKILA, a prognostic indicator, inhibits tumor metastasis by suppressing NF-kappaB/Slug mediated epithelial-mesenchymal transition in hepatocellular carcinoma</article-title><source>Int J Biol Sci</source><year>2020</year><volume>16</volume><issue>3</issue><fpage>495</fpage><lpage>503</lpage><pub-id pub-id-type="pmid">32015685</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/ijbs.39582</pub-id><pub-id pub-id-type="pmcid">PMC6990899</pub-id></element-citation><mixed-citation id="mc-CR61" publication-type="journal">Chen R, Cheng Q, Owusu-Ansah KG, Song G, Jiang D, Zhou L, Xu X, Wu J, Zheng S. NKILA, a prognostic indicator, inhibits tumor metastasis by suppressing NF-kappaB/Slug mediated epithelial-mesenchymal transition in hepatocellular carcinoma. Int J Biol Sci. 2020;16(3):495&#8211;503.<pub-id pub-id-type="pmid">32015685</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/ijbs.39582</pub-id><pub-id pub-id-type="pmcid">PMC6990899</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>W</given-names></name><name name-style="western"><surname>Fan</surname><given-names>H</given-names></name></person-group><article-title>Long non-coding RNA PANDAR correlates with poor prognosis and promotes tumorigenesis in hepatocellular carcinoma</article-title><source>Biomed Pharmacother</source><year>2015</year><volume>72</volume><fpage>113</fpage><lpage>118</lpage><pub-id pub-id-type="pmid">26054684</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2015.04.014</pub-id></element-citation><mixed-citation id="mc-CR62" publication-type="journal">Peng W, Fan H. Long non-coding RNA PANDAR correlates with poor prognosis and promotes tumorigenesis in hepatocellular carcinoma. Biomed Pharmacother. 2015;72:113&#8211;8.<pub-id pub-id-type="pmid">26054684</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2015.04.014</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>TH</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>JH</given-names></name><name name-style="western"><surname>Lu</surname><given-names>SW</given-names></name><name name-style="western"><surname>Peng</surname><given-names>CX</given-names></name><name name-style="western"><surname>Que</surname><given-names>HX</given-names></name><name name-style="western"><surname>Lu</surname><given-names>WL</given-names></name><name name-style="western"><surname>Mao</surname><given-names>JF</given-names></name></person-group><article-title>Prognostic significance of long non-coding RNA PCAT-1 expression in human hepatocellular carcinoma</article-title><source>Int J Clin Exp Pathol</source><year>2015</year><volume>8</volume><issue>4</issue><fpage>4126</fpage><lpage>4131</lpage><pub-id pub-id-type="pmid">26097602</pub-id><pub-id pub-id-type="pmcid">PMC4466989</pub-id></element-citation><mixed-citation id="mc-CR63" publication-type="journal">Yan TH, Yang H, Jiang JH, Lu SW, Peng CX, Que HX, Lu WL, Mao JF. Prognostic significance of long non-coding RNA PCAT-1 expression in human hepatocellular carcinoma. Int J Clin Exp Pathol. 2015;8(4):4126&#8211;31.<pub-id pub-id-type="pmid">26097602</pub-id><pub-id pub-id-type="pmcid">PMC4466989</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ji</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>P</given-names></name></person-group><article-title>LncRNA POLR2J4 plays a biomarker role in hepatitis B virus-related hepatocellular carcinoma through regulating miR-214-3p</article-title><source>Turk J Gastroenterol</source><year>2024</year><volume>35</volume><issue>10</issue><fpage>787</fpage><lpage>794</lpage><pub-id pub-id-type="pmid">39412398</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5152/tjg.2024.24150</pub-id><pub-id pub-id-type="pmcid">PMC11465190</pub-id></element-citation><mixed-citation id="mc-CR64" publication-type="journal">Ji Y, Chen X, Liu X, Huang J, Liu P. LncRNA POLR2J4 plays a biomarker role in hepatitis B virus-related hepatocellular carcinoma through regulating miR-214-3p. Turk J Gastroenterol. 2024;35(10):787&#8211;94.<pub-id pub-id-type="pmid">39412398</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5152/tjg.2024.24150</pub-id><pub-id pub-id-type="pmcid">PMC11465190</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D</given-names></name><name name-style="western"><surname>Meng</surname><given-names>Q</given-names></name></person-group><article-title>Linc-POU3F3 is overexpressed in hepatocellular carcinoma and regulates cell proliferation, migration and invasion</article-title><source>Biomed Pharmacother</source><year>2018</year><volume>105</volume><fpage>683</fpage><lpage>689</lpage><pub-id pub-id-type="pmid">29906746</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2018.06.006</pub-id></element-citation><mixed-citation id="mc-CR65" publication-type="journal">Li Y, Li Y, Wang D, Meng Q. Linc-POU3F3 is overexpressed in hepatocellular carcinoma and regulates cell proliferation, migration and invasion. Biomed Pharmacother. 2018;105:683&#8211;9.<pub-id pub-id-type="pmid">29906746</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2018.06.006</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bai</surname><given-names>H</given-names></name><name name-style="western"><surname>Luo</surname><given-names>X</given-names></name><name name-style="western"><surname>Liao</surname><given-names>D</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>W</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>M</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>B</given-names></name></person-group><article-title>Long noncoding RNA PTTG3P expression is an unfavorable prognostic marker for patients with hepatocellular carcinoma</article-title><source>Technol Cancer Res Treat</source><year>2019</year><volume>18</volume><fpage>1533033819887981</fpage><pub-id pub-id-type="pmid">31829099</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1533033819887981</pub-id><pub-id pub-id-type="pmcid">PMC6909275</pub-id></element-citation><mixed-citation id="mc-CR66" publication-type="journal">Bai H, Luo X, Liao D, Xiong W, Zeng M, Zheng B. Long noncoding RNA PTTG3P expression is an unfavorable prognostic marker for patients with hepatocellular carcinoma. Technol Cancer Res Treat. 2019;18:1533033819887981.<pub-id pub-id-type="pmid">31829099</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1533033819887981</pub-id><pub-id pub-id-type="pmcid">PMC6909275</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>T</given-names></name><name name-style="western"><surname>Cao</surname><given-names>C</given-names></name><name name-style="western"><surname>Wu</surname><given-names>D</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L</given-names></name></person-group><article-title>SNHG3 correlates with malignant status and poor prognosis in hepatocellular carcinoma</article-title><source>Tumour Biol</source><year>2016</year><volume>37</volume><issue>2</issue><fpage>2379</fpage><lpage>2385</lpage><pub-id pub-id-type="pmid">26373735</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13277-015-4052-4</pub-id></element-citation><mixed-citation id="mc-CR67" publication-type="journal">Zhang T, Cao C, Wu D, Liu L. SNHG3 correlates with malignant status and poor prognosis in hepatocellular carcinoma. Tumour Biol. 2016;37(2):2379&#8211;85.<pub-id pub-id-type="pmid">26373735</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13277-015-4052-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>JH</given-names></name><name name-style="western"><surname>Wei</surname><given-names>HW</given-names></name><name name-style="western"><surname>Yang</surname><given-names>HG</given-names></name></person-group><article-title>Long noncoding RNA SNHG15, a potential prognostic biomarker for hepatocellular carcinoma</article-title><source>Eur Rev Med Pharmacol Sci</source><year>2016</year><volume>20</volume><issue>9</issue><fpage>1720</fpage><lpage>1724</lpage><pub-id pub-id-type="pmid">27212162</pub-id></element-citation><mixed-citation id="mc-CR68" publication-type="journal">Zhang JH, Wei HW, Yang HG. Long noncoding RNA SNHG15, a potential prognostic biomarker for hepatocellular carcinoma. Eur Rev Med Pharmacol Sci. 2016;20(9):1720&#8211;4.<pub-id pub-id-type="pmid">27212162</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>QJ</given-names></name><name name-style="western"><surname>Li</surname><given-names>DZ</given-names></name><name name-style="western"><surname>Lin</surname><given-names>BY</given-names></name><name name-style="western"><surname>Geng</surname><given-names>L</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>SS</given-names></name></person-group><article-title>SNHG16 promotes hepatocellular carcinoma development via activating ECM receptor interaction pathway</article-title><source>Hepatobiliary Pancreat Dis Int</source><year>2022</year><volume>21</volume><issue>1</issue><fpage>41</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">34600815</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.hbpd.2021.09.006</pub-id></element-citation><mixed-citation id="mc-CR69" publication-type="journal">Zhang QJ, Li DZ, Lin BY, Geng L, Yang Z, Zheng SS. SNHG16 promotes hepatocellular carcinoma development via activating ECM receptor interaction pathway. Hepatobiliary Pancreat Dis Int. 2022;21(1):41&#8211;9.<pub-id pub-id-type="pmid">34600815</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.hbpd.2021.09.006</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>XM</given-names></name><name name-style="western"><surname>Teng</surname><given-names>F</given-names></name></person-group><article-title>Up-regulation of long non-coding RNA Sox2ot promotes hepatocellular carcinoma cell metastasis and correlates with poor prognosis</article-title><source>Int J Clin Exp Pathol</source><year>2015</year><volume>8</volume><issue>4</issue><fpage>4008</fpage><lpage>4014</lpage><pub-id pub-id-type="pmid">26097588</pub-id><pub-id pub-id-type="pmcid">PMC4466975</pub-id></element-citation><mixed-citation id="mc-CR70" publication-type="journal">Shi XM, Teng F. Up-regulation of long non-coding RNA Sox2ot promotes hepatocellular carcinoma cell metastasis and correlates with poor prognosis. Int J Clin Exp Pathol. 2015;8(4):4008&#8211;14.<pub-id pub-id-type="pmid">26097588</pub-id><pub-id pub-id-type="pmcid">PMC4466975</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>H</given-names></name><name name-style="western"><surname>Bai</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xu</surname><given-names>C</given-names></name><name name-style="western"><surname>He</surname><given-names>X</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Ma</surname><given-names>D</given-names></name></person-group><article-title>The tissue expression levels of SUMO1P 3 may be a reliable prognostic biomarker to predict the clinical outcomes in patients with HCC</article-title><source>Medicine (Baltimore)</source><year>2020</year><volume>99</volume><issue>46</issue><fpage>e21291</fpage><pub-id pub-id-type="pmid">33181633</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MD.0000000000021291</pub-id><pub-id pub-id-type="pmcid">PMC7668506</pub-id></element-citation><mixed-citation id="mc-CR71" publication-type="journal">Yu H, Bai Y, Xu C, He X, Liu Q, Ma D. The tissue expression levels of SUMO1P 3 may be a reliable prognostic biomarker to predict the clinical outcomes in patients with HCC. Medicine (Baltimore). 2020;99(46):e21291.<pub-id pub-id-type="pmid">33181633</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MD.0000000000021291</pub-id><pub-id pub-id-type="pmcid">PMC7668506</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qian</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ge</surname><given-names>Y</given-names></name><name name-style="western"><surname>Song</surname><given-names>W</given-names></name><name name-style="western"><surname>Fan</surname><given-names>H</given-names></name></person-group><article-title>Elevated LncRNA TRERNA1 correlated with activation of HIF-1alpha predicts poor prognosis in hepatocellular carcinoma</article-title><source>Pathol Res Pract</source><year>2021</year><volume>227</volume><fpage>153612</fpage><pub-id pub-id-type="pmid">34560417</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.prp.2021.153612</pub-id></element-citation><mixed-citation id="mc-CR72" publication-type="journal">Qian Y, Li Y, Ge Y, Song W, Fan H. Elevated LncRNA TRERNA1 correlated with activation of HIF-1alpha predicts poor prognosis in hepatocellular carcinoma. Pathol Res Pract. 2021;227: 153612.<pub-id pub-id-type="pmid">34560417</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.prp.2021.153612</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lei</surname><given-names>GL</given-names></name><name name-style="western"><surname>Fan</surname><given-names>HX</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name><name name-style="western"><surname>Niu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>TL</given-names></name><name name-style="western"><surname>Yu</surname><given-names>LX</given-names></name><name name-style="western"><surname>Hong</surname><given-names>ZX</given-names></name><name name-style="western"><surname>Yan</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>XL</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>SG</given-names></name><name name-style="western"><surname>Ren</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Yang</surname><given-names>PH</given-names></name></person-group><article-title>Long non-coding ribonucleic acid W5 inhibits progression and predicts favorable prognosis in hepatocellular carcinoma</article-title><source>World J Gastroenterol</source><year>2021</year><volume>27</volume><issue>1</issue><fpage>55</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">33505150</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3748/wjg.v27.i1.55</pub-id><pub-id pub-id-type="pmcid">PMC7789065</pub-id></element-citation><mixed-citation id="mc-CR73" publication-type="journal">Lei GL, Fan HX, Wang C, Niu Y, Li TL, Yu LX, Hong ZX, Yan J, Wang XL, Zhang SG, Ren MJ, Yang PH. Long non-coding ribonucleic acid W5 inhibits progression and predicts favorable prognosis in hepatocellular carcinoma. World J Gastroenterol. 2021;27(1):55&#8211;68.<pub-id pub-id-type="pmid">33505150</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3748/wjg.v27.i1.55</pub-id><pub-id pub-id-type="pmcid">PMC7789065</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeng</surname><given-names>Z</given-names></name><name name-style="western"><surname>Dong</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Dong</surname><given-names>Z</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y</given-names></name></person-group><article-title>The expression level and clinical significance of lncRNA X91348 in hepatocellular carcinoma</article-title><source>Artif Cells Nanomed Biotechnol</source><year>2019</year><volume>47</volume><issue>1</issue><fpage>3067</fpage><lpage>3071</lpage><pub-id pub-id-type="pmid">31349749</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/21691401.2019.1640228</pub-id></element-citation><mixed-citation id="mc-CR74" publication-type="journal">Zeng Z, Dong J, Li Y, Dong Z, Liu Z, Huang J, Wang Y, Zhen Y, Lu Y. The expression level and clinical significance of lncRNA X91348 in hepatocellular carcinoma. Artif Cells Nanomed Biotechnol. 2019;47(1):3067&#8211;71.<pub-id pub-id-type="pmid">31349749</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/21691401.2019.1640228</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>T</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>H</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>S</given-names></name></person-group><article-title>Serum exosomal long noncoding RNA CRNDE as a prognostic biomarker for hepatocellular carcinoma</article-title><source>J Clin Lab Anal</source><year>2021</year><volume>35</volume><issue>11</issue><fpage>e23959</fpage><pub-id pub-id-type="pmid">34612554</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcla.23959</pub-id><pub-id pub-id-type="pmcid">PMC8605167</pub-id></element-citation><mixed-citation id="mc-CR75" publication-type="journal">Wang T, Zhu H, Xiao M, Zhou S. Serum exosomal long noncoding RNA CRNDE as a prognostic biomarker for hepatocellular carcinoma. J Clin Lab Anal. 2021;35(11): e23959.<pub-id pub-id-type="pmid">34612554</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcla.23959</pub-id><pub-id pub-id-type="pmcid">PMC8605167</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR76"><label>76.</label><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kunadirek</surname><given-names>P</given-names></name><name name-style="western"><surname>Pinjaroen</surname><given-names>N</given-names></name><name name-style="western"><surname>Nookaew</surname><given-names>I</given-names></name><name name-style="western"><surname>Tangkijvanich</surname><given-names>P</given-names></name><name name-style="western"><surname>Chuaypen</surname><given-names>N</given-names></name></person-group><article-title>Transcriptomic analyses reveal long non-coding RNA in peripheral blood mononuclear cells as a novel biomarker for diagnosis and prognosis of hepatocellular carcinoma</article-title><source>Int J Mol Sci</source><year>2022</year><volume>23</volume><issue>14</issue><fpage>7882</fpage><pub-id pub-id-type="pmid">35887228</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms23147882</pub-id><pub-id pub-id-type="pmcid">PMC9324406</pub-id></element-citation><mixed-citation id="mc-CR76" publication-type="journal">Kunadirek P, Pinjaroen N, Nookaew I, Tangkijvanich P, Chuaypen N. Transcriptomic analyses reveal long non-coding RNA in peripheral blood mononuclear cells as a novel biomarker for diagnosis and prognosis of hepatocellular carcinoma. Int J Mol Sci. 2022;23(14):7882.<pub-id pub-id-type="pmid">35887228</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms23147882</pub-id><pub-id pub-id-type="pmcid">PMC9324406</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR77"><label>77.</label><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>ZK</given-names></name><name name-style="western"><surname>Pang</surname><given-names>C</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Duan</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>WC</given-names></name></person-group><article-title>Serum long noncoding RNA urothelial carcinoma-associated 1: a novel biomarker for diagnosis and prognosis of hepatocellular carcinoma</article-title><source>J Int Med Res</source><year>2018</year><volume>46</volume><issue>1</issue><fpage>348</fpage><lpage>356</lpage><pub-id pub-id-type="pmid">28856933</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0300060517726441</pub-id><pub-id pub-id-type="pmcid">PMC6011314</pub-id></element-citation><mixed-citation id="mc-CR77" publication-type="journal">Zheng ZK, Pang C, Yang Y, Duan Q, Zhang J, Liu WC. Serum long noncoding RNA urothelial carcinoma-associated 1: a novel biomarker for diagnosis and prognosis of hepatocellular carcinoma. J Int Med Res. 2018;46(1):348&#8211;56.<pub-id pub-id-type="pmid">28856933</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0300060517726441</pub-id><pub-id pub-id-type="pmcid">PMC6011314</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR78"><label>78.</label><citation-alternatives><element-citation id="ec-CR78" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sui</surname><given-names>J</given-names></name><name name-style="western"><surname>Miao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Han</surname><given-names>J</given-names></name><name name-style="western"><surname>Nan</surname><given-names>H</given-names></name><name name-style="western"><surname>Shen</surname><given-names>B</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wu</surname><given-names>W</given-names></name><name name-style="western"><surname>Liu</surname><given-names>T</given-names></name><name name-style="western"><surname>Xu</surname><given-names>S</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S</given-names></name><name name-style="western"><surname>Yin</surname><given-names>L</given-names></name><name name-style="western"><surname>Pu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liang</surname><given-names>G</given-names></name></person-group><article-title>Systematic analyses of a novel lncRNA-associated signature as the prognostic biomarker for Hepatocellular Carcinoma</article-title><source>Cancer Med</source><year>2018</year><volume>7</volume><issue>7</issue><fpage>3240</fpage><lpage>3256</lpage><pub-id pub-id-type="pmid">29761859</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cam4.1541</pub-id><pub-id pub-id-type="pmcid">PMC6051236</pub-id></element-citation><mixed-citation id="mc-CR78" publication-type="journal">Sui J, Miao Y, Han J, Nan H, Shen B, Zhang X, Zhang Y, Wu Y, Wu W, Liu T, Xu S, Yang S, Yin L, Pu Y, Liang G. Systematic analyses of a novel lncRNA-associated signature as the prognostic biomarker for Hepatocellular Carcinoma. Cancer Med. 2018;7(7):3240&#8211;56.<pub-id pub-id-type="pmid">29761859</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cam4.1541</pub-id><pub-id pub-id-type="pmcid">PMC6051236</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR79"><label>79.</label><citation-alternatives><element-citation id="ec-CR79" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>Y</given-names></name><name name-style="western"><surname>Luo</surname><given-names>T</given-names></name><name name-style="western"><surname>Dong</surname><given-names>D</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name></person-group><article-title>Characterization of long non-coding RNAs to reveal potential prognostic biomarkers in hepatocellular carcinoma</article-title><source>Gene</source><year>2018</year><volume>663</volume><fpage>148</fpage><lpage>156</lpage><pub-id pub-id-type="pmid">29684484</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.gene.2018.04.053</pub-id></element-citation><mixed-citation id="mc-CR79" publication-type="journal">Ma Y, Luo T, Dong D, Wu X, Wang Y. Characterization of long non-coding RNAs to reveal potential prognostic biomarkers in hepatocellular carcinoma. Gene. 2018;663:148&#8211;56.<pub-id pub-id-type="pmid">29684484</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.gene.2018.04.053</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR80"><label>80.</label><citation-alternatives><element-citation id="ec-CR80" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>QJ</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L</given-names></name><name name-style="western"><surname>Liu</surname><given-names>FF</given-names></name></person-group><article-title>Identification of a five-long non-coding RNA signature to improve the prognosis prediction for patients with hepatocellular carcinoma</article-title><source>World J Gastroenterol</source><year>2018</year><volume>24</volume><issue>30</issue><fpage>3426</fpage><lpage>3439</lpage><pub-id pub-id-type="pmid">30122881</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3748/wjg.v24.i30.3426</pub-id><pub-id pub-id-type="pmcid">PMC6092581</pub-id></element-citation><mixed-citation id="mc-CR80" publication-type="journal">Zhao QJ, Zhang J, Xu L, Liu FF. Identification of a five-long non-coding RNA signature to improve the prognosis prediction for patients with hepatocellular carcinoma. World J Gastroenterol. 2018;24(30):3426&#8211;39.<pub-id pub-id-type="pmid">30122881</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3748/wjg.v24.i30.3426</pub-id><pub-id pub-id-type="pmcid">PMC6092581</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR81"><label>81.</label><citation-alternatives><element-citation id="ec-CR81" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liao</surname><given-names>X</given-names></name><name name-style="western"><surname>Yang</surname><given-names>C</given-names></name><name name-style="western"><surname>Huang</surname><given-names>R</given-names></name><name name-style="western"><surname>Han</surname><given-names>C</given-names></name><name name-style="western"><surname>Yu</surname><given-names>T</given-names></name><name name-style="western"><surname>Huang</surname><given-names>K</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Yu</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>G</given-names></name><name name-style="western"><surname>Su</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Qin</surname><given-names>W</given-names></name><name name-style="western"><surname>Deng</surname><given-names>J</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>X</given-names></name><name name-style="western"><surname>Ye</surname><given-names>X</given-names></name><name name-style="western"><surname>Peng</surname><given-names>T</given-names></name></person-group><article-title>Identification of potential prognostic long non-coding RNA biomarkers for predicting survival in patients with hepatocellular carcinoma</article-title><source>Cell Physiol Biochem</source><year>2018</year><volume>48</volume><issue>5</issue><fpage>1854</fpage><lpage>1869</lpage><pub-id pub-id-type="pmid">30092592</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000492507</pub-id></element-citation><mixed-citation id="mc-CR81" publication-type="journal">Liao X, Yang C, Huang R, Han C, Yu T, Huang K, Liu X, Yu L, Zhu G, Su H, Wang X, Qin W, Deng J, Zeng X, Ye X, Peng T. Identification of potential prognostic long non-coding RNA biomarkers for predicting survival in patients with hepatocellular carcinoma. Cell Physiol Biochem. 2018;48(5):1854&#8211;69.<pub-id pub-id-type="pmid">30092592</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000492507</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR82"><label>82.</label><citation-alternatives><element-citation id="ec-CR82" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>F</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Song</surname><given-names>X</given-names></name><name name-style="western"><surname>Jing</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>F</given-names></name><name name-style="western"><surname>Yu</surname><given-names>S</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H</given-names></name></person-group><article-title>A five lncRNA signature for prognosis prediction in hepatocellular carcinoma</article-title><source>Mol Med Rep</source><year>2019</year><volume>19</volume><issue>6</issue><fpage>5237</fpage><lpage>5250</lpage><pub-id pub-id-type="pmid">31059056</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/mmr.2019.10203</pub-id><pub-id pub-id-type="pmcid">PMC6522922</pub-id></element-citation><mixed-citation id="mc-CR82" publication-type="journal">Sun Y, Zhang F, Wang L, Song X, Jing J, Zhang F, Yu S, Liu H. A five lncRNA signature for prognosis prediction in hepatocellular carcinoma. Mol Med Rep. 2019;19(6):5237&#8211;50.<pub-id pub-id-type="pmid">31059056</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/mmr.2019.10203</pub-id><pub-id pub-id-type="pmcid">PMC6522922</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR83"><label>83.</label><citation-alternatives><element-citation id="ec-CR83" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gu</surname><given-names>JX</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Miao</surname><given-names>RC</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>XH</given-names></name><name name-style="western"><surname>Fu</surname><given-names>YN</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>JY</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C</given-names></name><name name-style="western"><surname>Qu</surname><given-names>K</given-names></name></person-group><article-title>Six-long non-coding RNA signature predicts recurrence-free survival in hepatocellular carcinoma</article-title><source>World J Gastroenterol</source><year>2019</year><volume>25</volume><issue>2</issue><fpage>220</fpage><lpage>232</lpage><pub-id pub-id-type="pmid">30670911</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3748/wjg.v25.i2.220</pub-id><pub-id pub-id-type="pmcid">PMC6337021</pub-id></element-citation><mixed-citation id="mc-CR83" publication-type="journal">Gu JX, Zhang X, Miao RC, Xiang XH, Fu YN, Zhang JY, Liu C, Qu K. Six-long non-coding RNA signature predicts recurrence-free survival in hepatocellular carcinoma. World J Gastroenterol. 2019;25(2):220&#8211;32.<pub-id pub-id-type="pmid">30670911</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3748/wjg.v25.i2.220</pub-id><pub-id pub-id-type="pmcid">PMC6337021</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR84"><label>84.</label><citation-alternatives><element-citation id="ec-CR84" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>C</given-names></name><name name-style="western"><surname>Guo</surname><given-names>K</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name></person-group><article-title>A novel seven-lncrna signature for prognosis prediction in hepatocellular carcinoma</article-title><source>J Cell Biochem</source><year>2019</year><volume>120</volume><issue>1</issue><fpage>213</fpage><lpage>223</lpage><pub-id pub-id-type="pmid">30206981</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcb.27321</pub-id></element-citation><mixed-citation id="mc-CR84" publication-type="journal">Yan J, Zhou C, Guo K, Li Q, Wang Z. A novel seven-lncrna signature for prognosis prediction in hepatocellular carcinoma. J Cell Biochem. 2019;120(1):213&#8211;23.<pub-id pub-id-type="pmid">30206981</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcb.27321</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR85"><label>85.</label><citation-alternatives><element-citation id="ec-CR85" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ouyang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>P</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>He</surname><given-names>T</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q</given-names></name></person-group><article-title>Comprehensive bioinformatics analysis reveals potential lncRNA biomarkers for overall survival in patients with hepatocellular carcinoma: an on-line individual risk calculator based on TCGA cohort</article-title><source>Cancer Cell Int</source><year>2019</year><volume>19</volume><fpage>174</fpage><pub-id pub-id-type="pmid">31312112</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12935-019-0890-2</pub-id><pub-id pub-id-type="pmcid">PMC6611026</pub-id></element-citation><mixed-citation id="mc-CR85" publication-type="journal">Zhang Z, Ouyang Y, Huang Y, Wang P, Li J, He T, Liu Q. Comprehensive bioinformatics analysis reveals potential lncRNA biomarkers for overall survival in patients with hepatocellular carcinoma: an on-line individual risk calculator based on TCGA cohort. Cancer Cell Int. 2019;19:174.<pub-id pub-id-type="pmid">31312112</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12935-019-0890-2</pub-id><pub-id pub-id-type="pmcid">PMC6611026</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR86"><label>86.</label><citation-alternatives><element-citation id="ec-CR86" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Yang</surname><given-names>R</given-names></name><name name-style="western"><surname>Li</surname><given-names>C</given-names></name></person-group><article-title>Identification of long noncoding RNA biomarkers for hepatocellular carcinoma using single-sample networks</article-title><source>Biomed Res Int</source><year>2020</year><volume>2020</volume><fpage>8579651</fpage><pub-id pub-id-type="pmid">33299877</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2020/8579651</pub-id><pub-id pub-id-type="pmcid">PMC7700720</pub-id></element-citation><mixed-citation id="mc-CR86" publication-type="journal">Yu X, Zhang J, Yang R, Li C. Identification of long noncoding RNA biomarkers for hepatocellular carcinoma using single-sample networks. Biomed Res Int. 2020;2020:8579651.<pub-id pub-id-type="pmid">33299877</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2020/8579651</pub-id><pub-id pub-id-type="pmcid">PMC7700720</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR87"><label>87.</label><citation-alternatives><element-citation id="ec-CR87" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gu</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Sha</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>W</given-names></name></person-group><article-title>A prognostic model composed of four long noncoding RNAs predicts the overall survival of Asian patients with hepatocellular carcinoma</article-title><source>Cancer Med</source><year>2020</year><volume>9</volume><issue>16</issue><fpage>5719</fpage><lpage>5730</lpage><pub-id pub-id-type="pmid">32946170</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cam4.3275</pub-id><pub-id pub-id-type="pmcid">PMC7433813</pub-id></element-citation><mixed-citation id="mc-CR87" publication-type="journal">Gu X, Li H, Sha L, Zhao W. A prognostic model composed of four long noncoding RNAs predicts the overall survival of Asian patients with hepatocellular carcinoma. Cancer Med. 2020;9(16):5719&#8211;30.<pub-id pub-id-type="pmid">32946170</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cam4.3275</pub-id><pub-id pub-id-type="pmcid">PMC7433813</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR88"><label>88.</label><citation-alternatives><element-citation id="ec-CR88" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ye</surname><given-names>J</given-names></name><name name-style="western"><surname>Wei</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name></person-group><article-title>Long non-coding RNA-based risk scoring system predicts prognosis of alcohol-related hepatocellular carcinoma</article-title><source>Mol Med Rep</source><year>2020</year><volume>22</volume><issue>2</issue><fpage>997</fpage><lpage>1007</lpage><pub-id pub-id-type="pmid">32468063</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/mmr.2020.11179</pub-id><pub-id pub-id-type="pmcid">PMC7339747</pub-id></element-citation><mixed-citation id="mc-CR88" publication-type="journal">Luo Y, Ye J, Wei J, Zhang J, Li Y. Long non-coding RNA-based risk scoring system predicts prognosis of alcohol-related hepatocellular carcinoma. Mol Med Rep. 2020;22(2):997&#8211;1007.<pub-id pub-id-type="pmid">32468063</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/mmr.2020.11179</pub-id><pub-id pub-id-type="pmcid">PMC7339747</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR89"><label>89.</label><citation-alternatives><element-citation id="ec-CR89" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sun</surname><given-names>L</given-names></name></person-group><article-title>A four-long noncoding RNA signature predicts survival of hepatocellular carcinoma patients</article-title><source>J Clin Lab Anal</source><year>2020</year><volume>34</volume><issue>9</issue><fpage>e23377</fpage><pub-id pub-id-type="pmid">32474975</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcla.23377</pub-id><pub-id pub-id-type="pmcid">PMC7521318</pub-id></element-citation><mixed-citation id="mc-CR89" publication-type="journal">Jiang H, Zhao L, Chen Y, Sun L. A four-long noncoding RNA signature predicts survival of hepatocellular carcinoma patients. J Clin Lab Anal. 2020;34(9): e23377.<pub-id pub-id-type="pmid">32474975</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcla.23377</pub-id><pub-id pub-id-type="pmcid">PMC7521318</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR90"><label>90.</label><citation-alternatives><element-citation id="ec-CR90" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>H</given-names></name><name name-style="western"><surname>Liu</surname><given-names>TT</given-names></name><name name-style="western"><surname>Feng</surname><given-names>YM</given-names></name><name name-style="western"><surname>Xie</surname><given-names>XY</given-names></name><name name-style="western"><surname>Su</surname><given-names>XN</given-names></name><name name-style="western"><surname>Qi</surname><given-names>JN</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Qin</surname><given-names>CY</given-names></name></person-group><article-title>Prognostic effect of a novel long noncoding RNA signature and comparison with clinical staging systems for patients with hepatitis B virus-related hepatocellular carcinoma after hepatectomy</article-title><source>J Dig Dis</source><year>2020</year><volume>21</volume><issue>11</issue><fpage>650</fpage><lpage>663</lpage><pub-id pub-id-type="pmid">32959529</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/1751-2980.12941</pub-id></element-citation><mixed-citation id="mc-CR90" publication-type="journal">Wu H, Liu TT, Feng YM, Xie XY, Su XN, Qi JN, Zhu Q, Qin CY. Prognostic effect of a novel long noncoding RNA signature and comparison with clinical staging systems for patients with hepatitis B virus-related hepatocellular carcinoma after hepatectomy. J Dig Dis. 2020;21(11):650&#8211;63.<pub-id pub-id-type="pmid">32959529</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/1751-2980.12941</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR91"><label>91.</label><citation-alternatives><element-citation id="ec-CR91" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>X</given-names></name><name name-style="western"><surname>Bai</surname><given-names>Z</given-names></name><name name-style="western"><surname>Li</surname><given-names>C</given-names></name><name name-style="western"><surname>Sheng</surname><given-names>C</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name></person-group><article-title>Identification of a novel eight-lncRNA prognostic signature for HBV-HCC and analysis of their functions based on coexpression and ceRNA networks</article-title><source>Biomed Res Int</source><year>2020</year><volume>2020</volume><fpage>8765461</fpage><pub-id pub-id-type="pmid">32382578</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2020/8765461</pub-id><pub-id pub-id-type="pmcid">PMC7180394</pub-id></element-citation><mixed-citation id="mc-CR91" publication-type="journal">Zhao X, Bai Z, Li C, Sheng C, Li H. Identification of a novel eight-lncRNA prognostic signature for HBV-HCC and analysis of their functions based on coexpression and ceRNA networks. Biomed Res Int. 2020;2020:8765461.<pub-id pub-id-type="pmid">32382578</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2020/8765461</pub-id><pub-id pub-id-type="pmcid">PMC7180394</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR92"><label>92.</label><citation-alternatives><element-citation id="ec-CR92" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>X</given-names></name><name name-style="western"><surname>Dou</surname><given-names>M</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Jiao</surname><given-names>D</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Yao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Han</surname><given-names>X</given-names></name></person-group><article-title>Screening prognosis-related lncRNAs based on WGCNA to establish a new risk score for predicting prognosis in patients with hepatocellular carcinoma</article-title><source>J Immunol Res</source><year>2021</year><volume>2021</volume><fpage>5518908</fpage><pub-id pub-id-type="pmid">34426790</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2021/5518908</pub-id><pub-id pub-id-type="pmcid">PMC8380184</pub-id></element-citation><mixed-citation id="mc-CR92" publication-type="journal">Zhou X, Dou M, Liu Z, Jiao D, Li Z, Chen J, Li J, Yao Y, Li L, Li Y, Han X. Screening prognosis-related lncRNAs based on WGCNA to establish a new risk score for predicting prognosis in patients with hepatocellular carcinoma. J Immunol Res. 2021;2021:5518908.<pub-id pub-id-type="pmid">34426790</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2021/5518908</pub-id><pub-id pub-id-type="pmcid">PMC8380184</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR93"><label>93.</label><citation-alternatives><element-citation id="ec-CR93" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>S</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ye</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name></person-group><article-title>LncRNA expression-based risk scoring system can predict survival of tumor-positive patients with hepatocellular carcinoma</article-title><source>Asian Pac J Cancer Prev</source><year>2021</year><volume>22</volume><issue>12</issue><fpage>3741</fpage><lpage>3753</lpage><pub-id pub-id-type="pmid">34967552</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.31557/APJCP.2021.22.12.3741</pub-id><pub-id pub-id-type="pmcid">PMC9080350</pub-id></element-citation><mixed-citation id="mc-CR93" publication-type="journal">Wu S, Deng Y, Luo Y, Ye J, Liu Z. LncRNA expression-based risk scoring system can predict survival of tumor-positive patients with hepatocellular carcinoma. Asian Pac J Cancer Prev. 2021;22(12):3741&#8211;53.<pub-id pub-id-type="pmid">34967552</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.31557/APJCP.2021.22.12.3741</pub-id><pub-id pub-id-type="pmcid">PMC9080350</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR94"><label>94.</label><citation-alternatives><element-citation id="ec-CR94" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>C</given-names></name><name name-style="western"><surname>Qi</surname><given-names>X</given-names></name></person-group><article-title>Development and validation of a 4-lncrna combined prediction model for patients with hepatocellular carcinoma</article-title><source>Adv Clin Exp Med</source><year>2022</year><volume>31</volume><issue>10</issue><fpage>1087</fpage><lpage>1097</lpage><pub-id pub-id-type="pmid">35913371</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.17219/acem/150256</pub-id></element-citation><mixed-citation id="mc-CR94" publication-type="journal">Xu C, Qi X. Development and validation of a 4-lncrna combined prediction model for patients with hepatocellular carcinoma. Adv Clin Exp Med. 2022;31(10):1087&#8211;97.<pub-id pub-id-type="pmid">35913371</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.17219/acem/150256</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR95"><label>95.</label><citation-alternatives><element-citation id="ec-CR95" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gan</surname><given-names>B</given-names></name><name name-style="western"><surname>He</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y</given-names></name><name name-style="western"><surname>Mao</surname><given-names>L</given-names></name><name name-style="western"><surname>Liao</surname><given-names>C</given-names></name><name name-style="western"><surname>Deng</surname><given-names>G</given-names></name></person-group><article-title>Identification of a novel lncRNA prognostic signature and analysis of functional lncRNA AC115619.1 in hepatocellular carcinoma</article-title><source>Front Pharmacol</source><year>2023</year><volume>14</volume><fpage>1167418</fpage><pub-id pub-id-type="pmid">37614318</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2023.1167418</pub-id><pub-id pub-id-type="pmcid">PMC10442647</pub-id></element-citation><mixed-citation id="mc-CR95" publication-type="journal">Gan B, He Y, Ma Y, Mao L, Liao C, Deng G. Identification of a novel lncRNA prognostic signature and analysis of functional lncRNA AC115619.1 in hepatocellular carcinoma. Front Pharmacol. 2023;14:1167418.<pub-id pub-id-type="pmid">37614318</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2023.1167418</pub-id><pub-id pub-id-type="pmcid">PMC10442647</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR96"><label>96.</label><citation-alternatives><element-citation id="ec-CR96" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name><name name-style="western"><surname>Wu</surname><given-names>GZ</given-names></name><name name-style="western"><surname>Wu</surname><given-names>T</given-names></name><name name-style="western"><surname>Shang</surname><given-names>HH</given-names></name><name name-style="western"><surname>Wang</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Fisher</surname><given-names>D</given-names></name><name name-style="western"><surname>Hiens</surname><given-names>NTT</given-names></name><name name-style="western"><surname>Musabaev</surname><given-names>E</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L</given-names></name></person-group><article-title>Cell cycle-related LncRNA-based prognostic model for hepatocellular carcinoma: integrating immune microenvironment and treatment response</article-title><source>Curr Med Sci</source><year>2024</year><volume>44</volume><issue>6</issue><fpage>1217</fpage><lpage>1231</lpage><pub-id pub-id-type="pmid">39681799</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11596-024-2924-9</pub-id></element-citation><mixed-citation id="mc-CR96" publication-type="journal">Chen L, Wu GZ, Wu T, Shang HH, Wang WJ, Fisher D, Hiens NTT, Musabaev E, Zhao L. Cell cycle-related LncRNA-based prognostic model for hepatocellular carcinoma: integrating immune microenvironment and treatment response. Curr Med Sci. 2024;44(6):1217&#8211;31.<pub-id pub-id-type="pmid">39681799</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11596-024-2924-9</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR97"><label>97.</label><citation-alternatives><element-citation id="ec-CR97" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>H</given-names></name><name name-style="western"><surname>Yao</surname><given-names>H</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J</given-names></name></person-group><article-title>Cellular senescence-related long noncoding ribonucleic acids: predicting prognosis in hepatocellular carcinoma</article-title><source>Cancer Rep (Hoboken)</source><year>2023</year><volume>6</volume><issue>4</issue><fpage>e1791</fpage><pub-id pub-id-type="pmid">36726348</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cnr2.1791</pub-id><pub-id pub-id-type="pmcid">PMC10075286</pub-id></element-citation><mixed-citation id="mc-CR97" publication-type="journal">Huang H, Yao H, Wei Y, Chen M, Sun J. Cellular senescence-related long noncoding ribonucleic acids: predicting prognosis in hepatocellular carcinoma. Cancer Rep (Hoboken). 2023;6(4): e1791.<pub-id pub-id-type="pmid">36726348</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cnr2.1791</pub-id><pub-id pub-id-type="pmcid">PMC10075286</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR98"><label>98.</label><citation-alternatives><element-citation id="ec-CR98" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhong</surname><given-names>Z</given-names></name><name name-style="western"><surname>Xu</surname><given-names>M</given-names></name><name name-style="western"><surname>Tan</surname><given-names>J</given-names></name></person-group><article-title>Identification of an oxidative stress-related lncRNA signature for predicting prognosis and chemotherapy in patients with hepatocellular carcinoma</article-title><source>Pathol Oncol Res</source><year>2022</year><volume>28</volume><fpage>1610670</fpage><pub-id pub-id-type="pmid">36277962</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/pore.2022.1610670</pub-id><pub-id pub-id-type="pmcid">PMC9579291</pub-id></element-citation><mixed-citation id="mc-CR98" publication-type="journal">Zhong Z, Xu M, Tan J. Identification of an oxidative stress-related lncRNA signature for predicting prognosis and chemotherapy in patients with hepatocellular carcinoma. Pathol Oncol Res. 2022;28:1610670.<pub-id pub-id-type="pmid">36277962</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/pore.2022.1610670</pub-id><pub-id pub-id-type="pmcid">PMC9579291</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR99"><label>99.</label><citation-alternatives><element-citation id="ec-CR99" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>G</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ye</surname><given-names>R</given-names></name><name name-style="western"><surname>Yue</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Huang</surname><given-names>T</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Q</given-names></name></person-group><article-title>Development and validation of an ECM-related prognostic signature to predict the immune landscape of human hepatocellular carcinoma</article-title><source>BMC Cancer</source><year>2022</year><volume>22</volume><issue>1</issue><fpage>1036</fpage><pub-id pub-id-type="pmid">36195857</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12885-022-10049-w</pub-id><pub-id pub-id-type="pmcid">PMC9531523</pub-id></element-citation><mixed-citation id="mc-CR99" publication-type="journal">Wu G, Yang Y, Ye R, Yue H, Zhang H, Huang T, Liu M, Zheng Y, Wang Y, Zhou Y, Guo Q. Development and validation of an ECM-related prognostic signature to predict the immune landscape of human hepatocellular carcinoma. BMC Cancer. 2022;22(1):1036.<pub-id pub-id-type="pmid">36195857</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12885-022-10049-w</pub-id><pub-id pub-id-type="pmcid">PMC9531523</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR100"><label>100.</label><citation-alternatives><element-citation id="ec-CR100" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Lai</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhuang</surname><given-names>L</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name></person-group><article-title>Identification of novel tumor microenvironment-related long noncoding RNAs to determine the prognosis and response to immunotherapy of hepatocellular carcinoma patients</article-title><source>Front Mol Biosci</source><year>2021</year><volume>8</volume><fpage>781307</fpage><pub-id pub-id-type="pmid">35004851</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmolb.2021.781307</pub-id><pub-id pub-id-type="pmcid">PMC8739902</pub-id></element-citation><mixed-citation id="mc-CR100" publication-type="journal">Huang S, Zhang J, Lai X, Zhuang L, Wu J. Identification of novel tumor microenvironment-related long noncoding RNAs to determine the prognosis and response to immunotherapy of hepatocellular carcinoma patients. Front Mol Biosci. 2021;8: 781307.<pub-id pub-id-type="pmid">35004851</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmolb.2021.781307</pub-id><pub-id pub-id-type="pmcid">PMC8739902</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR101"><label>101.</label><citation-alternatives><element-citation id="ec-CR101" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>W</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>H</given-names></name></person-group><article-title>Anoikis-related lncRNA signature predicts prognosis and is associated with immune infiltration in hepatocellular carcinoma</article-title><source>Anticancer Drugs</source><year>2024</year><volume>35</volume><issue>5</issue><fpage>466</fpage><lpage>480</lpage><pub-id pub-id-type="pmid">38507233</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CAD.0000000000001589</pub-id></element-citation><mixed-citation id="mc-CR101" publication-type="journal">Zhu J, Zhao W, Yang J, Liu C, Wang Y, Zhao H. Anoikis-related lncRNA signature predicts prognosis and is associated with immune infiltration in hepatocellular carcinoma. Anticancer Drugs. 2024;35(5):466&#8211;80.<pub-id pub-id-type="pmid">38507233</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CAD.0000000000001589</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR102"><label>102.</label><citation-alternatives><element-citation id="ec-CR102" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J</given-names></name><name name-style="western"><surname>Mo</surname><given-names>J</given-names></name><name name-style="western"><surname>Wei</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>He</surname><given-names>F</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>L</given-names></name></person-group><article-title>Identification and validation of PANoptosis-related LncRNAs prognosis system in hepatocellular carcinoma</article-title><source>Sci Rep</source><year>2025</year><volume>15</volume><issue>1</issue><fpage>6030</fpage><pub-id pub-id-type="pmid">39972122</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-025-90498-y</pub-id><pub-id pub-id-type="pmcid">PMC11840146</pub-id></element-citation><mixed-citation id="mc-CR102" publication-type="journal">Shu Q, Zhu J, Mo J, Wei X, Zhu Z, Chen X, He F, Zhong L. Identification and validation of PANoptosis-related LncRNAs prognosis system in hepatocellular carcinoma. Sci Rep. 2025;15(1):6030.<pub-id pub-id-type="pmid">39972122</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-025-90498-y</pub-id><pub-id pub-id-type="pmcid">PMC11840146</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR103"><label>103.</label><citation-alternatives><element-citation id="ec-CR103" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liao</surname><given-names>LE</given-names></name><name name-style="western"><surname>Hu</surname><given-names>DD</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y</given-names></name></person-group><article-title>A four-methylated lncRNAs-based prognostic signature for hepatocellular carcinoma</article-title><source>Genes (Basel)</source><year>2020</year><volume>11</volume><issue>8</issue><fpage>908</fpage><pub-id pub-id-type="pmid">32784402</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/genes11080908</pub-id><pub-id pub-id-type="pmcid">PMC7463540</pub-id></element-citation><mixed-citation id="mc-CR103" publication-type="journal">Liao LE, Hu DD, Zheng Y. A four-methylated lncRNAs-based prognostic signature for hepatocellular carcinoma. Genes (Basel). 2020;11(8):908.<pub-id pub-id-type="pmid">32784402</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/genes11080908</pub-id><pub-id pub-id-type="pmcid">PMC7463540</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR104"><label>104.</label><citation-alternatives><element-citation id="ec-CR104" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>C</given-names></name><name name-style="western"><surname>Li</surname><given-names>R</given-names></name><name name-style="western"><surname>Deng</surname><given-names>T</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Chen</surname><given-names>K</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>H</given-names></name><name name-style="western"><surname>Chen</surname><given-names>G</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name></person-group><article-title>Identification and validation of a prognostic prediction model of m6A regulator-related LncRNAs in hepatocellular carcinoma</article-title><source>Front Mol Biosci</source><year>2021</year><volume>8</volume><fpage>784553</fpage><pub-id pub-id-type="pmid">34988119</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmolb.2021.784553</pub-id><pub-id pub-id-type="pmcid">PMC8721125</pub-id></element-citation><mixed-citation id="mc-CR104" publication-type="journal">Jin C, Li R, Deng T, Li J, Yang Y, Li H, Chen K, Xiong H, Chen G, Wang Y. Identification and validation of a prognostic prediction model of m6A regulator-related LncRNAs in hepatocellular carcinoma. Front Mol Biosci. 2021;8: 784553.<pub-id pub-id-type="pmid">34988119</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmolb.2021.784553</pub-id><pub-id pub-id-type="pmcid">PMC8721125</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR105"><label>105.</label><mixed-citation publication-type="other">Li L, Xie R, Lu G. Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma. Biosci Rep. 2021; 41 (6).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1042/BSR20210760</pub-id><pub-id pub-id-type="pmcid">PMC8188173</pub-id><pub-id pub-id-type="pmid">34027555</pub-id></mixed-citation></ref><ref id="CR106"><label>106.</label><citation-alternatives><element-citation id="ec-CR106" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>B</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Lang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Tao</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>R</given-names></name><name name-style="western"><surname>Zhan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>K</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>J</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yu</surname><given-names>S</given-names></name></person-group><article-title>M6A-related lncRNAs predict clinical outcome and regulate the tumor immune microenvironment in hepatocellular carcinoma</article-title><source>BMC Cancer</source><year>2022</year><volume>22</volume><issue>1</issue><fpage>867</fpage><pub-id pub-id-type="pmid">35941582</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12885-022-09925-2</pub-id><pub-id pub-id-type="pmcid">PMC9361634</pub-id></element-citation><mixed-citation id="mc-CR106" publication-type="journal">Chen B, Yang Z, Lang Z, Tao Q, Zhang R, Zhan Y, Xu X, Zhu K, Zheng J, Yu Z, Yu S. M6A-related lncRNAs predict clinical outcome and regulate the tumor immune microenvironment in hepatocellular carcinoma. BMC Cancer. 2022;22(1):867.<pub-id pub-id-type="pmid">35941582</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12885-022-09925-2</pub-id><pub-id pub-id-type="pmcid">PMC9361634</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR107"><label>107.</label><citation-alternatives><element-citation id="ec-CR107" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>W</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>W</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S</given-names></name></person-group><article-title>Prognostic signature and tumor immune landscape of N7-methylguanosine-related lncRNAs in hepatocellular carcinoma</article-title><source>Front Genet</source><year>2022</year><volume>13</volume><fpage>906496</fpage><pub-id pub-id-type="pmid">35938009</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fgene.2022.906496</pub-id><pub-id pub-id-type="pmcid">PMC9354608</pub-id></element-citation><mixed-citation id="mc-CR107" publication-type="journal">Wei W, Liu C, Wang M, Jiang W, Wang C, Zhang S. Prognostic signature and tumor immune landscape of N7-methylguanosine-related lncRNAs in hepatocellular carcinoma. Front Genet. 2022;13: 906496.<pub-id pub-id-type="pmid">35938009</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fgene.2022.906496</pub-id><pub-id pub-id-type="pmcid">PMC9354608</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR108"><label>108.</label><citation-alternatives><element-citation id="ec-CR108" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>BH</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>JH</given-names></name><name name-style="western"><surname>Luo</surname><given-names>T</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>ZJ</given-names></name><name name-style="western"><surname>Liu</surname><given-names>XY</given-names></name><name name-style="western"><surname>Li</surname><given-names>LQ</given-names></name></person-group><article-title>Signature of prognostic epithelial-mesenchymal transition related long noncoding RNAs (ERLs) in hepatocellular carcinoma</article-title><source>Medicine (Baltimore)</source><year>2021</year><volume>100</volume><issue>30</issue><fpage>e26762</fpage><pub-id pub-id-type="pmid">34397721</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MD.0000000000026762</pub-id><pub-id pub-id-type="pmcid">PMC8322489</pub-id></element-citation><mixed-citation id="mc-CR108" publication-type="journal">Xu BH, Jiang JH, Luo T, Jiang ZJ, Liu XY, Li LQ. Signature of prognostic epithelial-mesenchymal transition related long noncoding RNAs (ERLs) in hepatocellular carcinoma. Medicine (Baltimore). 2021;100(30): e26762.<pub-id pub-id-type="pmid">34397721</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MD.0000000000026762</pub-id><pub-id pub-id-type="pmcid">PMC8322489</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR109"><label>109.</label><citation-alternatives><element-citation id="ec-CR109" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tao</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>T</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>P</given-names></name><name name-style="western"><surname>Liang</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>E</given-names></name></person-group><article-title>Identification of an EMT-related lncRNA signature and LINC01116 as an immune-related oncogene in hepatocellular carcinoma</article-title><source>Aging (Albany NY)</source><year>2022</year><volume>14</volume><issue>3</issue><fpage>1473</fpage><lpage>1491</lpage><pub-id pub-id-type="pmid">35148283</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/aging.203888</pub-id><pub-id pub-id-type="pmcid">PMC8876905</pub-id></element-citation><mixed-citation id="mc-CR109" publication-type="journal">Tao H, Zhang Y, Yuan T, Li J, Liu J, Xiong Y, Zhu J, Huang Z, Wang P, Liang H, Zhang E. Identification of an EMT-related lncRNA signature and LINC01116 as an immune-related oncogene in hepatocellular carcinoma. Aging (Albany NY). 2022;14(3):1473&#8211;91.<pub-id pub-id-type="pmid">35148283</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/aging.203888</pub-id><pub-id pub-id-type="pmcid">PMC8876905</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR110"><label>110.</label><citation-alternatives><element-citation id="ec-CR110" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Ma</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yang</surname><given-names>M</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J</given-names></name><name name-style="western"><surname>Luo</surname><given-names>J</given-names></name><name name-style="western"><surname>Yan</surname><given-names>Z</given-names></name></person-group><article-title>Identification of epithelial mesenchymal transition-related lncRNAs associated with prognosis and tumor immune microenvironment of hepatocellular carcinoma</article-title><source>Dis Markers</source><year>2022</year><volume>2022</volume><fpage>6335155</fpage><pub-id pub-id-type="pmid">35111268</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2022/6335155</pub-id><pub-id pub-id-type="pmcid">PMC8802097</pub-id></element-citation><mixed-citation id="mc-CR110" publication-type="journal">Zhou Y, Wang L, Zhang W, Ma J, Zhang Z, Yang M, Yu J, Luo J, Yan Z. Identification of epithelial mesenchymal transition-related lncRNAs associated with prognosis and tumor immune microenvironment of hepatocellular carcinoma. Dis Markers. 2022;2022:6335155.<pub-id pub-id-type="pmid">35111268</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2022/6335155</pub-id><pub-id pub-id-type="pmcid">PMC8802097</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR111"><label>111.</label><citation-alternatives><element-citation id="ec-CR111" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>DP</given-names></name><name name-style="western"><surname>Liao</surname><given-names>MM</given-names></name><name name-style="western"><surname>Tong</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>WQ</given-names></name><name name-style="western"><surname>Peng</surname><given-names>DT</given-names></name><name name-style="western"><surname>Lai</surname><given-names>JP</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>YH</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Tong</surname><given-names>GD</given-names></name></person-group><article-title>Construction of a genome instability-derived lncRNA-based risk scoring system for the prognosis of hepatocellular carcinoma</article-title><source>Aging (Albany NY)</source><year>2021</year><volume>13</volume><issue>22</issue><fpage>24621</fpage><lpage>24639</lpage><pub-id pub-id-type="pmid">34799469</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/aging.203698</pub-id><pub-id pub-id-type="pmcid">PMC8660619</pub-id></element-citation><mixed-citation id="mc-CR111" publication-type="journal">Huang DP, Liao MM, Tong JJ, Yuan WQ, Peng DT, Lai JP, Zeng YH, Qiu YJ, Tong GD. Construction of a genome instability-derived lncRNA-based risk scoring system for the prognosis of hepatocellular carcinoma. Aging (Albany NY). 2021;13(22):24621&#8211;39.<pub-id pub-id-type="pmid">34799469</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/aging.203698</pub-id><pub-id pub-id-type="pmcid">PMC8660619</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR112"><label>112.</label><citation-alternatives><element-citation id="ec-CR112" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>X</given-names></name><name name-style="western"><surname>Miao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Cai</surname><given-names>T</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L</given-names></name><name name-style="western"><surname>Mi</surname><given-names>D</given-names></name></person-group><article-title>Identification of mutator-derived lncRNA signatures of genomic instability for promoting the clinical outcome in hepatocellular carcinoma</article-title><source>Comput Math Methods Med</source><year>2021</year><volume>2021</volume><fpage>1205029</fpage><pub-id pub-id-type="pmid">34840594</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2021/1205029</pub-id><pub-id pub-id-type="pmcid">PMC8613502</pub-id></element-citation><mixed-citation id="mc-CR112" publication-type="journal">Tang X, Miao Y, Wang J, Cai T, Yang L, Mi D. Identification of mutator-derived lncRNA signatures of genomic instability for promoting the clinical outcome in hepatocellular carcinoma. Comput Math Methods Med. 2021;2021:1205029.<pub-id pub-id-type="pmid">34840594</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2021/1205029</pub-id><pub-id pub-id-type="pmcid">PMC8613502</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR113"><label>113.</label><citation-alternatives><element-citation id="ec-CR113" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name><name name-style="western"><surname>Ren</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>N</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>R</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M</given-names></name><name name-style="western"><surname>Cai</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lin</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Xie</surname><given-names>X</given-names></name><name name-style="western"><surname>Dang</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Z</given-names></name></person-group><article-title>A mutation-related long noncoding RNA signature of genome instability predicts immune infiltration and hepatocellular carcinoma prognosis</article-title><source>Front Genet</source><year>2021</year><volume>12</volume><fpage>779554</fpage><pub-id pub-id-type="pmid">34880908</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fgene.2021.779554</pub-id><pub-id pub-id-type="pmcid">PMC8645863</pub-id></element-citation><mixed-citation id="mc-CR113" publication-type="journal">Wu J, Ren X, Wang N, Zhou R, Chen M, Cai Y, Lin S, Zhang H, Xie X, Dang C, Zhang S, Zhou Z. A mutation-related long noncoding RNA signature of genome instability predicts immune infiltration and hepatocellular carcinoma prognosis. Front Genet. 2021;12: 779554.<pub-id pub-id-type="pmid">34880908</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fgene.2021.779554</pub-id><pub-id pub-id-type="pmcid">PMC8645863</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR114"><label>114.</label><citation-alternatives><element-citation id="ec-CR114" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>JS</given-names></name><name name-style="western"><surname>Huang</surname><given-names>XQ</given-names></name><name name-style="western"><surname>Yang</surname><given-names>XZ</given-names></name><name name-style="western"><surname>Niu</surname><given-names>FY</given-names></name><name name-style="western"><surname>Lin</surname><given-names>JR</given-names></name><name name-style="western"><surname>Ma</surname><given-names>L</given-names></name><name name-style="western"><surname>Shi</surname><given-names>YX</given-names></name><name name-style="western"><surname>Li</surname><given-names>XS</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>P</given-names></name><name name-style="western"><surname>Gao</surname><given-names>S</given-names></name><name name-style="western"><surname>Li</surname><given-names>F</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y</given-names></name></person-group><article-title>A somatic mutation-derived LncRNA signatures of genomic instability predicts the prognosis and tumor microenvironment immune characters in hepatocellular carcinoma</article-title><source>Hepatol Int</source><year>2022</year><volume>16</volume><issue>5</issue><fpage>1220</fpage><lpage>1233</lpage><pub-id pub-id-type="pmid">35947245</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12072-022-10375-y</pub-id></element-citation><mixed-citation id="mc-CR114" publication-type="journal">Jin C, Zhao JS, Huang XQ, Yang XZ, Niu FY, Lin JR, Ma L, Shi YX, Li XS, Jiang P, Gao S, Li F, Song Y. A somatic mutation-derived LncRNA signatures of genomic instability predicts the prognosis and tumor microenvironment immune characters in hepatocellular carcinoma. Hepatol Int. 2022;16(5):1220&#8211;33.<pub-id pub-id-type="pmid">35947245</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12072-022-10375-y</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR115"><label>115.</label><citation-alternatives><element-citation id="ec-CR115" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Z</given-names></name><name name-style="western"><surname>Jin</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wu</surname><given-names>G</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>H</given-names></name><name name-style="western"><surname>Xu</surname><given-names>B</given-names></name><name name-style="western"><surname>Wen</surname><given-names>Z</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y</given-names></name></person-group><article-title>Bioinformatics analysis and experimental verification of five metabolism-related lncRNAs as prognostic models for hepatocellular carcinoma</article-title><source>Medicine (Baltimore)</source><year>2022</year><volume>101</volume><issue>4</issue><fpage>e28694</fpage><pub-id pub-id-type="pmid">35089224</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MD.0000000000028694</pub-id><pub-id pub-id-type="pmcid">PMC8797488</pub-id></element-citation><mixed-citation id="mc-CR115" publication-type="journal">Wang W, Deng Z, Jin Z, Wu G, Wang J, Zhu H, Xu B, Wen Z, Guo Y. Bioinformatics analysis and experimental verification of five metabolism-related lncRNAs as prognostic models for hepatocellular carcinoma. Medicine (Baltimore). 2022;101(4): e28694.<pub-id pub-id-type="pmid">35089224</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MD.0000000000028694</pub-id><pub-id pub-id-type="pmcid">PMC8797488</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR116"><label>116.</label><citation-alternatives><element-citation id="ec-CR116" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Qian</surname><given-names>J</given-names></name><name name-style="western"><surname>Yao</surname><given-names>N</given-names></name><name name-style="western"><surname>Pocha</surname><given-names>C</given-names></name><name name-style="western"><surname>Kang</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Angelico</surname><given-names>R</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>G</given-names></name></person-group><article-title>Identification of metabolism-related long non-coding RNA (lncRNA) signature predicts prognosis and immune infiltrates in hepatocellular carcinoma</article-title><source>Ann Transl Med</source><year>2022</year><volume>10</volume><issue>10</issue><fpage>595</fpage><pub-id pub-id-type="pmid">35722420</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.21037/atm-22-2194</pub-id><pub-id pub-id-type="pmcid">PMC9201179</pub-id></element-citation><mixed-citation id="mc-CR116" publication-type="journal">Wang X, Qian J, Yao N, Pocha C, Kang KJ, Angelico R, Zhu G. Identification of metabolism-related long non-coding RNA (lncRNA) signature predicts prognosis and immune infiltrates in hepatocellular carcinoma. Ann Transl Med. 2022;10(10):595.<pub-id pub-id-type="pmid">35722420</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.21037/atm-22-2194</pub-id><pub-id pub-id-type="pmcid">PMC9201179</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR117"><label>117.</label><citation-alternatives><element-citation id="ec-CR117" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lei</surname><given-names>H</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>T</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>H</given-names></name><name name-style="western"><surname>Hu</surname><given-names>X</given-names></name></person-group><article-title>A novel cholesterol metabolism-related lncRNA signature predicts the prognosis of patients with hepatocellular carcinoma and their response to immunotherapy</article-title><source>Front Biosci (Landmark Ed)</source><year>2024</year><volume>29</volume><issue>3</issue><fpage>129</fpage><pub-id pub-id-type="pmid">38538256</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.31083/j.fbl2903129</pub-id></element-citation><mixed-citation id="mc-CR117" publication-type="journal">Lei H, Xiang T, Zhu H, Hu X. A novel cholesterol metabolism-related lncRNA signature predicts the prognosis of patients with hepatocellular carcinoma and their response to immunotherapy. Front Biosci (Landmark Ed). 2024;29(3):129.<pub-id pub-id-type="pmid">38538256</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.31083/j.fbl2903129</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR118"><label>118.</label><citation-alternatives><element-citation id="ec-CR118" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cui</surname><given-names>H</given-names></name><name name-style="western"><surname>Lian</surname><given-names>J</given-names></name><name name-style="western"><surname>Xu</surname><given-names>B</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>H</given-names></name><name name-style="western"><surname>Shi</surname><given-names>J</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Han</surname><given-names>T</given-names></name></person-group><article-title>Identification of a bile acid and bile salt metabolism-related lncRNA signature for predicting prognosis and treatment response in hepatocellular carcinoma</article-title><source>Sci Rep</source><year>2023</year><volume>13</volume><issue>1</issue><fpage>19512</fpage><pub-id pub-id-type="pmid">37945918</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-023-46805-6</pub-id><pub-id pub-id-type="pmcid">PMC10636107</pub-id></element-citation><mixed-citation id="mc-CR118" publication-type="journal">Cui H, Lian J, Xu B, Yu Z, Xiang H, Shi J, Gao Y, Han T. Identification of a bile acid and bile salt metabolism-related lncRNA signature for predicting prognosis and treatment response in hepatocellular carcinoma. Sci Rep. 2023;13(1):19512.<pub-id pub-id-type="pmid">37945918</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-023-46805-6</pub-id><pub-id pub-id-type="pmcid">PMC10636107</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR119"><label>119.</label><citation-alternatives><element-citation id="ec-CR119" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Mo</surname><given-names>J</given-names></name></person-group><article-title>Immune-related long noncoding RNA signature for predicting survival and immune checkpoint blockade in hepatocellular carcinoma</article-title><source>J Cell Physiol</source><year>2020</year><volume>235</volume><issue>12</issue><fpage>9304</fpage><lpage>9316</lpage><pub-id pub-id-type="pmid">32330311</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcp.29730</pub-id></element-citation><mixed-citation id="mc-CR119" publication-type="journal">Zhang Y, Zhang L, Xu Y, Wu X, Zhou Y, Mo J. Immune-related long noncoding RNA signature for predicting survival and immune checkpoint blockade in hepatocellular carcinoma. J Cell Physiol. 2020;235(12):9304&#8211;16.<pub-id pub-id-type="pmid">32330311</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcp.29730</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR120"><label>120.</label><citation-alternatives><element-citation id="ec-CR120" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Huang</surname><given-names>W</given-names></name></person-group><article-title>Identification of immune-related lncRNA signature for predicting immune checkpoint blockade and prognosis in hepatocellular carcinoma</article-title><source>Int Immunopharmacol</source><year>2021</year><volume>92</volume><fpage>107333</fpage><pub-id pub-id-type="pmid">33486322</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.intimp.2020.107333</pub-id></element-citation><mixed-citation id="mc-CR120" publication-type="journal">Xu Q, Wang Y, Huang W. Identification of immune-related lncRNA signature for predicting immune checkpoint blockade and prognosis in hepatocellular carcinoma. Int Immunopharmacol. 2021;92: 107333.<pub-id pub-id-type="pmid">33486322</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.intimp.2020.107333</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR121"><label>121.</label><citation-alternatives><element-citation id="ec-CR121" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>M</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Q</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name><name name-style="western"><surname>Xian</surname><given-names>S</given-names></name><name name-style="western"><surname>Dai</surname><given-names>F</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Fan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F</given-names></name><name name-style="western"><surname>Yang</surname><given-names>D</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Z</given-names></name><name name-style="western"><surname>Tan</surname><given-names>W</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Y</given-names></name></person-group><article-title>Identification of a nine immune-related lncRNA signature as a novel diagnostic biomarker for hepatocellular carcinoma</article-title><source>Biomed Res Int</source><year>2021</year><volume>2021</volume><fpage>9798231</fpage><pub-id pub-id-type="pmid">33506049</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2021/9798231</pub-id><pub-id pub-id-type="pmcid">PMC7808810</pub-id></element-citation><mixed-citation id="mc-CR121" publication-type="journal">Yuan M, Wang Y, Sun Q, Liu S, Xian S, Dai F, Zhang L, Fan Y, Wang F, Yang D, Zheng Y, Deng Z, Tan W, Liu Y, Cheng Y. Identification of a nine immune-related lncRNA signature as a novel diagnostic biomarker for hepatocellular carcinoma. Biomed Res Int. 2021;2021:9798231.<pub-id pub-id-type="pmid">33506049</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2021/9798231</pub-id><pub-id pub-id-type="pmcid">PMC7808810</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR122"><label>122.</label><citation-alternatives><element-citation id="ec-CR122" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>R</given-names></name><name name-style="western"><surname>Jin</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>W</given-names></name><name name-style="western"><surname>Liang</surname><given-names>R</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>H</given-names></name></person-group><article-title>Development of a novel immune-related lncRNA prognostic signature for patients with hepatocellular carcinoma</article-title><source>BMC Gastroenterol</source><year>2022</year><volume>22</volume><issue>1</issue><fpage>450</fpage><pub-id pub-id-type="pmid">36344926</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12876-022-02540-2</pub-id><pub-id pub-id-type="pmcid">PMC9639314</pub-id></element-citation><mixed-citation id="mc-CR122" publication-type="journal">Li R, Jin C, Zhao W, Liang R, Xiong H. Development of a novel immune-related lncRNA prognostic signature for patients with hepatocellular carcinoma. BMC Gastroenterol. 2022;22(1):450.<pub-id pub-id-type="pmid">36344926</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12876-022-02540-2</pub-id><pub-id pub-id-type="pmcid">PMC9639314</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR123"><label>123.</label><citation-alternatives><element-citation id="ec-CR123" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Jin</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wu</surname><given-names>G</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Xu</surname><given-names>B</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>H</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wen</surname><given-names>Z</given-names></name></person-group><article-title>Bioinformatics analysis for constructing a six-immune-related long noncoding RNA signature as a prognostic model of hepatocellular carcinoma</article-title><source>Biomed Res Int</source><year>2022</year><volume>2022</volume><fpage>2093437</fpage><pub-id pub-id-type="pmid">35845962</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2022/2093437</pub-id><pub-id pub-id-type="pmcid">PMC9283041</pub-id></element-citation><mixed-citation id="mc-CR123" publication-type="journal">Wang J, Jin Z, Wu G, Wang J, Xu B, Zhu H, Guo Y, Wen Z. Bioinformatics analysis for constructing a six-immune-related long noncoding RNA signature as a prognostic model of hepatocellular carcinoma. Biomed Res Int. 2022;2022:2093437.<pub-id pub-id-type="pmid">35845962</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2022/2093437</pub-id><pub-id pub-id-type="pmcid">PMC9283041</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR124"><label>124.</label><citation-alternatives><element-citation id="ec-CR124" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xin</surname><given-names>C</given-names></name><name name-style="western"><surname>Huang</surname><given-names>B</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M</given-names></name><name name-style="western"><surname>Yan</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>K</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name></person-group><article-title>Construction and validation of an immune-related LncRNA prognostic model for hepatocellular carcinoma</article-title><source>Cytokine</source><year>2022</year><volume>156</volume><fpage>155923</fpage><pub-id pub-id-type="pmid">35667281</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cyto.2022.155923</pub-id></element-citation><mixed-citation id="mc-CR124" publication-type="journal">Xin C, Huang B, Chen M, Yan H, Zhu K, Chen L, Jiang C, Zhang J, Wu Y. Construction and validation of an immune-related LncRNA prognostic model for hepatocellular carcinoma. Cytokine. 2022;156: 155923.<pub-id pub-id-type="pmid">35667281</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cyto.2022.155923</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR125"><label>125.</label><citation-alternatives><element-citation id="ec-CR125" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>S</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Stalin</surname><given-names>A</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Tan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Z</given-names></name><name name-style="western"><surname>You</surname><given-names>L</given-names></name><name name-style="western"><surname>Ye</surname><given-names>P</given-names></name><name name-style="western"><surname>Fu</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name></person-group><article-title>Identification of an immune-related 6-lncRNA panel with a good performance for prognostic prediction in hepatocellular carcinoma by integrated bioinformatics analysis</article-title><source>Medicine (Baltimore)</source><year>2023</year><volume>102</volume><issue>29</issue><fpage>e33990</fpage><pub-id pub-id-type="pmid">37478241</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MD.0000000000033990</pub-id><pub-id pub-id-type="pmcid">PMC10662904</pub-id></element-citation><mixed-citation id="mc-CR125" publication-type="journal">Lu S, Liu X, Wu C, Zhang J, Stalin A, Huang Z, Tan Y, Wu Z, You L, Ye P, Fu C, Zhang X, Wu J. Identification of an immune-related 6-lncRNA panel with a good performance for prognostic prediction in hepatocellular carcinoma by integrated bioinformatics analysis. Medicine (Baltimore). 2023;102(29): e33990.<pub-id pub-id-type="pmid">37478241</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MD.0000000000033990</pub-id><pub-id pub-id-type="pmcid">PMC10662904</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR126"><label>126.</label><citation-alternatives><element-citation id="ec-CR126" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kong</surname><given-names>R</given-names></name><name name-style="western"><surname>Wang</surname><given-names>N</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>CL</given-names></name><name name-style="western"><surname>Lu</surname><given-names>J</given-names></name></person-group><article-title>Prognostic value of an immune long non-coding RNA signature in liver hepatocellular carcinoma</article-title><source>J Microbiol Biotechnol</source><year>2024</year><volume>34</volume><issue>4</issue><fpage>958</fpage><lpage>968</lpage><pub-id pub-id-type="pmid">38494878</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4014/jmb.2308.08022</pub-id><pub-id pub-id-type="pmcid">PMC11091670</pub-id></element-citation><mixed-citation id="mc-CR126" publication-type="journal">Kong R, Wang N, Zhou CL, Lu J. Prognostic value of an immune long non-coding RNA signature in liver hepatocellular carcinoma. J Microbiol Biotechnol. 2024;34(4):958&#8211;68.<pub-id pub-id-type="pmid">38494878</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4014/jmb.2308.08022</pub-id><pub-id pub-id-type="pmcid">PMC11091670</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR127"><label>127.</label><citation-alternatives><element-citation id="ec-CR127" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>M</given-names></name><name name-style="western"><surname>Gu</surname><given-names>W</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name></person-group><article-title>Molecular subtypes and a prognostic model for hepatocellular carcinoma based on immune- and immunogenic cell death-related lncRNAs</article-title><source>Front Immunol</source><year>2022</year><volume>13</volume><fpage>1043827</fpage><pub-id pub-id-type="pmid">36479122</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2022.1043827</pub-id><pub-id pub-id-type="pmcid">PMC9720162</pub-id></element-citation><mixed-citation id="mc-CR127" publication-type="journal">He M, Gu W, Gao Y, Liu Y, Liu J, Li Z. Molecular subtypes and a prognostic model for hepatocellular carcinoma based on immune- and immunogenic cell death-related lncRNAs. Front Immunol. 2022;13:1043827.<pub-id pub-id-type="pmid">36479122</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2022.1043827</pub-id><pub-id pub-id-type="pmcid">PMC9720162</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR128"><label>128.</label><citation-alternatives><element-citation id="ec-CR128" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Fang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M</given-names></name></person-group><article-title>Identification of a novel prognostic signature for HCC and analysis of costimulatory molecule-related lncRNA AC099850.3</article-title><source>Sci Rep</source><year>2022</year><volume>12</volume><issue>1</issue><fpage>9954</fpage><pub-id pub-id-type="pmid">35705628</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-022-13792-z</pub-id><pub-id pub-id-type="pmcid">PMC9200812</pub-id></element-citation><mixed-citation id="mc-CR128" publication-type="journal">Wang Q, Fang Q, Huang Y, Zhou J, Liu M. Identification of a novel prognostic signature for HCC and analysis of costimulatory molecule-related lncRNA AC099850.3. Sci Rep. 2022;12(1):9954.<pub-id pub-id-type="pmid">35705628</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-022-13792-z</pub-id><pub-id pub-id-type="pmcid">PMC9200812</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR129"><label>129.</label><citation-alternatives><element-citation id="ec-CR129" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Lin</surname><given-names>L</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tao</surname><given-names>Q</given-names></name><name name-style="western"><surname>Lang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>J</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Z</given-names></name></person-group><article-title>Machine learning integrations develop an antigen-presenting-cells and T-cells-infiltration derived LncRNA signature for improving clinical outcomes in hepatocellular carcinoma</article-title><source>BMC Cancer</source><year>2023</year><volume>23</volume><issue>1</issue><fpage>284</fpage><pub-id pub-id-type="pmid">36978017</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12885-023-10766-w</pub-id><pub-id pub-id-type="pmcid">PMC10053113</pub-id></element-citation><mixed-citation id="mc-CR129" publication-type="journal">Wang X, Chen J, Lin L, Li Y, Tao Q, Lang Z, Zheng J, Yu Z. Machine learning integrations develop an antigen-presenting-cells and T-cells-infiltration derived LncRNA signature for improving clinical outcomes in hepatocellular carcinoma. BMC Cancer. 2023;23(1):284.<pub-id pub-id-type="pmid">36978017</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12885-023-10766-w</pub-id><pub-id pub-id-type="pmcid">PMC10053113</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR130"><label>130.</label><citation-alternatives><element-citation id="ec-CR130" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deng</surname><given-names>X</given-names></name><name name-style="western"><surname>Bi</surname><given-names>Q</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>Z</given-names></name><name name-style="western"><surname>Guo</surname><given-names>W</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name></person-group><article-title>Identification of a five-autophagy-related-lncRNA signature as a novel prognostic biomarker for hepatocellular carcinoma</article-title><source>Front Mol Biosci</source><year>2020</year><volume>7</volume><fpage>611626</fpage><pub-id pub-id-type="pmid">33505990</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmolb.2020.611626</pub-id><pub-id pub-id-type="pmcid">PMC7831610</pub-id></element-citation><mixed-citation id="mc-CR130" publication-type="journal">Deng X, Bi Q, Chen S, Chen X, Li S, Zhong Z, Guo W, Li X, Deng Y, Yang Y. Identification of a five-autophagy-related-lncRNA signature as a novel prognostic biomarker for hepatocellular carcinoma. Front Mol Biosci. 2020;7: 611626.<pub-id pub-id-type="pmid">33505990</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmolb.2020.611626</pub-id><pub-id pub-id-type="pmcid">PMC7831610</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR131"><label>131.</label><citation-alternatives><element-citation id="ec-CR131" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>F</given-names></name><name name-style="western"><surname>Sun</surname><given-names>ZG</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name></person-group><article-title>Development and validation of a prognostic signature associated with tumor microenvironment based on autophagy-related lncRNA analysis in hepatocellular carcinoma</article-title><source>Front Med (Lausanne)</source><year>2021</year><volume>8</volume><fpage>762570</fpage><pub-id pub-id-type="pmid">34970559</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmed.2021.762570</pub-id><pub-id pub-id-type="pmcid">PMC8712323</pub-id></element-citation><mixed-citation id="mc-CR131" publication-type="journal">Deng Y, Zhang F, Sun ZG, Wang S. Development and validation of a prognostic signature associated with tumor microenvironment based on autophagy-related lncRNA analysis in hepatocellular carcinoma. Front Med (Lausanne). 2021;8: 762570.<pub-id pub-id-type="pmid">34970559</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmed.2021.762570</pub-id><pub-id pub-id-type="pmcid">PMC8712323</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR132"><label>132.</label><citation-alternatives><element-citation id="ec-CR132" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Fu</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L</given-names></name></person-group><article-title>The prognostic value of an autophagy-related lncRNA signature in hepatocellular carcinoma</article-title><source>BMC Bioinformatics</source><year>2021</year><volume>22</volume><issue>1</issue><fpage>217</fpage><pub-id pub-id-type="pmid">33910497</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12859-021-04123-6</pub-id><pub-id pub-id-type="pmcid">PMC8080392</pub-id></element-citation><mixed-citation id="mc-CR132" publication-type="journal">Yang S, Zhou Y, Zhang X, Wang L, Fu J, Zhao X, Yang L. The prognostic value of an autophagy-related lncRNA signature in hepatocellular carcinoma. BMC Bioinformatics. 2021;22(1):217.<pub-id pub-id-type="pmid">33910497</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12859-021-04123-6</pub-id><pub-id pub-id-type="pmcid">PMC8080392</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR133"><label>133.</label><citation-alternatives><element-citation id="ec-CR133" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ge</surname><given-names>F</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>A</given-names></name><name name-style="western"><surname>Rudan</surname><given-names>O</given-names></name><name name-style="western"><surname>Setiawan</surname><given-names>MF</given-names></name><name name-style="western"><surname>Gonzalez-Carmona</surname><given-names>MA</given-names></name><name name-style="western"><surname>Kornek</surname><given-names>MT</given-names></name><name name-style="western"><surname>Strassburg</surname><given-names>CP</given-names></name><name name-style="western"><surname>Schmid</surname><given-names>M</given-names></name><name name-style="western"><surname>Schmidt-Wolf</surname><given-names>IGH</given-names></name></person-group><article-title>Immunoautophagy-related long noncoding RNA (IAR-lncRNA) signature predicts survival in hepatocellular carcinoma</article-title><source>Biology</source><year>2021</year><pub-id pub-id-type="pmid">34943216</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biology10121301</pub-id><pub-id pub-id-type="pmcid">PMC8698564</pub-id></element-citation><mixed-citation id="mc-CR133" publication-type="journal">Wang Y, Ge F, Sharma A, Rudan O, Setiawan MF, Gonzalez-Carmona MA, Kornek MT, Strassburg CP, Schmid M, Schmidt-Wolf IGH. Immunoautophagy-related long noncoding RNA (IAR-lncRNA) signature predicts survival in hepatocellular carcinoma. Biology. 2021. 10.3390/biology10121301.<pub-id pub-id-type="pmid">34943216</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biology10121301</pub-id><pub-id pub-id-type="pmcid">PMC8698564</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR134"><label>134.</label><citation-alternatives><element-citation id="ec-CR134" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>A</given-names></name><name name-style="western"><surname>Li</surname><given-names>T</given-names></name><name name-style="western"><surname>Xie</surname><given-names>X</given-names></name><name name-style="western"><surname>Xia</surname><given-names>J</given-names></name></person-group><article-title>Computational identification of immune- and ferroptosis-related LncRNA signature for prognosis of hepatocellular carcinoma</article-title><source>Front Mol Biosci</source><year>2021</year><volume>8</volume><fpage>759173</fpage><pub-id pub-id-type="pmid">34901153</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmolb.2021.759173</pub-id><pub-id pub-id-type="pmcid">PMC8655914</pub-id></element-citation><mixed-citation id="mc-CR134" publication-type="journal">Huang A, Li T, Xie X, Xia J. Computational identification of immune- and ferroptosis-related LncRNA signature for prognosis of hepatocellular carcinoma. Front Mol Biosci. 2021;8: 759173.<pub-id pub-id-type="pmid">34901153</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmolb.2021.759173</pub-id><pub-id pub-id-type="pmcid">PMC8655914</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR135"><label>135.</label><citation-alternatives><element-citation id="ec-CR135" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>G</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Wei</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name><name name-style="western"><surname>Feng</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G</given-names></name></person-group><article-title>A novel ferroptosis-related long non-coding RNA prognostic signature correlates with genomic heterogeneity, immunosuppressive phenotype, and drug sensitivity in hepatocellular carcinoma</article-title><source>Front Immunol</source><year>2022</year><volume>13</volume><fpage>929089</fpage><pub-id pub-id-type="pmid">35874689</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2022.929089</pub-id><pub-id pub-id-type="pmcid">PMC9304774</pub-id></element-citation><mixed-citation id="mc-CR135" publication-type="journal">Li G, Liu Y, Zhang Y, Xu Y, Zhang J, Wei X, Zhang Z, Zhang C, Feng J, Li Q, Wang G. A novel ferroptosis-related long non-coding RNA prognostic signature correlates with genomic heterogeneity, immunosuppressive phenotype, and drug sensitivity in hepatocellular carcinoma. Front Immunol. 2022;13: 929089.<pub-id pub-id-type="pmid">35874689</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2022.929089</pub-id><pub-id pub-id-type="pmcid">PMC9304774</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR136"><label>136.</label><citation-alternatives><element-citation id="ec-CR136" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fu</surname><given-names>P</given-names></name><name name-style="western"><surname>Gong</surname><given-names>B</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Q</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Shan</surname><given-names>R</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Yan</surname><given-names>S</given-names></name></person-group><article-title>Combined identification of three lncRNAs in serum as effective diagnostic and prognostic biomarkers for hepatitis B virus-related hepatocellular carcinoma</article-title><source>Int J Cancer</source><year>2022</year><volume>151</volume><issue>10</issue><fpage>1824</fpage><lpage>1834</lpage><pub-id pub-id-type="pmid">35802466</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijc.34201</pub-id></element-citation><mixed-citation id="mc-CR136" publication-type="journal">Fu P, Gong B, Li H, Luo Q, Huang Z, Shan R, Li J, Yan S. Combined identification of three lncRNAs in serum as effective diagnostic and prognostic biomarkers for hepatitis B virus-related hepatocellular carcinoma. Int J Cancer. 2022;151(10):1824&#8211;34.<pub-id pub-id-type="pmid">35802466</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijc.34201</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR137"><label>137.</label><citation-alternatives><element-citation id="ec-CR137" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xu</surname><given-names>S</given-names></name></person-group><article-title>A ferroptosis-associated lncRNAs signature predicts the prognosis of hepatocellular carcinoma</article-title><source>Medicine (Baltimore)</source><year>2022</year><volume>101</volume><issue>28</issue><fpage>e29546</fpage><pub-id pub-id-type="pmid">35839000</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MD.0000000000029546</pub-id><pub-id pub-id-type="pmcid">PMC11132323</pub-id></element-citation><mixed-citation id="mc-CR137" publication-type="journal">Wang D, Zhang L, Zhang Y, Zhang Y, Xu S. A ferroptosis-associated lncRNAs signature predicts the prognosis of hepatocellular carcinoma. Medicine (Baltimore). 2022;101(28): e29546.<pub-id pub-id-type="pmid">35839000</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MD.0000000000029546</pub-id><pub-id pub-id-type="pmcid">PMC11132323</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR138"><label>138.</label><citation-alternatives><element-citation id="ec-CR138" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lian</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name><name name-style="western"><surname>Lu</surname><given-names>H</given-names></name></person-group><article-title>A ferroptosis-related LncRNA signature associated with prognosis, tumor immune environment, and genome instability in hepatocellular carcinoma</article-title><source>Comput Math Methods Med</source><year>2022</year><volume>2022</volume><fpage>6284540</fpage><pub-id pub-id-type="pmid">36035299</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2022/6284540</pub-id><pub-id pub-id-type="pmcid">PMC9410853</pub-id></element-citation><mixed-citation id="mc-CR138" publication-type="journal">Lian J, Zhang C, Lu H. A ferroptosis-related LncRNA signature associated with prognosis, tumor immune environment, and genome instability in hepatocellular carcinoma. Comput Math Methods Med. 2022;2022:6284540.<pub-id pub-id-type="pmid">36035299</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2022/6284540</pub-id><pub-id pub-id-type="pmcid">PMC9410853</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR139"><label>139.</label><citation-alternatives><element-citation id="ec-CR139" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>X</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S</given-names></name></person-group><article-title>A prognostic signature based on the expression profile of the ferroptosis-related long non-coding RNAs in hepatocellular carcinoma</article-title><source>Adv Clin Exp Med</source><year>2022</year><volume>31</volume><issue>10</issue><fpage>1099</fpage><lpage>1109</lpage><pub-id pub-id-type="pmid">35581934</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.17219/acem/149566</pub-id></element-citation><mixed-citation id="mc-CR139" publication-type="journal">Lin X, Yang S. A prognostic signature based on the expression profile of the ferroptosis-related long non-coding RNAs in hepatocellular carcinoma. Adv Clin Exp Med. 2022;31(10):1099&#8211;109.<pub-id pub-id-type="pmid">35581934</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.17219/acem/149566</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR140"><label>140.</label><citation-alternatives><element-citation id="ec-CR140" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>X</given-names></name><name name-style="western"><surname>Mei</surname><given-names>M</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name><name name-style="western"><surname>Guo</surname><given-names>J</given-names></name><name name-style="western"><surname>Du</surname><given-names>F</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name></person-group><article-title>Ferroptosis-related long non-coding RNA signature predicts the prognosis of hepatocellular carcinoma</article-title><source>Aging (Albany NY)</source><year>2022</year><volume>14</volume><issue>9</issue><fpage>4069</fpage><lpage>4084</lpage><pub-id pub-id-type="pmid">35550563</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/aging.204073</pub-id><pub-id pub-id-type="pmcid">PMC9134948</pub-id></element-citation><mixed-citation id="mc-CR140" publication-type="journal">Yang X, Mei M, Yang J, Guo J, Du F, Liu S. Ferroptosis-related long non-coding RNA signature predicts the prognosis of hepatocellular carcinoma. Aging (Albany NY). 2022;14(9):4069&#8211;84.<pub-id pub-id-type="pmid">35550563</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/aging.204073</pub-id><pub-id pub-id-type="pmcid">PMC9134948</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR141"><label>141.</label><citation-alternatives><element-citation id="ec-CR141" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Song</surname><given-names>C</given-names></name><name name-style="western"><surname>Mu</surname><given-names>T</given-names></name><name name-style="western"><surname>Hu</surname><given-names>J</given-names></name><name name-style="western"><surname>Feng</surname><given-names>H</given-names></name></person-group><article-title>Prognostic signature constructed of seven ferroptosis-related lncRNAs predicts the prognosis of HBV-related HCC</article-title><source>J Gastrointest Cancer</source><year>2024</year><volume>55</volume><issue>1</issue><fpage>444</fpage><lpage>456</lpage><pub-id pub-id-type="pmid">38006465</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12029-023-00977-6</pub-id></element-citation><mixed-citation id="mc-CR141" publication-type="journal">Wang W, Wang L, Song C, Mu T, Hu J, Feng H. Prognostic signature constructed of seven ferroptosis-related lncRNAs predicts the prognosis of HBV-related HCC. J Gastrointest Cancer. 2024;55(1):444&#8211;56.<pub-id pub-id-type="pmid">38006465</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12029-023-00977-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR142"><label>142.</label><citation-alternatives><element-citation id="ec-CR142" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>R</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q</given-names></name><name name-style="western"><surname>Yu</surname><given-names>X</given-names></name><name name-style="western"><surname>Hou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yan</surname><given-names>L</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ji</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Fang</surname><given-names>M</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>M</given-names></name></person-group><article-title>Integrating bulk and single-cell RNA sequencing data to establish necroptosis-related lncRNA risk model and analyze the immune microenvironment in hepatocellular carcinoma</article-title><source>Heliyon</source><year>2023</year><volume>9</volume><issue>11</issue><fpage>e22083</fpage><pub-id pub-id-type="pmid">38034714</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.heliyon.2023.e22083</pub-id><pub-id pub-id-type="pmcid">PMC10685373</pub-id></element-citation><mixed-citation id="mc-CR142" publication-type="journal">Zhang R, Li Q, Yu X, Hou Y, Yan L, Gao Y, Ji L, Zhang X, Fang M, Huang L, Yu Z, Gao Y, Li M. Integrating bulk and single-cell RNA sequencing data to establish necroptosis-related lncRNA risk model and analyze the immune microenvironment in hepatocellular carcinoma. Heliyon. 2023;9(11): e22083.<pub-id pub-id-type="pmid">38034714</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.heliyon.2023.e22083</pub-id><pub-id pub-id-type="pmcid">PMC10685373</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR143"><label>143.</label><citation-alternatives><element-citation id="ec-CR143" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>H</given-names></name><name name-style="western"><surname>Hou</surname><given-names>G</given-names></name><name name-style="western"><surname>Lan</surname><given-names>T</given-names></name><name name-style="western"><surname>Xue</surname><given-names>S</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name></person-group><article-title>Identification and validation of a five-necroptosis-related lncRNAs signature for prognostic prediction in hepatocellular carcinoma</article-title><source>Heliyon</source><year>2024</year><volume>10</volume><issue>18</issue><fpage>e37403</fpage><pub-id pub-id-type="pmid">39309864</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.heliyon.2024.e37403</pub-id><pub-id pub-id-type="pmcid">PMC11415698</pub-id></element-citation><mixed-citation id="mc-CR143" publication-type="journal">Chen H, Hou G, Lan T, Xue S, Xu L, Feng Q, Zeng Y, Wang H. Identification and validation of a five-necroptosis-related lncRNAs signature for prognostic prediction in hepatocellular carcinoma. Heliyon. 2024;10(18): e37403.<pub-id pub-id-type="pmid">39309864</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.heliyon.2024.e37403</pub-id><pub-id pub-id-type="pmcid">PMC11415698</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR144"><label>144.</label><citation-alternatives><element-citation id="ec-CR144" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>G</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name></person-group><article-title>A novel cuproptosis-related LncRNA signature to predict prognosis in hepatocellular carcinoma</article-title><source>Sci Rep</source><year>2022</year><volume>12</volume><issue>1</issue><fpage>11325</fpage><pub-id pub-id-type="pmid">35790864</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-022-15251-1</pub-id><pub-id pub-id-type="pmcid">PMC9256635</pub-id></element-citation><mixed-citation id="mc-CR144" publication-type="journal">Zhang G, Sun J, Zhang X. A novel cuproptosis-related LncRNA signature to predict prognosis in hepatocellular carcinoma. Sci Rep. 2022;12(1):11325.<pub-id pub-id-type="pmid">35790864</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-022-15251-1</pub-id><pub-id pub-id-type="pmcid">PMC9256635</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR145"><label>145.</label><citation-alternatives><element-citation id="ec-CR145" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ren</surname><given-names>H</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H</given-names></name><name name-style="western"><surname>Dong</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S</given-names></name></person-group><article-title>Comprehensive analysis of cuproptosis-related long non-coding RNAs in prognosis, immune microenvironment infiltration and chemotherapy response of hepatocellular carcinoma</article-title><source>Medicine (Baltimore)</source><year>2023</year><volume>102</volume><issue>50</issue><fpage>e36611</fpage><pub-id pub-id-type="pmid">38115286</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MD.0000000000036611</pub-id><pub-id pub-id-type="pmcid">PMC10727658</pub-id></element-citation><mixed-citation id="mc-CR145" publication-type="journal">Ren H, Zheng J, Zhu Y, Wang L, Liu J, Xu H, Dong J, Zhang S. Comprehensive analysis of cuproptosis-related long non-coding RNAs in prognosis, immune microenvironment infiltration and chemotherapy response of hepatocellular carcinoma. Medicine (Baltimore). 2023;102(50): e36611.<pub-id pub-id-type="pmid">38115286</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MD.0000000000036611</pub-id><pub-id pub-id-type="pmcid">PMC10727658</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR146"><label>146.</label><citation-alternatives><element-citation id="ec-CR146" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>L</given-names></name><name name-style="western"><surname>Jia</surname><given-names>X</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tian</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lin</surname><given-names>J</given-names></name></person-group><article-title>Creation of a prognostic model using cuproptosis-associated long noncoding RNAs in hepatocellular carcinoma</article-title><source>Int J Mol Sci</source><year>2023</year><volume>24</volume><issue>12</issue><fpage>9987</fpage><pub-id pub-id-type="pmid">37373132</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms24129987</pub-id><pub-id pub-id-type="pmcid">PMC10298112</pub-id></element-citation><mixed-citation id="mc-CR146" publication-type="journal">Yang L, Jia X, Fu Y, Tian J, Liu Y, Lin J. Creation of a prognostic model using cuproptosis-associated long noncoding RNAs in hepatocellular carcinoma. Int J Mol Sci. 2023;24(12):9987.<pub-id pub-id-type="pmid">37373132</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms24129987</pub-id><pub-id pub-id-type="pmcid">PMC10298112</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR147"><label>147.</label><citation-alternatives><element-citation id="ec-CR147" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>M</given-names></name><name name-style="western"><surname>Lu</surname><given-names>L</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ma</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name></person-group><article-title>Prognostic analysis of hepatocellular carcinoma based on cuproptosis -associated lncRNAs</article-title><source>BMC Gastroenterol</source><year>2024</year><volume>24</volume><issue>1</issue><fpage>142</fpage><pub-id pub-id-type="pmid">38654165</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12876-024-03219-6</pub-id><pub-id pub-id-type="pmcid">PMC11040954</pub-id></element-citation><mixed-citation id="mc-CR147" publication-type="journal">Wei M, Lu L, Luo Z, Ma J, Wang J. Prognostic analysis of hepatocellular carcinoma based on cuproptosis -associated lncRNAs. BMC Gastroenterol. 2024;24(1):142.<pub-id pub-id-type="pmid">38654165</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12876-024-03219-6</pub-id><pub-id pub-id-type="pmcid">PMC11040954</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR148"><label>148.</label><citation-alternatives><element-citation id="ec-CR148" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><name name-style="western"><surname>Bai</surname><given-names>H</given-names></name><name name-style="western"><surname>Fei</surname><given-names>S</given-names></name><name name-style="western"><surname>Miao</surname><given-names>B</given-names></name></person-group><article-title>A cuproptosis-related LncRNA risk model for predicting prognosis and immunotherapeutic efficacy in patients with hepatocellular carcinoma</article-title><source>Biochem Genet</source><year>2024</year><volume>62</volume><issue>3</issue><fpage>2332</fpage><lpage>2351</lpage><pub-id pub-id-type="pmid">37898914</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10528-023-10539-x</pub-id></element-citation><mixed-citation id="mc-CR148" publication-type="journal">Wang S, Bai H, Fei S, Miao B. A cuproptosis-related LncRNA risk model for predicting prognosis and immunotherapeutic efficacy in patients with hepatocellular carcinoma. Biochem Genet. 2024;62(3):2332&#8211;51.<pub-id pub-id-type="pmid">37898914</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10528-023-10539-x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR149"><label>149.</label><citation-alternatives><element-citation id="ec-CR149" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Shang</surname><given-names>J</given-names></name><name name-style="western"><surname>Hu</surname><given-names>B</given-names></name><name name-style="western"><surname>Shi</surname><given-names>H</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Jiao</surname><given-names>T</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Lu</surname><given-names>S</given-names></name></person-group><article-title>Prognosis and tumour immune microenvironment of patients with hepatocellular carcinoma by a novel pyroptosis-related lncRNA signature</article-title><source>Front Immunol</source><year>2022</year><volume>13</volume><fpage>836576</fpage><pub-id pub-id-type="pmid">35812396</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2022.836576</pub-id><pub-id pub-id-type="pmcid">PMC9263208</pub-id></element-citation><mixed-citation id="mc-CR149" publication-type="journal">Zhang Z, Shang J, Hu B, Shi H, Cao Y, Li J, Jiao T, Zhang W, Lu S. Prognosis and tumour immune microenvironment of patients with hepatocellular carcinoma by a novel pyroptosis-related lncRNA signature. Front Immunol. 2022;13: 836576.<pub-id pub-id-type="pmid">35812396</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2022.836576</pub-id><pub-id pub-id-type="pmcid">PMC9263208</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR150"><label>150.</label><citation-alternatives><element-citation id="ec-CR150" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Xia</surname><given-names>F</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Peng</surname><given-names>J</given-names></name><name name-style="western"><surname>Kang</surname><given-names>F</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Hong</surname><given-names>Q</given-names></name></person-group><article-title>Identification and validation of a novel pyroptosis-related lncRNAs signature associated with prognosis and immune regulation of hepatocellular carcinoma</article-title><source>Sci Rep</source><year>2022</year><volume>12</volume><issue>1</issue><fpage>8886</fpage><pub-id pub-id-type="pmid">35614201</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-022-13046-y</pub-id><pub-id pub-id-type="pmcid">PMC9133103</pub-id></element-citation><mixed-citation id="mc-CR150" publication-type="journal">Zhang Z, Xia F, Xu Z, Peng J, Kang F, Li J, Zhang W, Hong Q. Identification and validation of a novel pyroptosis-related lncRNAs signature associated with prognosis and immune regulation of hepatocellular carcinoma. Sci Rep. 2022;12(1):8886.<pub-id pub-id-type="pmid">35614201</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-022-13046-y</pub-id><pub-id pub-id-type="pmcid">PMC9133103</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR151"><label>151.</label><citation-alternatives><element-citation id="ec-CR151" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>T</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sun</surname><given-names>T</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Ding</surname><given-names>C</given-names></name><name name-style="western"><surname>Lan</surname><given-names>R</given-names></name><name name-style="western"><surname>He</surname><given-names>Q</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name></person-group><article-title>The pyroptosis-related long noncoding RNA signature predicts prognosis and indicates immunotherapeutic efficiency in hepatocellular carcinoma</article-title><source>Front Cell Dev Biol</source><year>2022</year><volume>10</volume><fpage>779269</fpage><pub-id pub-id-type="pmid">35712653</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcell.2022.779269</pub-id><pub-id pub-id-type="pmcid">PMC9195296</pub-id></element-citation><mixed-citation id="mc-CR151" publication-type="journal">Wang T, Yang Y, Sun T, Qiu H, Wang J, Ding C, Lan R, He Q, Wang W. The pyroptosis-related long noncoding RNA signature predicts prognosis and indicates immunotherapeutic efficiency in hepatocellular carcinoma. Front Cell Dev Biol. 2022;10: 779269.<pub-id pub-id-type="pmid">35712653</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcell.2022.779269</pub-id><pub-id pub-id-type="pmcid">PMC9195296</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR152"><label>152.</label><citation-alternatives><element-citation id="ec-CR152" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gu</surname><given-names>X</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shen</surname><given-names>D</given-names></name><name name-style="western"><surname>Mao</surname><given-names>Y</given-names></name></person-group><article-title>Construction of a prognostic model for disulfidptosis-related long noncoding RNAs in R0 resected hepatocellular carcinoma and analysis of their impact on malignant behavior</article-title><source>BMC Cancer</source><year>2024</year><volume>24</volume><issue>1</issue><fpage>1068</fpage><pub-id pub-id-type="pmid">39210306</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12885-024-12816-3</pub-id><pub-id pub-id-type="pmcid">PMC11363604</pub-id></element-citation><mixed-citation id="mc-CR152" publication-type="journal">Gu X, Wei Y, Shen D, Mao Y. Construction of a prognostic model for disulfidptosis-related long noncoding RNAs in R0 resected hepatocellular carcinoma and analysis of their impact on malignant behavior. BMC Cancer. 2024;24(1):1068.<pub-id pub-id-type="pmid">39210306</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12885-024-12816-3</pub-id><pub-id pub-id-type="pmcid">PMC11363604</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR153"><label>153.</label><citation-alternatives><element-citation id="ec-CR153" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>L</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Z</given-names></name><name name-style="western"><surname>Xing</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>D</given-names></name></person-group><article-title>Integrating bioinformatics and experimental validation to unveil disulfidptosis-related lncRNAs as prognostic biomarker and therapeutic target in hepatocellular carcinoma</article-title><source>Cancer Cell Int</source><year>2024</year><volume>24</volume><issue>1</issue><fpage>30</fpage><pub-id pub-id-type="pmid">38218909</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12935-023-03208-x</pub-id><pub-id pub-id-type="pmcid">PMC10788009</pub-id></element-citation><mixed-citation id="mc-CR153" publication-type="journal">Xu L, Chen S, Li Q, Chen X, Xu Y, Zhou Y, Li J, Guo Z, Xing J, Chen D. Integrating bioinformatics and experimental validation to unveil disulfidptosis-related lncRNAs as prognostic biomarker and therapeutic target in hepatocellular carcinoma. Cancer Cell Int. 2024;24(1):30.<pub-id pub-id-type="pmid">38218909</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12935-023-03208-x</pub-id><pub-id pub-id-type="pmcid">PMC10788009</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR154"><label>154.</label><citation-alternatives><element-citation id="ec-CR154" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>K</given-names></name><name name-style="western"><surname>Dai</surname><given-names>C</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J</given-names></name><name name-style="western"><surname>Xia</surname><given-names>C</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name><name name-style="western"><surname>Xu</surname><given-names>N</given-names></name><name name-style="western"><surname>Wu</surname><given-names>T</given-names></name></person-group><article-title>Disulfidptosis-related lncRNA signatures assess immune microenvironment and drug sensitivity in hepatocellular carcinoma</article-title><source>Comput Biol Med</source><year>2024</year><volume>169</volume><fpage>107930</fpage><pub-id pub-id-type="pmid">38199215</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.compbiomed.2024.107930</pub-id></element-citation><mixed-citation id="mc-CR154" publication-type="journal">Xu K, Dai C, Yang J, Xu J, Xia C, Li J, Zhang C, Xu N, Wu T. Disulfidptosis-related lncRNA signatures assess immune microenvironment and drug sensitivity in hepatocellular carcinoma. Comput Biol Med. 2024;169: 107930.<pub-id pub-id-type="pmid">38199215</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.compbiomed.2024.107930</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR155"><label>155.</label><citation-alternatives><element-citation id="ec-CR155" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khorkova</surname><given-names>O</given-names></name><name name-style="western"><surname>Stahl</surname><given-names>J</given-names></name><name name-style="western"><surname>Joji</surname><given-names>A</given-names></name><name name-style="western"><surname>Volmar</surname><given-names>CH</given-names></name><name name-style="western"><surname>Zeier</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wahlestedt</surname><given-names>C</given-names></name></person-group><article-title>Long non-coding RNA-targeting therapeutics: discovery and development update</article-title><source>Expert Opin Drug Discov</source><year>2023</year><volume>18</volume><issue>9</issue><fpage>1011</fpage><lpage>1029</lpage><pub-id pub-id-type="pmid">37466388</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/17460441.2023.2236552</pub-id></element-citation><mixed-citation id="mc-CR155" publication-type="journal">Khorkova O, Stahl J, Joji A, Volmar CH, Zeier Z, Wahlestedt C. Long non-coding RNA-targeting therapeutics: discovery and development update. Expert Opin Drug Discov. 2023;18(9):1011&#8211;29.<pub-id pub-id-type="pmid">37466388</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/17460441.2023.2236552</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR156"><label>156.</label><citation-alternatives><element-citation id="ec-CR156" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coan</surname><given-names>M</given-names></name><name name-style="western"><surname>Haefliger</surname><given-names>S</given-names></name><name name-style="western"><surname>Ounzain</surname><given-names>S</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>R</given-names></name></person-group><article-title>Targeting and engineering long non-coding RNAs for cancer therapy</article-title><source>Nat Rev Genet</source><year>2024</year><volume>25</volume><issue>8</issue><fpage>578</fpage><lpage>595</lpage><pub-id pub-id-type="pmid">38424237</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41576-024-00693-2</pub-id></element-citation><mixed-citation id="mc-CR156" publication-type="journal">Coan M, Haefliger S, Ounzain S, Johnson R. Targeting and engineering long non-coding RNAs for cancer therapy. Nat Rev Genet. 2024;25(8):578&#8211;95.<pub-id pub-id-type="pmid">38424237</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41576-024-00693-2</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR157"><label>157.</label><citation-alternatives><element-citation id="ec-CR157" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anfossi</surname><given-names>S</given-names></name><name name-style="western"><surname>Babayan</surname><given-names>A</given-names></name><name name-style="western"><surname>Pantel</surname><given-names>K</given-names></name><name name-style="western"><surname>Calin</surname><given-names>GA</given-names></name></person-group><article-title>Clinical utility of circulating non-coding RNAs - an update</article-title><source>Nat Rev Clin Oncol</source><year>2018</year><volume>15</volume><issue>9</issue><fpage>541</fpage><lpage>563</lpage><pub-id pub-id-type="pmid">29784926</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41571-018-0035-x</pub-id></element-citation><mixed-citation id="mc-CR157" publication-type="journal">Anfossi S, Babayan A, Pantel K, Calin GA. Clinical utility of circulating non-coding RNAs - an update. Nat Rev Clin Oncol. 2018;15(9):541&#8211;63.<pub-id pub-id-type="pmid">29784926</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41571-018-0035-x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR158"><label>158.</label><citation-alternatives><element-citation id="ec-CR158" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karaca Dogan</surname><given-names>B</given-names></name><name name-style="western"><surname>Salman Yilmaz</surname><given-names>S</given-names></name><name name-style="western"><surname>Izgi</surname><given-names>GN</given-names></name><name name-style="western"><surname>Ozen</surname><given-names>M</given-names></name></person-group><article-title>Circulating non-coding RNAs as a tool for liquid biopsy in solid tumors</article-title><source>Epigenomics</source><year>2025</year><volume>17</volume><issue>5</issue><fpage>335</fpage><lpage>358</lpage><pub-id pub-id-type="pmid">40040488</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/17501911.2025.2467021</pub-id><pub-id pub-id-type="pmcid">PMC11970797</pub-id></element-citation><mixed-citation id="mc-CR158" publication-type="journal">Karaca Dogan B, Salman Yilmaz S, Izgi GN, Ozen M. Circulating non-coding RNAs as a tool for liquid biopsy in solid tumors. Epigenomics. 2025;17(5):335&#8211;58.<pub-id pub-id-type="pmid">40040488</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/17501911.2025.2467021</pub-id><pub-id pub-id-type="pmcid">PMC11970797</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR159"><label>159.</label><citation-alternatives><element-citation id="ec-CR159" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>W</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>B</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><name name-style="western"><surname>Gu</surname><given-names>D</given-names></name></person-group><article-title>Circulating lncRNAs serve as diagnostic markers for hepatocellular carcinoma</article-title><source>Cell Physiol Biochem</source><year>2017</year><volume>44</volume><issue>1</issue><fpage>125</fpage><lpage>132</lpage><pub-id pub-id-type="pmid">29130980</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000484589</pub-id></element-citation><mixed-citation id="mc-CR159" publication-type="journal">Yuan W, Sun Y, Liu L, Zhou B, Wang S, Gu D. Circulating lncRNAs serve as diagnostic markers for hepatocellular carcinoma. Cell Physiol Biochem. 2017;44(1):125&#8211;32.<pub-id pub-id-type="pmid">29130980</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000484589</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR160"><label>160.</label><citation-alternatives><element-citation id="ec-CR160" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sukowati</surname><given-names>CHC</given-names></name><name name-style="western"><surname>Cabral</surname><given-names>LKD</given-names></name><name name-style="western"><surname>Tiribelli</surname><given-names>C</given-names></name><name name-style="western"><surname>Pascut</surname><given-names>D</given-names></name></person-group><article-title>Circulating long and circular noncoding RNA as non-invasive diagnostic tools of hepatocellular carcinoma</article-title><source>Biomedicines</source><year>2021</year><volume>9</volume><issue>1</issue><fpage>90</fpage><pub-id pub-id-type="pmid">33477833</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biomedicines9010090</pub-id><pub-id pub-id-type="pmcid">PMC7832835</pub-id></element-citation><mixed-citation id="mc-CR160" publication-type="journal">Sukowati CHC, Cabral LKD, Tiribelli C, Pascut D. Circulating long and circular noncoding RNA as non-invasive diagnostic tools of hepatocellular carcinoma. Biomedicines. 2021;9(1):90.<pub-id pub-id-type="pmid">33477833</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biomedicines9010090</pub-id><pub-id pub-id-type="pmcid">PMC7832835</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>